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Abstract
Screening chemical compounds against genome-wide mutant arrays identifies genetic
perturbations that cause sensitivity or resistance to compounds of interest. The result-
ing chemical-genetic interaction profiles contain information on the cellular functions
perturbed by compounds and can be used to elucidate their modes of action. When
performed at high throughput, chemical-genetic interaction screens can be used to func-
tionally profile entire libraries of chemical compounds in an unbiased manner to identify
promising compounds with diverse modes of action.
My contributions to the field of chemical-genetic interaction screening come pri-
marily in the form of two software pipelines, called BEAN-counter and CG-TARGET,
that were developed to interface with the large-scale datasets generated from screens of
thousands of compounds performed by collaborators. The former pipeline processes the
raw data into chemical-genetic interaction scores and provides tools to remove system-
atic biases and other unwanted signals from large-scale datasets. The latter provides
for interpretation of chemical-genetic interaction profiles via a compendium of refer-
ence genetic interaction profiles, with a focus on controlling the false discovery rate and
prioritizing the highest-confidence predictions for further study. Enabled by the tools
I developed to analyze and interpret these data, our collaboration characterized novel
compounds, identified general trends surrounding the interactions between compounds
and biological systems, and demonstrated the value of performing chemical-genetic in-
teraction screens to functionally annotate compounds at high throughput.
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Chapter 1
Introduction
A practical understanding of the nature of interactions between chemical compounds
and biological systems is essential for the development of safe and effective chemicals.
Such chemicals possess the potential to dramatically improve the quality of human life
while posing minimal risk to organisms that are exposed to them indirectly. Indeed,
it has been shown that pharmaceutical – and in general, biomedical – has directly
contributed to improvements in various health-related outcomes over time [1, 2].
However, much remains to be discovered about the nature of interactions between
chemical compounds and biological systems. One manifestation of this knowledge gap
is the myriad pharmaceutical candidates that fail in clinical trials despite promising
results in preclinical testing, including in animal models. A recent estimate puts the
probability of FDA approval for a compound beginning a Phase I clinical trial at just
under 14%, with this probability strikingly low for oncology (3.4%) and for diseases that
affect fewer than 200,000 individuals every year ("orphan" diseases, 6.2%). Additionally,
certain side effects only become apparent after pharmaceuticals have entered the market
and are severe enough to remove the compound from the market. Due to this and other
factors, the cost of developing a new pharmaceutical surpassed $1 billion nearly two
decades ago and is climbing, potentially still at an exponential rate [3]. A recent study
estimates this cost at nearly $3 billion [4].
Compounding the inherent difficulty of discovering useful compounds is the possi-
bility that they will become ineffective over time. For example, certain pharmaceuticals
– in particular, antibiotic, antifungal, and anticancer agents – may be initially effective
against a pathogen or tumor, only to be rendered ineffective by various drug resistance
mechanisms. Indeed, antibiotic and antifungal resistance is a growing problem around
1
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the globe [5–9]. The proliferation of and lax regulations on antibiotics have created
a breeding ground for “superbugs” resistant to most known antibiotics. In addition,
pathogenic fungi, which as eukaryotes are particularly hard to treat without severe
side effects to the host, now show resistance to all major classes of antifungal agents.
While drug resistance cannot spread in cancer in the same way as in bacteria and fungi,
resistance to promising targeted therapies is now commonplace. In some cases, the
drug-resistant tumors are even more aggressive and very difficult to treat [10, 11].
In addition to the difficulties faced by the health care industry, government regu-
latory agencies face immense challenges in testing the tens of thousands of compounds
generated by human activity for potential toxicity, both to humans and the environ-
ment. Traditional toxicity testing is conducted using animal models, which are expen-
sive, potentially irrelevant to human biology, and controversial. The pure expense of
these tests causes massive backlogs in the testing process. For example, only ~1500 of
the ~85,000 compounds used by consumers or industry have been tested for long-term
carcinogenicity, the standard assay for which is rodent-based [12, 13].
1.1 From endpoint-focused to compound-centric discovery
In general, the most advanced technologies to discover compounds with useful activities
have been developed for, matured in, and been concentrated within the pharmaceutical
industry. In general, pharmaceutical discovery requires screening through a very large
number of compounds – often hundreds of thousands – necessitating the development
of high-throughput assays that measure relatively simple endpoints. These endpoint-
focused screens, the two major types of which are described in section 1.1.1, focus on one
or a small number of easily-measured effects induced by compounds. Endpoint-focused
screens can be contrasted with compound-centric screens that are designed to, given a
set of compounds of interest, identify their potentially useful activities across a variety
of biological functions.
1.1.1 Endpoint-focused drug discovery: target-based vs. phenotypic
screening
Much of the work over the past 2-3 decades to discover new pharmaceuticals has
employed various high-throughput, target-based screening techniques to identify com-
pounds that act on a specific molecular entity in the cell. These efforts rely on multiple
assumptions about how the interaction between a candidate molecule and the target
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propagates through a biological system into a desired effect. For example, many high-
throughput screening techniques are designed to detect if a compound binds to the given
target under the assumption that binding will lead to inhibition. Furthermore, use of
these techniques assumes that small molecule inhibition of a single, predefined, “ideal”
target will actually induce the desired biological effect.
However, target-based approaches possess many technical and biological blind spots
due their focus on one specific activity. These assays suffer generally from high rates of
false positives and as such require stringent statistical analysis of “hit” compounds. Pan-
assay interference compounds (PAINS), which possess certain structures or properties
that enable them to show activity across a range of high-throughput screens, cause many
of these false positives [14, 15]. Even when assumptions hold such that a candidate
molecule binds to its target and induces a desired phenotype, further experiments are
required to assess activities of the candidate molecule throughout the rest of the cell.
The extreme example of this is the next generation of toxicity testing, the goal of which
is to move to in vitro methods as much as possible when characterizing all potential
deleterious effects of a new compound. The current battery of in vitro toxicity tests
involves hundreds of assays [16].
Phenotypic screening assays, which focus on a desired biological outcome rather
than activity against a target, have re-emerged in recent years as a contrast and com-
plement to target-based screening approaches [17, 18]. In fact, phenotypic screening
is the original pharmaceutical discovery approach, as its most primitive implementa-
tions (typically serendipitous observations of, for example, health benefits from certain
plants or inhibition of bacterial growth in the presence of a mold) predate target-based
methods by centuries. In current phenotypic screening efforts, cells (or even microtis-
sues or organoids) are treated with compounds and examined for various phenotypes
ranging from visual (e.g. cellular morphology) to molecular (gene expression). Because
phenotypic screens occur in a whole cell context, the observed activity of a compound
reflects its interactions with the entire biological system, providing more insight into its
potential off-target effects. Additionally, these screens require no a priori knowledge of
a compound’s target in order to determine if it induces a potentially desirable pheno-
type. Despite these advantages, phenotypic screening is traditionally more expensive
than target-based approaches, and much additional effort may be required to elucidate
the molecular target(s) of a compound to ensure that the phenotype of interest is not
induced by nonspecific effects such as general stress or interference with transcriptional
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or translational machinery. In general, successful phenotypic screens result from ex-
perimental systems in which the measured phenotypes accurately reflect the desired
organismal phenotypes, and care must be taken to ensure these two endpoints align
[17].
1.1.2 Functional profiles as unbiased phenotypic endpoints
Advances in biotechnology over the past two decades have enabled the development
of quantitative phenotyping assays that generate high-dimensional profiles reflecting
the functional effects of cellular perturbations (e.g. gene deletions, stress conditions,
drugs). These functional profiles can be treated as phenotypes, albeit intermediate ones
depending on how they were measured, as the values contained in them reflect the
responses of different components of a biological system to specific stimuli. The first
genome-wide functional profiles were generated using technologies such as microarrays or
serial analysis of gene expression and reflected genome-wide changes in gene expression
due to progression through the cell cycle or changes in environmental conditions [19–21].
Because functional profiles are quantitative in nature, they can be readily analyzed
using mathematical, statistical, and machine learning techniques to gain new knowledge
about biological function. High similarity between two functional profiles implies that
the cells that gave rise to those two profiles were in similar states; if the functional
profiles were obtained upon perturbing the cells, high profile similarity would suggest
functional similarity between the perturbations. For example, in a landmark study on
functional profiling in S. cerevisiae, measurements of gene expression in yeast during
the cell cycle were shown to be consistent between cells in the same phase of the cell
cycle [20]. Additionally, because the profiles consisted of gene expression measurements,
the genes’ profiles across the time points could be grouped using hierarchical clustering
to identify sets of genes with similar behavior across different cell cycle phases [21]. In
another yeast study, changes in gene expression were measured across a range of stressful
environmental conditions such as oxidative stress or heat shock [22]. By clustering genes
based on their expression similarity across the different stress conditions, the authors
were able to identify groups of genes that were induced or repressed regardless of the
specific stress condition and other groups of genes for which expression changed only
under specific stress conditions.
In addition to enabling the clustering of genes into groups of similar function,
similarity-based comparisons between functional profiles present the opportunity to
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match the profiles of perturbations with unknown functional consequences to a database
of perturbations with known effects. For example, a compendium of gene expression
profiles obtained across 300 gene mutants was used to assign a diverse range of func-
tions to eight previously uncharacterized genes in S. cerevisiae, simply by finding the
most similar expression profile within the compendium to those of mutants for these
eight genes [23]. A large enough compendium of functional profiles would allow for
the functional annotation of a large fraction of an organism’s entire genome. It would
also serve as a reference for the interpretation of expression changes induced by phar-
maceutical agents, potentially identifying modes of action for uncharacterized bioactive
compounds.
In organisms with facile genetics such as yeast, the creation of genome-wide mutant
collections enabled a different type of functional profiling whose development occurred
concomitantly with that of microarray technology. The construction of genetic mu-
tants is one of the hallmark methods in genetic analysis and has enabled the study
of gene function from the cellular to the organismal level. As such, a genome-wide
collection of genetic mutants provides an unbiased source of functional information re-
flecting the overall state of the cell. In contrast to gene expression profiles, which reflect
programmed cellular responses to the cell’s internal and external environment, mutant
responses obtained upon perturbation of the cell reflect genetic dependencies that may
not be detectable from gene expression changes. By systematically removing pieces of
a biological system to reveal these dependencies, one can reveal the structure of the
underlying biological network.
The functional profiles obtained from genome-wide mutant collections reflect the
ability of thousands of mutants to grow (referred to as fitness) under different genetic
or environmental perturbations. Generally, the fitness values are summarized as “inter-
action” scores that compare the observed fitness of a mutant subject to a perturbation
against a null expectation of fitness derived from the perturbation-induced and individ-
ual mutant fitnesses. When the observed fitness is greater than the expected fitness, the
interaction score will be greater than zero, signifying a positive interaction. Observed
fitness values less than those expected are deemed negative interactions. An extreme
example of a negative interaction is synthetic lethality, which occurs when the com-
bined effect of mutant and perturbation, predicted from their individual effects to yield
a nonzero fitness, results in cell death instead.
The first functional profiling experiments that used a collection of genetic mutants
were performed in S. cerevisiae with the goal of identifying drug-target relationships
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[24]. Specifically, these experiments used heterozygous diploid mutants, meaning that
in each mutant strain, the number of copies of one gene was reduced from two (the wild-
type level) to one. The central hypothesis of these experiments is that the heterozygous
diploid mutant of a gene whose product is targeted by a drug will selectively exhibit
sensitivity (a negative interaction) to that drug, if that gene is essential for growth. In
these initial experiments across a few hundred strains, multiple known drug-target rela-
tionships were identified, validating this hypothesis. Subsequent studies have expanded
on this idea to screen for drug targets in heterozygous diploid mutants representing the
entire yeast essential genome [25, 26].
Fitness-based functional profiles can also be obtained using deletion mutants, which
yield complementary information to heterozygous mutants. In contrast to heterozygous
diploid profiles, which are relatively limited to the detection of drug-target relation-
ships for essential genes, deletion profiles across the nonessential genome of an organism
provide a more global assessment of the functional effects of a perturbation and are use-
ful beyond the characterization of compound function. While deletions of nonessential
genes do not yield fitness phenotypes in standard laboratory conditions, a perturbation
may reveal a role for some of these genes in growth [25]. One can then infer which
biological processes are important for survival in the presence of the perturbation from
the identity of the mutants that exhibit altered fitness. Because the aforementioned
extreme example of synthetic lethality is rare, the power of deletion profiles thus rests
in the less extreme, quantitative changes in fitness that occur in specific sets of genes
that are functionally connected to the perturbation.
In a landmark paper, the power of fitness-based functional profiling of deletion mu-
tants was fully demonstrated through the generation of ~1700 genome-wide genetic
interaction profiles in S. cerevisiae [27]. In these experiments, each perturbation intro-
duced into the deletion collection of ~4000 mutants was a second gene mutation—mostly
deletions for nonessential genes, and ~300 hypomorphic or conditional mutants for es-
sential genes. Overall, ~6 million pairwise gene mutants were constructed and scored
for fitness-based interactions against the null expectation derived from their individual
mutant fitnesses. On this genomic scale, a network derived from pairwise profile simi-
larities revealed functionally-informative structure at multiple levels of resolution, from
the clustering of genes into ~20 broad biological processes to identification of protein
complexes and the functional annotation of poorly-characterized genes. A previously
uncharacterized compound, subsequently named Erodoxin, was even linked to its tar-
get gene ERO1 by comparing its functional profile against the same deletion mutants
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to this genomic-scale genetic interaction network. Subsequent efforts have further ex-
panded this network to a truly global interaction network by generating all possible
pairs of mutants across essential and nonessential genes [28].
While the generation of a global genetic interaction network resulted in a tremen-
dous functional genomics resource for the yeast and systems biology communities, the
experimental system used to generate this network may not be amenable, due to cost or
otherwise, to genetic analysis of other types of perturbations or to further scale-up. The
general procedure to generate a genetic interaction profile is to cross a “query” mutant
strain into a collection of mutants individually arrayed onto agar plates (two arrays
exists: one spanning nonessential genes, and the other spanning essentials). As a result,
the generation of one genetic interaction profile requires dozens to hundreds of plates
and a large amount of the query material. This is not a constraint when the query is a
mutant that can be regrown. However, it is a constraint when generating other types
of interaction profiles and the query is a material that cannot be regenerated, such as a
chemical compound. The screening of rare compounds is, therefore, almost certainly not
compatible with this format. Scaling up to screen thousands of compounds is also not
compatible with the array-based format, both in terms of material cost and availability
– due to the sheer quantity of required compound – and time required.
Fortunately, the very first chemical-genetic interaction experiments provide an al-
ternative experimental strategy that is more amenable to high-throughput screens with
limited quantities of the perturbing agent [24]. By genetically barcoding the mutants,
one can grow an entire collection of mutants in a pool and use measurements of bar-
code abundance as a proxy for fitness. Thus, the thousands of individual experiments
required to generate a genetic interaction profile can be compressed into one test tube.
Further increases in throughput have been realized by moving from microarray to sec-
ond generation sequencing-based barcode abundance measurements [29, 30]. While the
former requires one microarray to generate each profile, the latter enables barcodes from
multiple pools to be quantified simultaneously by introducing indexed primers during
the barcode amplification step. Both of these advances have dramatically increased
throughput of chemical-genetic interaction screens.
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1.1.3 Compound-centric discovery via high-throughput chemical-genetic
interaction screening
The field of chemical genomics broadly concerns itself with the identification of com-
pounds that together can perturb the functions of all genes across the cell. The desired
endpoints of research in this field are chemicals with well-defined biological activity
against a specific target (or perhaps multiple targets or even a specific biological pro-
cess), which are referred to as molecular probes. Such probes are potentially useful
as pharmaceutical lead compounds, but the opportunities for molecular probes spread
beyond the clinic into basic research. For example, molecular probes possess certain
advantages over genetic manipulation, such as general ease of use and their ability to
modulate the activity of a specific target in an organism in a dose- and time-dependent
manner without the need for genetic manipulation. This experimental flexibility could
allow for more detailed investigations of synergy between the effects of multiple probes
over introducing the relevant combinations of genetic perturbations. Further, the pur-
suit of molecular probes that can collectively target the entire genome of an organism
will likely reveal which proteins or other targets are the easiest or most difficult to per-
turb and which targets cause the most downstream effects in the cell or organism when
perturbed. Thus, the goals of chemical genomics overlap substantially with those in
drug discovery and toxicology testing but also reflect a more basic desire to character-
ize general trends governing the interactions between chemical entities and biological
systems.
Given the goals of chemical genomics, unbiased functional profiling approaches are
well-suited for assessing the biological activity of compounds across the cell. As pre-
viously mentioned, much of the seminal work in functional profiling recognized the
ability of both gene expression and mutant fitness profiles to provide information on
compound function [23, 24]. Further work in the functional profiling of compounds has
expanded the number of compounds tested in either gene expression or mutant fitness-
based assays into the tens of thousands (or even hundreds of thousands) of compounds
[25, 26, 31–37]. The most ambitious chemical functional profiling project to date is the
Connectivity Map (CMap), which is part of the NIH Library of Integrated Network-
based Cellular Signatures (LINCS) program [35–37]. The stated goal of this project
is to create a functional signature “lookup table” that allows researchers to infer the
functional consequences of cellular perturbations in their own experiments by linking
the resulting gene expression patterns to those induced by known perturbations. These
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perturbations now include nearly 500,000 signatures derived from ~20,000 chemicals
and activation or inhibition/knockout of over 5,000 genes. In addition to predicting
broad mode of action for hundreds of uncharacterized compounds and validating spe-
cific mechanism of action predictions for two kinase inhibitors, members of the CMap
project have also used their compendium of functional signatures to assess interactions
between drugs and allelic variants as well as interpret the results of clinical trials.
Chemical-genetic interaction profiling, which involves the identification of function-
ally informative mutants with fitness defects or advantages in the presence of a com-
pound, has proven itself particularly useful in the elucidation of compound mode of
action. The pioneering efforts in this area were enabled by the development of S. cere-
visiae systematic mutant collections near the turn of the millennium [24, 31, 32, 38–40].
Most of the compounds screened in these initial experiments had a history of use as
molecular probes, therapeutics (antifungal or otherwise), or agrochemicals. Some of
them possessed known modes of action in yeast, which enabled validation of the dif-
ferent experimental systems employed in these experiments. However, many of the
compounds were not annotated with well-defined modes of action despite their broad
use, and thus these screens provided the opportunity to demonstrate the power of unbi-
ased genetic approaches for rapid annotation of compound function. Almost all of these
studies identified unexpected chemical-genetic interactions for known probes or pharma-
ceuticals, and some were even able to interpret the yeast-based functional annotations
in the context of side effects for human therapeutics [32, 41].
The next round of major advances in chemical-genetic interaction experiments fo-
cused primarily on increasing their throughput. With the proofs-of-principle demon-
strated on tens or hundreds of compounds that possessed at least some level of char-
acterization, the idea of annotating a large number of novel compounds to expand the
boundaries of known chemical space could become a reality. Coupled with through-
put increases conferred by pooled screening of barcoded mutants with microarray-based
readouts (or by screening against a 200-fold smaller set of mutants), subsequent large-
scale chemical-genetic interaction screens consistently achieved throughputs in the low
thousands of compounds [25, 26, 33, 42]. In addition to annotating hundreds of novel
compounds with predicted functions (or even protein targets), these screens enabled
the inference of global insights about gene and compound functional. Some examples
of these insights include the findings that chemical perturbations can reveal fitness
phenotypes for nearly all nonessential gene mutants and enable annotation of poorly
characterized genes [25, 33], that the cellular responses to chemical perturbations can be
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grouped into a relatively small number of general responses [26], and even that chemical-
genetic interaction profiles enable the prediction of synergistic compound pairs [42, 43].
Further increases in the throughput of chemical-genetic interaction screening have
required creative approaches for overcoming limitations imposed by the experimental
readouts. Despite the increases in throughput afforded by second generation sequencing,
this technology still presented major challenges in terms of cost when considering the
sequencing depth required to quantify barcode abundance from the combination of
thousands of mutant strains and tens of thousands of compounds. One strategy to
mitigate this limitation is to leverage the redundancy inherent in genome-wide profiles
and perform screens based on a diagnostic set of mutants that maximally captures the
information present in the full mutant set. This strategy enabled the construction of
the CMap – populated with tens of thousands of gene expression signatures inferred
from measurements on a reduced transcript set – and a recent array-based screen of
over 4000 compounds across 242 yeast deletion mutants [35, 36, 42, 43].
Our broader chemical genomics collaboration embraced this approach to increasing
throughput for our goal of rapidly characterizing the first 10,000 compounds of the
RIKEN Natural Product Depository and six other compound collections with hundreds
to thousands of compounds. Leveraging the concept that a chemical-genetic interac-
tion profile should resemble the genetic interaction profile of its target (or of the genes
involved in its target process), we designed a diagnostic subset of mutants that would
optimally recapitulate similarities between chemical-genetic and genetic interaction pro-
files [31, 44]. By integrating our diagnostic profiles with this genome-wide compendium
of functional profiles, our aim was to retain the ability to predict compound function
across the genome while dramatically increasing throughput. Indeed, our study con-
tained the largest single collection of chemical-genetic interaction profiles to date and
resulted in the annotation of 1522 compounds with high-confidence function predictions
via integration with genetic interaction profiles [34]. We also were able to characterize
the properties of entire compound libraries, such as the degrees of diversity and types of
biases in the functions their member compounds perturbed. Much of my work on this
project dealt with this integration and function prediction problem, and the results are
presented in our primary manuscript as well as chapter 3.
It is important to make a distinction between chemical-genetic interaction profiles
and more general “chemical genomic” profiles, which depending on the context can
be derived from mutant fitnesses or from in vitro activity values measured against a
library of protein targets, such as kinases [45]. As such, some ambiguity surrounds
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the exact definition of a “chemical genomic” or “chemogenomic” profile. Some claim
that chemogenomic profiles are only derived from activity measurements against target
proteins, but no clear consensus exists and the terms “chemogenomics” and “chemi-
cal genomics” are often used interchangeably. In this dissertation, I make an effort to
avoid potential confusion by directly referring to chemical-genetic interaction profiles.
Thus the “interactions” observed between chemicals and genes do not necessarily imply
physical interaction or even proximity to each other in the cell, but rather functional in-
teractions revealed when the chemical unexpectedly (compared to the null expectation)
alters the fitness of the mutant for that gene.
1.2 Analytical challenges in generating and interpreting
chemical-genetic interaction profiles
Screening thousands of compounds for chemical-genetic interactions presents various
challenges in generating, cleaning, and interpreting the resulting interaction profiles.
Most of these challenges and their solutions in my work have come in the context of soft-
ware pipeline development to support and standardize our broader collaboration’s data
analysis efforts, which can be seen by the BEAN-counter and CG-TARGET pipelines
associated with chapters 2 and 3, respectively. However, only the details most relevant
to understanding the principles behind a piece of software or how to use it typically
survive the publication process, and even if they survive they are often relegated to a
supplementary methods section. Yet, important lessons can be learned from discussing
some of the less glamorous details of biological data analysis. Some of these details are
provided in the protocol for using BEAN-counter in chapter 2 and also when I describe
the analysis of datasets from four different modes of chemical-genetic interaction screen
in chapter 4.
To provide some broader context about my work that extends beyond what has sur-
vived or will survive the publication process, I summarize below the major challenges
I encountered in dealing with large-scale chemical-genetic interaction data. Some of
these challenges receive more detailed treatment in subsequent chapters, but for those
that do not, I provide detail where appropriate to paint a more comprehensive picture
of the efforts that led to my contributions to the field over the past ~6 years. More
specifically, my role as lead developer of the BEAN-counter software pipeline over the
past ≥ 3 three years led me to confront the issues described in sections 1.2.1 and 1.2.2,
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and my role as creator and lead developer of the CG-TARGET pipeline gave me the
opportunity to solve some of the problems described in section 1.2.3. In both cases, I
found it important to develop software that can be used by relative non-experts and
also ensure that I leave time to pose further biological questions of the results. These
constraints led to hard decisions and compromises that ultimately resulted in the afore-
mentioned software pipelines—used by multiple collaborators across various levels of
computational expertise.
1.2.1 Generating interaction profiles from sequencing data
For the high-throughput screens discussed in this document, the steps involved in con-
verting raw sequencing data into chemical-genetic interaction scores are not exactly
trivial, and their computation-heavy nature was often in conflict with usability. When
I took over the development of the BEAN-counter (previously called “barseq-counter”)
pipeline, it could be run in “push-button” mode for small-scale screens using the di-
agnostic set of 310 S. cerevisiae mutants but required much more care for analyzing
large-scale datasets. The software, written primarily in Python, made multiple calls
out to MATLAB and compiled C++ code, including a hard-to-find application for ap-
proximate string matching, and none of the post-processing procedures described in
chapters 2 and 4 were organized into a standard framework at that point. I realized
that the software needed a reorganization and to be removed from these external depen-
dencies if I were to accomplish the goal of releasing a pipeline that relative non-expert
users could both install and run on their own computers. As such, I reimplemented
essentially the entire pipeline except for the core interaction-scoring algorithm.
The first step in converting raw sequencing data into interaction scores is deter-
mining the abundance of mutant barcodes in each pool. This requires parsing tens to
hundreds of millions of sequencing reads (tens of gigabytes uncompressed), looking for
reads that match the common priming site from the barcode PCR reaction, valid mu-
tant barcodes, and valid index tag sequences (introduced during PCR to allow parallel
analysis of the PCR products from multiple pools in the same Illumina sequencing lane).
Various naïve implementations of this task could require unacceptably large amounts of
time or memory, especially if one wants to allow for mismatches between the observed
and reference sequences. As a testament to the importance of this step, I have now
performed three major updates to the raw data parser that have progressively improved
the software’s speed, memory use, and repertoire of compatible data types. The latest
13
major update involved a complete redesign of the barcode-matching procedure to add
support for mutant libraries in which the genetic barcodes vary in length. In keeping
with my focus on usability, the parser is written purely in Python to avoid external
dependencies. Since Python, as an interpreted language, is slower than other possible
languages such as C, C++, or Java, I focused on optimizing the code and also ensuring
that parsing only needs to be performed once for each dataset. In fact, the only time
parsing must be performed again is when any of the inputs that govern the parsing pro-
cedure are incorrect, such as the expected structure of the input sequence or the supplied
reference sequences. Even misnamed samples or a rotated plate can be corrected after
the fact.
After obtaining mutant abundances, the next step in generating chemical-genetic
interaction profiles is to determine an expected abundance for each mutant and calcu-
late deviations from that abundance. In our experience, some mutants generate higher
abundance values than others, possibly due to biases in PCR. The null expectation for
mutant abundance must therefore be derived from control conditions that exhibit these
same biases, and this has worked in our experience. BEAN-counter uses locally-weighted
scatterplot smoothing (LOWESS) to determine expected mutant abundance and esti-
mate standard deviation [46, 47], both of which as functions of mutant abundance in
the control conditions. This procedure provides a highly empirical means to estimate
interactions in the context of multiplexed mutant pool analysis, but the original im-
plementation presented substantial usability issues. Specifically, all uses of LOWESS
were actually outsourced to MATLAB, which presented issues with maintaining the
link between Python and MATLAB over time and also the fact that MATLAB is not
free software. The switch to a pure Python version of LOWESS was quite challenging,
and I enlisted the help of first-year PhD student Henry Ward in making this transi-
tion. The algorithm itself is quadratic in time complexity, and the original version we
implemented was also quadratic in space complexity (this did not last long). The first
successful implementation was very slow until I realized that the default algorithm for
cubing a number in Python is float exponentiation and not simply multiplying the num-
ber by itself twice, which is much faster. The MATLAB LOWESS implementation was
also generally more robust to outlier abundance profiles that would violate some of the
assumptions of LOWESS. As such, every new dataset possessed the potential to break
the current LOWESS code and induce a round of debugging.
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1.2.2 Removing unwanted signals from large interaction datasets
In any high-throughput biological dataset, signals can emerge that result from small,
systematic variations in experimental conditions. Generally referred to as batch effects,
these variations can be detected in functional profiling experiments by comparing the
distributions of within-batch and between-batch profile correlations. These effects can
be removed from a dataset using either supervised or unsupervised machine learning
techniques. If the batch labels are known, it is preferable to use a supervised technique
such as linear discriminant analysis (LDA) to learn axes of variation in the data that
separate the batches and subsequently remove them. Indeed, LDA is the technique used
in BEAN-counter to remove batch effects. While I did not introduce this concept or
implement the original analysis, a substantial focus of early my work on BEAN-counter
was the standardization of the relevant evaluation steps, and thus I reimplemented
everything surrounding this analysis. As with the interaction scoring function in the
original barseq-counter pipeline, batch effect correction also involved a callout to MAT-
LAB, this time to a custom LDA script. I again enlisted Henry’s help to port this
procedure fully into Python. After difficulties using a Python LDA implementation
that was likely not designed to accommodate the removal of components, we settled
on an in-house implementation. In the process, I observed rather drastic differences in
the results from the two languages’ supposedly identical pseudoinverse procedures that
ultimately exerted little effect on the final results.
Additionally, some common signals observed in large datasets derive from a biological
origin, but one that reflects general biological effects instead of the desired specific
functional information. In almost all of our datasets, we have observed a dominant
signature that was essentially void of functionally useful information and appeared to
be related to growth inhibition. The occurrence of a prevalent yet unexplainable signal
in a high-throughput dataset is not localized to our experience, and various techniques
have been developed to identify and correct for such signals [48, 49]. One of my first
contributions to the project was spearheading the effort to remove this signature using
singular value decomposition (SVD). Equivalent to principal component analysis on
an uncentered, unscaled matrix, SVD is normally used to capture the main sources of
variance in a dataset. However, like our use of LDA, the goal here is to remove unwanted
sources of variance, and thus the SVD correction I implemented successively removes
components in order of most to least variance explained.
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1.2.3 Interpreting chemical-genetic interaction profiles
The interpretation of chemical-genetic interaction profiles has taken a few different
forms in the literature, and few sophisticated or standardized methods exist for this
task. One major barrier to the method development in this area is the lack of gold
standard compound-target annotations, which in general reduces the scope of bench-
marking efforts and severely limits possibilities in the realm of supervised techniques for
predicting compound-target associations. For supervised methods in general, the pre-
diction of compound-target associations for targets that span a range of functions would
require a giant corpus of compound-target annotations such that a sufficient number of
compounds were correctly annotated to each target (≥5, preferably ≥10). While this is
an admirable goal and in the same general direction as the pursuits of chemical-genetics,
the gap is too large between the current set of compound-target annotations and the
set needed to enable supervised machine learning across a range of biological functions.
Thus, I relied on parametric statistical techniques in my development of computational
methods to interpret chemical-genetic interaction profiles.
For essential genes, mutants that modulate the expression level a genes without
eliminating them entirely can directly implicate specific gene products as the targets of
compounds. This expression modulation can be achieved through altering copy number
of a gene or the stability of its transcript, and both types of mutants have demonstrated
the ability to identify drug targets of compounds in S. cerevisiae. As the common
use of these types of profiles is that of direct target identification, sophisticated analysis
techniques are neither prevalent nor likely necessary. The techniques that would be most
beneficial to these types of screens are those that prioritize observed compound-target
relationships according to the specificity of their chemical-genetic interactions.
Chemical-genetic interaction profiles consisting of nonessential gene deletion mutants
generally link compounds to their targets indirectly and reflect the structure of the un-
derlying biological network. However, indirect effects are not necessarily less informative
than direct effects. Unlike collections of essential gene mutants, which would generally
represent between 1/10 and 1/5 of the genome depending on the species, nonessential
mutants possess the potential to capture nearly genome-wide functional information.
The interactions inferred from deletion mutants reveal connections within and between
biological processes. Negative interactions expose genes that may perform a redundant
function or function in a redundant pathway to the target of the compound, such that
the cell can survive when one but not both of these genes are perturbed. In contrast,
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positive interactions may occur when the mutant and the compound’s target are in the
same pathway, as two perturbations to the same pathway may not yield any additional
fitness defects compared to one perturbation. In the rare and extreme case where a
compound is toxic to the cell but its target is nonessential, positive interactions may re-
veal the identity of the target itself (a classic example of this is the DNA topoisomerase
I inhibitor camptothecin, which shows strong a strong positive interaction with the top1
deletion mutant in S. cerevisiae).
The genome-wide functional information captured by nonessential deletion mutants
lends itself to integration with other functional data such as genetic interaction profiles.
This concept was first demonstrated nearly 15 years ago but has not been tested in
the context of high-throughput chemical-genetic interaction screens [31]. Traditional
high-throughput chemical screening approaches have suffered from high rates of false
positives due to a variety of biological and technical reasons. Thus, accurate estimation
and control of the false discovery rate is of particular importance in dealing with these
novel high-throughput chemical screening data, as is the ability to prioritize the most
interesting compound-target relationships across diverse biological functions.
1.3 Outline
In this dissertation, I describe my efforts to advance the state of the art in chemical-
genetic interaction screening through improvements in processing and interpreting the
data. These efforts coalesced into the development of two software pipelines my col-
laborators and I regularly use for data analysis. Through the development and use
of standardized computational tools, I have contributed to the community not only
the ability to analyze new datasets, but also key insights into how the data should be
analyzed and the nature of the information present in the data.
Chapter 2 presents a protocol reflecting my efforts to standardize procedures for
processing chemical-genetic interaction datasets, largely through my development of the
BEAN-counter software package. It is, in almost exactly the form presented here, cur-
rently under review for publication after one round of major revision. I describe the pro-
cedures for converting raw sequencing data into chemical-genetic interaction scores and
important experimental design considerations to ensure maximal information content in
the final dataset. The procedure outlined in this chapter was used to score interactions
for approximately 4 million chemical-by-mutant combinations in our recently-published
chemical-genetic interaction screen of nearly 14,000 chemical compounds across seven
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diverse compound collections. To make the analysis more accessible to readers and
potential users, I selected a representative subset of the data on which to demonstrate
analysis procedure specified in this chapter. BEAN-counter is open-source, written
in Python, and freely available for academic use at https://github.com/csbio/BEAN-
counter.
Chapter 3 focuses on my efforts to perform large-scale interpretation of chemical-
genetic interaction profiles using genetic interaction profiles. It is, in a form that reflects
one major revision of the chapter presented here, currently under review for publication.
These efforts culminated in the development of the CG-TARGET software pipeline,
which predicts the targets of compounds at the biological process level and places spe-
cial emphasis on controlling the false discovery rate and prioritizing hit compounds
for further validation. The method and its results were originally presented in the
manuscript that describes the key findings from our chemical genomics collaboration
[34], and I present here a detailed characterization of the method along with experimen-
tal validation of predicted biological process targets, focusing on inhibitors of tubulin
polymerization and cell cycle progression. The software performs similarly to or better
than a naïve approach on measures of prediction accuracy and much better in terms
of false discovery rate control. CG-TARGET is open-source, written in R, and freely
available for academic use at https://github.com/csbio/CG-TARGET.
In Chapter 4, I present insights gained from recently-generated chemical-genetic
interaction data obtained across a diverse range of mutant collections in yeast. These
datasets were obtained for the same set of ~high-confidence compounds identified by
performing CG-TARGET on our original diagnostic mutant screen. This alignment
on the compound axis enabled me to make meaningful comparisons across the datasets
regarding the effects of BEAN-counter’s post-processing procedures on various measures
of functional information content. These measures of functional information content
were also interesting on their own, and this analysis revealed some surprising information
about the nature of functional information present in the heterozygous diploid mutant
collection. The analyses in this chapter also confirmed intuitions that general growth
inhibition effects were responsible for the dominant signature observed across all of our
chemical-genetic interaction datasets and suggests alternative strategies for its removal.
Chapter 5 first restates my primary contributions to the field of chemical-genetic
interaction screening by summarizing the major findings of my work. It subsequently
describes logical future directions for my specific projects as well as the field in general,
focusing on improving the general applicability – rooted in accessibility, scalability,
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information extraction, and interpretability – of the combined experimental and ana-
lytical procedures. The broader context of my work and that of my collaborators is
explored, with an emphasis on the implications for similar screening techniques under-
going CRISPR-driven, rapid adoption in mammalian systems.
Chapter 2
Using BEAN-counter to quantify
genetic interactions from
multiplexed barcode sequencing
experiments
2.1 Introduction
Profiling the fitness of a genome-wide collection of mutants against different experi-
mental perturbations provides rich information on the functional effects of these per-
turbations inside the cell [24, 26–28, 31–34, 50, 51] Specifically, these screens allow the
inference of a functional interaction between a mutant and a perturbation when the
fitness of the mutant deviates from its expected fitness in the presence of the perturba-
tion. Each functional interaction is classified as either a positive or negative interaction,
meaning that the mutant was more or less fit than expected, respectively.
Fitness-based interaction screening has been applied across a variety of organisms
as a means to systematically infer functional relationships between pairs of genes or be-
tween genes and environmental conditions (e.g. chemical compounds, heat shock). For
example, when the perturbation introduced to the mutant collection is another genetic
perturbation, the observed genetic interactions represent functional connections within
cellular pathways as well as relationships between pathways that function together
within a larger biological process [27, 28]. This strategy was used in Saccharomyces
cerevisiae to construct the first complete genetic interaction network for an organism
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[28], and screening of genetic interaction networks is underway for many other model
organisms and in humans [52–57]. Another application of this approach is to perturb a
mutant collection with a chemical compound, which reveals the mutants that confer re-
sistance (positive interaction) or sensitivity (negative interaction) to the compound and
provides information on the compound’s mode of action [24–27, 31–34, 43, 50]. Thus,
fitness-based interaction screening provides a systematic framework for discovering gene
function, inferring the functional organization of the cell, and identifying promising new
therapeutic candidates.
The ability to perform fitness-based interaction screening in a pooled format provides
substantial gains in efficiency and throughput over screens performed against arrays of
individual mutants [29, 50]. By inserting unique DNA barcodes with common primer
sites for PCR-based amplification into the individual mutants, entire mutant collections
can be pooled and grown in competition, with the abundance of each genetic barcode
used as a proxy for fitness [29]. For chemical genomic screens, this pooled format enables
screening of rare and/or expensive compounds due to substantial reductions the amount
of required compound.
The introduction of massively parallel sequencing technology enabled another dra-
matic increase in the throughput of these screens [30, 34]. Originally, the genetic bar-
codes were quantified using microarrays specific to a collection of mutants, and one
microarray was required for each condition profiled against the collection. However,
current sequencing technology provides for the multiplexed quantification of barcode
abundance across multiple conditions, vastly increasing throughput and decreasing costs
for the barcode quantification step [30]. We leveraged this new technology to develop
a high-throughput chemical genomics screening platform in S. cerevisiae, enabling the
multiplexed quantification within one lane of Illumina HiSeq sequencing of genetic bar-
codes from a diagnostic collection of ~300 mutants screened in 768 independent experi-
ments (figure 2.1a) [34].
We developed the BEAN-counter software pipeline (Barcoded Experiment Analysis
for Next-generation sequencing) to address our need to process the data from high-
throughput, sequencing-based interaction screens in a systematic, reproducible manner
(figure 2.1b). The core of BEAN-counter is a simple pipeline to generate fitness-based
interaction scores from the raw data (figure 2.1b, i). This is accomplished by pars-
ing the raw sequencing data to determine barcode (mutant) and index tag (condition)
abundance, removing automatically-determined and user-defined mutants and condi-
tions that do not meet specific quality thresholds, and computing an interaction z-score
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(a)
(b)
Figure 2.1: Overview of multiplexed barcode sequencing experiments and their process-
ing using the BEAN-counter software. (a) A collection of barcoded mutants (denoted
by color) is subjected to both treatment and negative control conditions, followed by
PCR amplification of the genetic barcode sequences using indexed primers (indexing
sequences indicated with black/gray) and ultimately, massively parallel sequencing. (b)
(i) The core of the BEAN-counter software is a pipeline to process raw sequencing reads
into interaction z-scores, which are calculated by comparing each condition’s mutant
abundance profile against that of a mean profile derived from negative control con-
ditions. (ii) BEAN-counter also provides additional post-processing tools to remove
systematic effects and/or common yet uninformative signal, typically from datasets.
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for each mutant-condition pair. BEAN-counter possesses additional features to per-
form more complex processing tasks on the resulting interaction scores (figure 2.1b,
ii). These procedures are typically only applicable to large-scale screens (hundreds or
more conditions) and include the visualization and removal of systematic effects and
otherwise unexplained yet uninformative variance in the data. BEAN-counter has been
used to process dozens of screens containing between 1 and 10,000 compounds across
multiple model organism mutant collections (e.g. S. cerevisiae, E. coli, Z. mobilis) [58]
and thus encapsulates the knowledge we accrued throughout our experience developing
a high-throughput, sequencing-based interaction screening platform.
2.1.1 Applications
To comprehensively convey the potential applications of BEAN-counter, we describe
here some potentially relevant details about the core interaction scoring pipeline, the
basic format of our experiments, and finally specific recommendations for the types
of experiments that can be analyzed using BEAN-counter. For further details on the
interaction scoring algorithm, please see the supplementary note in the manuscript that
describes our application of this pipeline to a chemical-genetic interaction screen of
14,000 compounds [34].
To convert the raw sequencing data into abundances of all mutant-condition pairs,
each amplicon is matched to user-provided lists of expected gene barcode and index tag
sequences after first checking for the presence of the expected common primer sequence.
For the gene barcodes and index tags, BEAN-counter selects the closest-matching se-
quence within a user-specified error tolerance. BEAN-counter can match gene barcodes
(but not index tags) of varying length, and in this scenario, it will select the longest
sequence that satisfies the specified error tolerance. Amplicons are excluded if they
contain an observed sequence that matches equally well to multiple reference sequences
(these will account for a very small proportion of reads with proper barcode design).
BEAN-counter can only generate interaction scores for sequences it expects to find in
the data, but it does export information on observed but unmatched sequences for
troubleshooting purposes.
The output of interaction scoring is a z-score reflecting the direction and number of
standard deviations the observed abundance for a mutant-condition pair deviates from
its expected abundance. Thus, BEAN-counter does not report mutant fitness values
but rather deviations from a fitness-based expected value for each mutant-condition
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pair. Broadly, these scores are generated by comparing each condition’s profile of mu-
tant abundances against a mean profile of mutant abundances computed across a set
of negative control conditions. Specifically, each condition’s logged abundance profile is
LOWESS-normalized against the logged mean profile (using robust LOWESS to mit-
igate the effects of outliers), with deviations from the expected abundance computed
against the LOWESS line [46, 47]. A standard deviation is computed on these devia-
tions, while a continuous estimate of standard deviation in the negative control condi-
tions is computed as a function of strain abundance (using LOWESS on the squared
deviations). For each condition, the resulting interaction z-score for each mutant is
computed by dividing the calculated deviation by the largest of the two standard devi-
ations. As both treatment and negative control conditions are scored against the mean
mutant abundance profile derived from the negative control conditions, the resulting
dataset contains interaction profiles for both treatment and negative control conditions.
This enables the identification of technical effects that influence large groups of profiles
regardless of their treatment or control status and the removal of offending mutants
and/or conditions from the data.
Our chemical genomic screens are performed in 200 ÎĳL micro-cultures in 96-well
plates, where each well contains the pooled, barcoded mutant library challenged with
a different condition (figure 2.2a). Further experimental details are provided elsewhere
[34, 59]. The mutant libraries are grown under these conditions for a specified amount of
time (48 h for S. cerevisiae), after which the abundances of individual mutants from each
treatment condition are compared to the respective mutant abundance distributions
in the negative control conditions. We use indexed primers to amplify the genetic
barcodes via PCR, resulting in PCR amplicons that map uniquely to each condition and
mutant and can therefore be combined into a single lane of Illumina HiSeq sequencing
(figure 2.2b). As is evident from figure 2.2b, the PCR amplicons are designed to be
sequenced on Illumina machines.
Our specific experience is limited to Illumina HiSeq and MiSeq instruments, which
present unique challenges in amplicon sequencing applications. Since all amplicons
share the same common primer sequence, a 10% PhiX spike-in is required to provide
sequence diversity if the amplicons are not already sequenced in the presence of other
diverse sequences. This requirement for sequence diversity appears to be more stringent
among the newer Illumina NextSeq and NovaSeq instruments, which may require a 25%
PhiX spike-in or the use of indexed primers with variable-length index tags to provide
sufficient sequence diversity. Note that while the former approach is compatible with
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(a) (b)
(c) (d)
Figure 2.2: Design of large-scale, pooled and multiplexed chemical-genetic interaction
screens. (a) A barcoded collection of mutants is pooled and then competitively grown
in the presence of different chemical compounds. (b) Scheme for the generation of
PCR amplicons from pooled competition experiments that enables a high degree of
sample multiplexing (768-plex in our experiments). (c) Typical layout of positive and
negative control conditions in each screening plate. (d) Per-flow-cell sequencing scheme
to maximize coverage of index tags with negative control conditions. Each column
represents the samples combined into each sequencing lane (labeled L1 – L8 for each
lane in a HiSeq flow cell), and each row represents the samples amplified with a specific
plate of 96 unique indexed primers (labeled P1 – P8; 768 unique indexed primers in
total). The different configurations are optimal for different sizes of barcoded mutant
collection. We utilized (i) in our large-scale chemical-genomic screen that achieved
768-plex sample multiplexing across ~300 diagnostic mutants [34] . A screen against a
larger mutant collection, however, requires a decrease in sample multiplexing to ensure
sufficient sequencing depth for each sample. A 384-plex scheme (ii) is preferable for
collections of ~1000 mutants (such as a collection of yeast essential gene mutants),
as is a 96-plex scheme (iii) for collections of ~4000 mutants (such as the entire yeast
nonessential deletion collection).
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BEAN-counter, the latter is currently not. While another sequencing platform may be
compatible with PCR amplicons of this format (early work in this area utilized SOLiD
sequencing [30]), we have not tested BEAN-counter with any other next-generation se-
quencing technology and cannot speak to the appropriateness of our interaction scoring
model on the data from different sequencing platforms.
In this protocol, we describe the application of BEAN-counter to a subset of the data
(2592 out of 38,400 conditions) from our recently-published screen of nearly 14,000 chem-
ical compounds spanning natural products and derivatives, combinatorially-synthesized
compounds, and approved therapeutics and chemical probes with known modes of action
[34]. However, BEAN-counter is not limited to chemical-genetic interaction screening
and should be applicable to experiments that follow the same general design principles
as those described here and throughout this protocol. For successful analysis using
BEAN-counter, experiments should be designed as follows:
• As the null expectation is that each mutant is present at an expected nonzero
abundance in each condition (and deviations from that abundance are thus inter-
actions with a specific condition), experiments should be designed such that each
mutant is present at a sufficient, nonzero abundance in the negative control condi-
tions. The default detection limit is 20 counts per mutant-condition pair, and we
aim for an average of ≥ 100 counts per mutant-condition pair to ensure nearly all
strains meet this threshold. Strains that do not consistently meet this detection
limit are automatically removed during processing and cannot be analyzed using
BEAN-counter.
• At an absolute minimum, four negative controls should be included in a small-
scale screen. We recommend that negative controls comprise 5–15% of the screened
conditions and provide further details in the EXPERIMENTAL DESIGN section.
• The PCR amplicons to be analyzed by BEAN-counter should contain, in this
order, an index tag sequence derived from the indexed primers, a common priming
site that is the same across all amplicons, and a genetic barcode derived from each
mutant (figure 2.2b). Only the genetic barcode can vary in length.
• Index tag and genetic barcode sequences should be designed to be as dissimilar to
each other as possible to reduce ambiguous mappings from observed sequences to
the expected reference sequences. Each expected sequence should be a Levenshtein
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distance of at least two from all other expected sequences of that type, with greater
distances preferred if possible.
2.1.2 Experimental design
We previously demonstrated that we can combine the PCR products from at least 768
conditions into one lane of HiSeq sequencing (768-plex) when using our diagnostic pool
of ~300 S. cerevisiae deletion mutants [34], and in unpublished experiments we have
achieved at least 96-plex sample multiplexing across the collection of all S. cerevisiae
nonessential gene deletion mutants (~4000 mutants). The extent to which conditions can
be multiplexed has nearly doubled since we performed our original large-scale screens
due to the continual increases in Illumina sequencing depth. We recommend a sequenc-
ing depth that ensures an average of ≥ 100 reads per mutant per condition, which has
been sufficient for our screens across tens of thousands of conditions.
For large scale screens involving hundreds of compounds, experimental design consid-
erations must include more than just the sequencing depth. We recommend including in
each 96-well plate 4 negative control (for our chemical genomics experiments, this is the
solvent control, DMSO) and 4 positive control conditions (compounds with distinct and
well-characterized chemical-genetic profiles; in our case, we use benomyl, tunicamycin,
bortezomib, and methyl methanesulfonate) (figure 2.2c). This enables the identification
of any “flipped” (i.e. physically rotated) plates and ensures that the experiments in
each plate were successful.
Plates containing only negative control conditions (with 4 positive controls) should
also be screened to provide sufficient information regarding mutant fitness variability
in the absence of treatment conditions. Ideally, at least one of these plates would be
screened on each day for which a large number of other plates are screened. Additionally,
signatures associated with specific index tags can be detected if the screen is designed
such that multiple negative control conditions are tagged using the same indexed primer.
If such signatures are strong enough (determined via a profile correlation threshold),
the conditions associated with these offending index tags are automatically removed.
Examples of screening formats that pair each index tag with at least one negative control
condition are given in figure 2.2d.
Basic statistical intuition should guide the design of screens to both minimize batch
27
effects and maximize the probability of removing them. In the development of our high-
throughput chemical genomics assays in S. cerevisiae and other species, we have ob-
served signatures associated with conditions’ screening dates, screening plates, indexed
primer plates, index primer sequences, and sequencing lanes. We recommend perform-
ing three biological replicates for each condition, with the replicates ideally screened
in different plates, amplified using different indexed primers, and sequenced in different
lanes. Conditions should be grouped randomly to avoid instances where conditions with
similar biological effects are screened in the same batch, resulting in what appears to be
a batch effect but is actually biological similarity. For each day on which the conditions
are screened, negative controls should comprise ~5–15% of the screened conditions.
2.1.3 Comparison with existing tools
BEAN-counter addresses a need in the pooled interaction screening community for a
start-to-finish pipeline consisting of raw data processing, interaction scoring, and quality
control that includes approaches for correcting the effects of technical artifacts in the
data. Alternative tools can address some aspects of this conceptual pipeline and may
be complementary to BEAN-counter. For example, much work has been performed
to solve the problem of identifying common sequences within large collections (up to
millions) of sequences, and some of these approaches could be modified to count the
abundance of each index tag and barcode combination [60–67].
While most of these tools provide differing methods for clustering sequences based
on similarity across the entire observed sequence, the recently-published Bartender soft-
ware allows for the extraction and clustering of barcodes given an arbitrary PCR am-
plicon structure (including variable-length index tags and barcodes), which facilitates
the calculation of barcode abundance [67]. The edgeR package for R and the Barcas
software tool are also capable of processing PCR amplicon sequences of the same gen-
eral structure presented in this protocol into a count matrix, and like BEAN-counter,
they must be provided with expected barcodes and index tags prior to analyzing the
sequencing data [68–70]. Barcas offers additional functionality to deal with index tags
and/or barcodes with varying lengths and locations.
Both Barcas and edgeR are capable of scoring interactions, but only edgeR offers
the potential to remove batch effects by specifying them as covariates in its statistical
modeling framework (which is different from our approach based on Fisher’s linear
discriminate analysis). Other possible methods for supervised and unsupervised batch
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effect correction are found in the SVA package for R [48, 49, 71]. It is important to note
that the interaction scoring model used in BEAN-counter was developed specifically
for the data from our high-throughput, pooled chemical-genetic interaction screens, is
unique among the methods described here through its empirical estimation of variation
as a function of barcode abundance, and has been particularly useful for obtaining
high-quality, reproducible, functional information for the compounds in these screens.
Additionally, using edgeR or similar methods to score interactions may require different
experimental design considerations than those outlined in this protocol.
2.1.4 Limitations
BEAN-counter was designed to process amplicons with a fixed structure and known
index tag and genetic barcode sequences, as described above. The interaction z-score
it reports is based on the deviation from an expected relative abundance, which re-
quires sufficient barcode abundance in negative control conditions and depends on the
fitness distribution of other mutants in the pool in the condition of interest, ecologi-
cal interactions among mutants in the pool, and the number of generations over which
the pool is grown. Thus, BEAN-counter is not appropriate when barcodes are below
the detectable level in negative control conditions or when the composition of the pool
changes drastically in treatment vs. control conditions. Additionally, BEAN-counter
is not appropriate for tracking rare barcodes in a cell population, which requires tag-
ging the individual barcodes with unique molecular identifiers (UMIs) to quantify their
absolute abundances. Examples of experiments to which BEAN-counter should not
be applied include lineage tracking in a population of 500,000 uniquely-barcoded cells
[72] and screens in which the expected fitness of all mutants in the negative control
conditions is zero.
In general, BEAN-counter does not perform any quality control pre-processing on the
raw sequencing data, although, in our applications, we have not found this necessary.
Additionally, methods to summarize interaction scores at the gene level for multiple
mutants of the same gene (e.g. for a pooled CRISPR screen with multiple guide RNAs
per gene) are beyond the scope of this software.
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2.1.5 Required expertise
To run BEAN-counter, you should be familiar with running software from the command
line (preferably the Linux terminal), which also involves navigating the filesystem, creat-
ing directories, and transferring files. The pipeline is written completely in Python, and
thus knowledge of this programming language is a major advantage if errors arise. You
should also be familiar with using Java TreeView to visualize clustered heat maps. We
have predominantly used version 2 of Java TreeView (http://jtreeview.sourceforge.net/),
which has a user manual on its website. Version 3 of Java TreeView (in development,
but stable: https://bitbucket.org/TreeView3Dev/treeview3/) is also capable of viewing
the *.cdt files generated by BEAN-counter.
Additionally, it is important to make a distinction between the level of statistical
and/or data analysis training we recommend you possess for analyzing a screen of tens
of compounds versus one with thousands of compounds. Large-scale screens provide
more opportunities for the occurrence, detection, and removal of systematic effects, and
the extent to which these effects are removed depends on judgement calls you will make
at processing time. In section 2.1.6, we describe our thought processes surrounding
these judgement calls when processing chemical-genetic interaction data. However, if
you are interested in using BEAN-counter to analyze thousands of interaction profiles,
we believe you would benefit from a formal introduction to concepts in large-scale data
analysis – in particular, outlier detection, singular value decomposition and principal
component analysis, batch effect correction, and precision-recall (PR) and receiver-
operator characteristic (ROC) analysis.
2.1.6 Analysis overview
Analyses with BEAN-counter can be subdivided into three major steps: (1) setup, (2)
interaction scoring, (3) and post-processing – as outlined below. The setup and inter-
action scoring steps are heavily intertwined, as the setup process involves constructing
multiple configuration files and tables that are required for the interaction scoring step.
All scripts used during the post-processing step can be used in any order on any valid
matrix of interaction scores, as their parameters are instead specified via command line
arguments.
We specify here a few conventions that standardize how we refer to files and folders,
configuration parameters, and software commands. In this protocol, paths to files and
folders are italicized, and we assume that the user’s working directory is <dir>/. A
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directory within <dir>/ with the name “output” is therefore notated as <dir>/output/.
The names of the scripts that comprise BEAN-counter (and their arguments) are written
in monospace font (e.g. process_screen.py). Parameters within configuration files
are underlined and column names in gene barcode and sample information tables are
‘single-quoted.’
Setup: preparing files for processing
The primary BEAN-counter configuration file provides the pipeline with all of the in-
formation it needs to process raw fastq files into interaction scores (figure 2.3). The
configuration file (<dir>/config_files/config_file.yaml) specifies the locations of the
raw data (via the lane_location_file parameter), the tables that map index tags to the
screened conditions (sample_ table_file) and genetic barcodes to the mutant strains
(gene_barcode_file), and the file that determines how to read the index tags and bar-
codes from the raw PCR amplicon sequences (amplicon_struct_file). It is also used to
specify the thresholds for various quality control measures that determine which con-
ditions and/or mutants are automatically removed from the dataset. Setting up the
configuration file, other required files, and the recommended directory structure can be
performed manually or with the help of the setup_screen.py script. Chapter A describes
all parameters available to the configuration file and the setup_screen.py script.
Interaction scoring: iteratively scoring and filtering the data
Generating interaction z-scores from the raw sequencing data is accomplished using the
process_screen.py script, which contains six substeps that can be run individually if
necessary (figure 2.4a). Substep 1 parses the fastq files to generate per-lane matrices
containing the number of reads observed for each combination of index tag (condition)
and barcode (mutant). Substep 2 performs an initial round of interaction scoring for
each lane individually, the results of which are used to perform index tag quality control
(substep 3). In substeps 4 and 5, the per-lane count matrices are combined and filtered
based on the automatically- and user-determined filtering information (which mutants
and conditions should be retained/removed). Substep 6 generates the final interaction
matrix by scoring interactions using the combined, filtered count matrix.
The ability to perform the substeps in process_screen.py individually is particu-
larly useful due to the iterative nature of the interaction scoring process. Viewing the
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Figure 2.3: Schematic showing how the configuration file coordinates the processing
of pooled interaction screening data by specifying the location of the raw data, the
structure of the PCR amplicons, and the mappings from genetic barcode to mutant
and index tag to condition. Columns in bold are required in order to process data with
BEAN-counter.
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(a)
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(b)
Figure 2.4: Schematic of the steps involved in processing large-scale interaction screens
using BEAN-counter. (a) Individual substeps performed by the process_screen.py
script to score interactions from raw sequencing data. Locations of important output
files are shown in the right column within the <dir>/output/ folder. (b) BEAN-counter
provides post-processing tools to visualize and remove systematic biases and uninfor-
mative signal from the matrix of interaction z-scores, which is originally generated by
process_screen.py. The user must determine the sequence of post-processing steps
based on the severity and removability of these unwanted signals. The software also
includes tools to collapse profiles across replicate conditions and to export the data in
text-based formats for browsing in Java TreeView or further analysis in other program-
ming languages.
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final interaction matrix is usually what allows the user to identify conditions and/or mu-
tants that should be manually removed from the dataset. However, it is not necessary to
re-parse the raw data just to modify parameters that are incorporated at later substeps.
Using the --start 2 flag, for example, allows the user to proceed with the first round of
individual-lane interaction scoring (i.e. start at substep 2) as long as substep 1 (fastq
parsing) completed successfully. Similarly, most of the user-specified condition/mutant
filtering information (except the selection of negative controls for interaction scoring)
is not incorporated until the combined count matrix is filtered in substep 5. You can
therefore iterate rapidly on the substeps of matrix filtering and interaction scoring by in-
voking process_screen.py with the --start 5 flag after each modification of manual
or automatic filtering parameters.
BEAN-counter provides both automatic and manual methods for removing mutants
and conditions that do not meet specific quality control criteria. By default, mutants
that do not possess 20 or more counts for at least 25% of the conditions are removed,
as are conditions that do not possess 20 or more counts for at least 25% of the mu-
tants (these are advanced parameters in config_file.yaml). Strong interaction z-scores
in the profiles of negative control conditions should be dealt with by removing either the
offending mutants or negative controls; this choice is arbitrary and depends on which
information in the dataset is more valuable to retain. Mutants that are sensitive or
resistant to most conditions should also be removed, as their signal is almost certainly
not biologically relevant. In our experiments, many highly growth-inhibitory conditions
(< 50% compared to negative controls) reveal a common subset of resistant mutants
that are ultimately assigned very large positive interaction scores. We remove from the
dataset either these broadly-resistant mutants or the conditions that elicit the resis-
tance, as these mutants are not useful in interpreting compound mode of action and
their disproportionately-high scores present substantial challenges in post-processing
steps. For chemical genomics experiments, appropriate selection of compound screening
concentration mitigates this effect.
Post-processing: removing systematic biases and uninformative signal
Once a final matrix of interaction scores has been generated, BEAN-counter provides
“post-processing” tools to detect and remove systematic biases and common yet unin-
formative signal (figure 2.4b). These tools are most appropriate for large-scale screens
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(hundreds of compounds) and require more data analysis expertise than simply scor-
ing the interactions. To the latter point, post-processing is more iterative and reliant
on user judgement calls, as the individual post-processing scripts can be run in any
order so that the largest effects are removed first. The core tools in BEAN-counter
post-processing are Fisher’s linear discriminant analysis (LDA) and singular value de-
composition (SVD), both of which learn signals (referred to as components) that can
then be removed from the data. The general procedure for removing unwanted signal
from the interaction data is to determine if the signal exists, if it can be removed, and
how much should be removed based on metrics such as replicate correlation.
In these post-processing steps, the user must determine the number of LDA or
SVD components to remove within each type of correction and also the order in which
to apply the different types of correction (i.e. SVD before LDA batch correction, or
vice versa). BEAN-counter assists in making these decisions by providing appropriate
evaluation metrics in the form of histograms, PR curves, and ROC curves. With each
subsequent removal of an LDA or SVD component, the observed separation between
the distributions of within-batch and between-batch correlations should decrease in the
histograms, the area under the ROC curve should approach 0.5 (the y = x line), and
PR curves should show a decrease toward the final value in the curve (the background
precision). The success of batch effect correction can also be measured with respect
to replicate correlations (treating each set of replicates as a “batch”), in which case
the separation between replicate and non-replicate correlation distributions, the area
under the ROC curve, and the area under the PR curve should all increase. Because
these corrections are not foolproof, it is important to view a clustered heat map of each
corrected dataset. If an examination of the heat map suggests that substantial signal
was removed from the dataset despite minimal improvements in the evaluation plots,
it is likely that the batch effects were not correctable and that the batch correction
procedure was confounded by a strong signal correlated with many conditions in the
same batch.
For nearly every large-scale dataset we have generated, including screens against
deletion mutants of nonessential genes and hypomorphic mutants of essential genes,
we observe a common signal in 15-25% of mutants and more than 15% of conditions.
Growth inhibition appears necessary but not sufficient to induce this signal, and it ap-
pears to reflect a common general effect on mutant fitness (figure 2.5a). This signal is
ultimately responsible for spurious correlations that obscure more interesting and spe-
cific relationships between different conditions. BEAN-counter provides the ability to
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remove signals such as these via singular value decomposition (SVD), an unsupervised
technique that identifies the main axes of variation in a dataset (figure 2.5b). Starting
with the dimension of highest variation, the user can specify how many of these “SVD
components” to remove from the dataset in a successive manner (i.e. it is not possi-
ble within BEAN-counter to only remove the second SVD component). Removing this
signature from the dataset (in most cases, the first SVD component) typically changes
the observed bimodal distribution of replicate correlations and non-zero-centered dis-
tribution of non-replicate correlations (figure 2.5c, i) into a unimodal distribution of
replicate correlations and a zero-centered distribution of non-replicate correlations (fig-
ure 2.5c, ii). Precision-recall and receiver-operator characteristic (ROC) curves provide
a more objective and quantitative evaluation of this change, where increases in the area
under both curves reflect improvements in the ability of profile correlations to predict
if two conditions are replicates of each other (figure 2.5d) and the area under the ROC
curve also directly reflects the separation of the replicate and non-replicate correlation
distributions.
A batch effect is defined here as the occurrence of a higher than expected corre-
lation between conditions that are associated with the same technical attribute in an
experiment. We have observed higher than expected profile correlations for conditions
screened on the same day or in the same plate, amplified with the same indexed primer
or primers from the same 96-well plate, or sequenced in the same lane. BEAN-counter
provides batch effect correction via a multiclass implementation of Fisher’s linear dis-
criminant analysis (LDA), which has been used previously to correct batch effects in
genetic interaction data [73]. Because this is a supervised correction, the user must
specify the batch labels as well as other batches that could confound the detection
and removal of the effect in question. The batch correction script removes duplicate
instances of the confounding batches occurring within each batch of the interrogated
effect so that common signals between conditions that are expected to correlate with
each other are not mistaken for batch effects. As with the SVD correction, batch-related
signals are removed successively starting with those of the largest magnitude.
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(a) (b)
(c)
(d)
Figure 2.5: The large signature that we observe in and remove from most of our datasets.
(a) Chemical-genetic interaction profiles obtained directly after interaction scoring. (b)
Chemical-genetic interaction profiles after removal of one SVD component. (c) (i) His-
togram of the data in (a) showing the mean profile correlation (Pearson’s correlation
coefficient) within each group of compound replicates (“same compound,” mean group
correlation = 0.78) or between each pair of compounds (“different compound,” mean
group correlation = 0.15). (ii) Histogram of the data in (b) showing the mean profile
correlation within each group of compound replicates (mean = 0.73) or between each
pair of compounds (mean = 0.01). (d) (i) Precision-recall analysis to evaluate the ability
of profile correlation to predict if two profiles were generated by the same compound, for
0 and 1 SVD component-removed datasets. (ii) Receiver-operator characteristic analysis
on compound replicate correlations for 0 and 1 SVD component-removed datasets.
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2.2 Materials
2.2.1 Equipment
• Hardware: 64-bit computer running Linux (or Mac OS), with at least 4 GB of
RAM (8 GB recommended); the software may run on Windows with few or no
modifications, but we have not tested it in a Windows environment.
• Python 2.7, with the following libraries (required version number in parenthe-
ses): numpy (≥1.12.1), scipy (≥0.19.0), pandas (≥0.20.1), matplotlib (≥2.0.2),
scikit-learn (≥0.18.1), biopython (≥1.68), fastcluster (≥1.1.20), pyyaml (≥ 3.11),
networkx (≥1.11)
– The Conda environment manager for Python works well for in-
stalling Python and the above packages (https://conda.io/docs/user-
guide/install/index.html). If using Conda, packages can be obtained from
the Anaconda Cloud (https://anaconda.org).
• BEAN-counter software (available at https://github.com/csbio/BEAN-counter,
see Equipment Setup)
• Java TreeView (http://jtreeview.sourceforge.net/); this is the recommended ap-
plication for viewing clustered heat maps of interaction scores
• Data and configuration files (available from: http://csbio.cs.umn.edu/BEAN-
counter/, see equipment setup for download details)
2.2.2 Equipment setup
Downloading and installing the software
Python version 2.7 and the previously listed libraries (see Equipment) must be installed
in order to run the BEAN-counter software. If you are not familiar with the specifics
of installing Python and the required libraries on your system, contact your system
administrator for help.
BEAN-counter is hosted on GitHub at https://github.com/csbio/BEAN-counter.
The most up-to-date stable release can be found at https://github.com/csbio/BEAN-
counter/releases/. At the time of this protocol’s submission, the latest tagged release
is version 2.6.0 (please be sure to obtain the most up-to-date release). The following
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commands will download this version of the software to the user’s home directory and
unzip it (lines beginning with ’$’ indicate commands run from the terminal):
$ cd ~
$ wget https://github.com/csbio/BEAN-counter/tags/2.6.0.tar.gz .
$ tar -xzvf BEAN-counter-2.6.0.tar.gz
More advanced users can directly fork the GitHub repository to keep up with the
latest updates.
BEAN-counter requires an environment variable named BARSEQ_PATH that pro-
vides the path to the folder containing the BEAN-counter code. In the bash shell in
Linux and using the previous example, this is performed with the following command:
$ export BARSEQ_PATH=$HOME/BEAN-counter-2.6.0
Add the BEAN-counter master_scripts/ directory to your PATH environment vari-
able. This enables you to use the commands in this directory while working in another
directory (specifically, the directory specific to your screen), and is performed with the
following command:
$ export PATH=$PATH:$HOME/BEAN-counter-2.6.0/master_scripts
These two commands can be added to your ~/.bashrc file (or the relevant script that
is executed each time a new terminal is opened) so that you do not have to execute
them before each analysis session. Further tutorials on setting environment variables
are outside the scope of this protocol.
Once you know the technical format of your next screen (specifically, the pool
of barcoded mutants and the structure of the PCR amplicons), create the ap-
propriate mutant barcode table and amplicon structure files and add them to
their respective folders inside the BEAN-counter directory (data/gene_barcode_files/
and data/amplicon_struct_files/ ). We have made these files available at
http://csbio.cs.umn.edu/BEAN-counter/ for the different types of screens we have per-
formed. You may find these helpful if performing a screen in a similar format to ours
or attempting to reproduce one of our analyses.
2.3 Procedure
This procedure is a walk-through on a subset of the recently-published dataset con-
taining chemical-genetic interaction profiles for nearly 14,000 compounds across a di-
agnostic collection of 310 deletion mutants. Where necessary, we differentiate between
instructions specific to processing the example dataset and those applicable to dataset
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processing in general. A shell script containing all commands in the following procedure
is provided as supplementary manual 2.1. Steps marked with TROUBLESHOOTING
possess corresponding entries in table 2.1.
1. After installing BEAN-counter and its prerequisites, download the rel-
evant gene barcode table and amplicon structure file into the appropri-
ate directory inside the BEAN-counter data/ directory. In this case,
we download the gene barcode table for the diagnostic collection of 310
deletion mutants and the relevant amplicon structure file (provided as
supplementary data 1 and 2, respectively)
$ cd $HOME/BEAN-counter-2.6.0
$ wget http://csbio.cs.umn.edu/BEAN-counter/gene_barcode_files
/Sc_hap_del_mp_hs_v1.txt -P data/gene_barcode_files
$ wget http://csbio.cs.umn.edu/BEAN-counter/amplicon_struct_fi
les/Sc_hap_MP-WG-HET_ix10.yaml -P data/amplicon_struct_files
2. While designing your screen and/or while the PCR amplicons are se-
quenced, begin the process of setting up a directory that will contain
all of the raw and processed data. In this protocol, all subsequent com-
mands assume that the user’s working directory is <dir>. To create
and enter this directory, use the following commands:
$ mkdir -p <dir>
$ cd <dir>
3. Organize the working directory into different subfolders and generate
the required configuration, sample information, and gene barcode files.
In this protocol, the interactive setup_screen.py script will assist you
with this process. Enter the following command and responses to the
prompts (displayed as “>>>prompt: user_response”) to set up your
working directory (if ENTER, do not specify any response – the default
option will be used):
$ setup_screen.py -i
>>>config_file: ENTER
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>>>output_folder: ENTER
>>>lane_location_file: ENTER
>>>sample_table_file: ENTER
>>>gene_barcode_file: Sc_ hap_del_mp_hs_v1.txt
>>>amplicon_struct_file: Sc_hap_MP-WG-HET-MoBY.yaml
>>>num_lanes: 9
>>>new_sample_table: False
>>>verbosity: ENTER
>>>sub_screen_column: ENTER
>>>Would you like to specify advanced parameters? (y/n): n
>>>clobber: ENTER
If you make a mistake and must run setup_screen.py again, you may need
to set the “clobber” parameter to True in order to overwrite the original
output.
4. In step 3, the location of the sample information table was set to be
<dir>/sample_table/sample_table.txt, but the table itself was not cre-
ated by the script because we have provided it for you. Copy the sample
information table to <dir>/sample_table/ using this command:
$ wget http://csbio.cs.umn.edu/BEAN-counter/example_dataset/sa
mple_table/sample_table.txt -P sample_table
The sample information table is also provided as supplementary data 3.
5. Transfer the raw data for each lane into their respective directories in
<dir>/raw/. For this protocol, the following commands will download
the raw data for the first two sequencing lanes into its destination di-
rectory (there are 9 lanes in total: lane1–lane9):
$ wget http://csbio.cs.umn.edu/BEAN-counter/example_dataset
/raw/lane1/lane1_R1.fastq.gz -P raw/lane1
$ wget http://csbio.cs.umn.edu/BEAN-counter/example_dataset
/raw/lane2/lane2_R1.fastq.gz -P raw/lane2
BEAN-counter will read uncompressed fastq files as well as gzip, bzip2,
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(a) (b)
Figure 2.6: Typical barcode and index tag abundance distributions. Substantial devi-
ations from these distributions could be the result of errors in experimental or compu-
tational procedures and should be investigated. (a) Distribution of reads across index
tags. (b) Distribution of reads across genetic barcodes.
and zip-compressed files. These files must possess the “.fastq” extension
(and the additional relevant extension if compressed). Data files can
also be symbolically linked to their relevant raw data folders.
6. Perform the first round of interaction scoring from start to finish using
this command:
$ process_screen.py config_files/config_file.yaml
7. TROUBLESHOOTING
After the fastq parsing substep has completed, review the reports for
each sequencing lane contained in <dir>/output/reports/. In the typical
use case, most reads (> 80%) will possess the common primer sequence,
and most of these reads (> 80%) will map to both a mutant and a con-
dition. However, if the library of PCR amplicons from your experiment
was mixed 50/50 with a completely different library before sequencing,
then nearly half (> 40%) of the reads should possess the common primer
sequence. Typical distributions of reads mapped to each index tag and
barcode are shown in figure 2.6.
8. Once all interaction scoring substeps have completed, generate clustered
heat maps of the interaction scores. For this command, the parame-
ters after the config_file specify the columns of the barcode table (e.g.
‘Gene_name’) and sample information table (e.g. ‘name’), respectively,
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to be included in the row and column names of the heat map. Note that
only commas (not spaces) are allowed between the column names.
$ visualize_zscore_matrices.py config_files/config_file.yaml
Gene_name,Strain_ID screen_name,expt_id,name,lane,index_tag
_plate,index_tag_well,index_tag
9. Using Java TreeView, open the clustered heat map containing the final
interaction scores located at <dir>/output/interactions/all_lanes_filte
red/all_lanes_filtered_scaled_dev.cdt and browse the interaction data
to become familiar with it (figure 2.7a, i). Steps 10-15 will guide
you through manual quality control determinations.
10. TROUBLESHOOTING
First, evaluate the quality of the positive control conditions (figure 2.7a,
ii). This can be done in Java TreeView by searching for “arrays” with
the names of the positive control conditions. If four positive controls
were screened in every plate as recommended, each of these four condi-
tions should possess a large, easily-identifiable cluster in the heat map.
For this dataset, the four positive controls are Benomyl, Bortezomib,
Micafungin, and MMS.
11. TROUBLESHOOTING
Check the quality of the negative control conditions and mutant behav-
ior across these conditions (figure 2.5b). This can be done within Java
TreeView by searching for “arrays” with containing the string “DMSO”
and choosing the “Summary pop-up” option. If a mutant shows strong
interactions in more than a few of the negative control profiles, it is
likely that many of this mutant’s interactions in the complete dataset
are false positives. Keep track of the ‘Strain_ID’s of all such mutants
so they can be removed later. In this dataset, we flag 16 mutants for re-
moval based on their behavior in the negative control conditions. Their
identities are given in figure 2.7a, iii and supplementary data 4 (where
the value in the “include?” column is FALSE).
12. TROUBLESHOOTING
Likewise, flag negative control conditions for removal (keep track of
the ‘expt_id’ value) if they possess signal that is uncharacteristic of
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(a)
(b) (c)
Figure 2.7: Manual examination of the dataset to flag mutants and conditions for re-
moval. (a) (i) Chemical-genetic interaction profiles before manual removal of conditions
and mutants. (ii) Positive control conditions. MMS: methyl methanesulfonate. (iii)
Mutants flagged for removal from the dataset based on high variability of interaction
signal (resulting in interactions with most negative control conditions) and undesired
behavior in conditions of high growth inhibition (< 50% growth compared to negative
control conditions). (iv) Conditions flagged for manual removal from the dataset. Three
main classes were identified (from left to right): 1) treatment conditions that exhibit
almost exclusively positive interactions; 2) negative control profiles that exhibit a com-
mon signal that is inconsistent compared to other negative control profiles; and 3) a
combination of both negative control and treatment profiles that share a similar set of
strong, negatively interacting strains. (b) Interaction profiles for negative experimen-
tal control conditions (DMSO). (c) Chemical-genetic interaction profiles after manual
removal of conditions and mutants.
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the other negative control profiles and is not observed in the complete
dataset (these would be considered outlier control conditions). In this
dataset, we flag 24 negative control conditions for removal, and their
identities are given in supplementary data 5 (where the values in the
“include?” and “control?” columns are False and True, respectively).
13. Now, examine the entire matrix of interactions to identify mutants that
should be removed based on their behavior in non-control conditions.
Flag mutants that appear to interact with most conditions. If post-
processing steps will be performed, it may also be useful to flag mu-
tants that demonstrate extremely large positive interaction scores if the
conditions that induce these scores are important to retain (the large
scores can confound post-processing procedures). In the context of the
diagnostic 310 mutant collection, we often remove the gtr1 and avt5
mutants for this reason. For the example dataset, the strains with un-
acceptable behavior across all conditions were already flagged due to
their behavior in negative control conditions.
14. Additionally, flag conditions that do not appear to have valid interaction
profiles. This instruction is intentionally subjective, as the definition of
a “valid interaction profile” will depend on the mutant collection and
experimental setup. One commonly observed pattern among profiles
that we deem as invalid consists primarily of zero scores that are mixed
with a seemingly random set of large positive interaction scores. From
this dataset, we remove such profiles (figure 2.7a, iv, left-most columns)
as well as treatment conditions with profiles similar to the outlier nega-
tive control profiles (figure 2.7a, iv, right-most columns). In all, we flag
12 non-control conditions for removal.
PAUSEPOINT
Before continuing with the removal of manually-flagged conditions and mutants from
the dataset, be sure to document these signals and reflect on what might have caused
them. If you did not perform the experiments yourself, consult with your experimentalist
colleague(s) to identify possible links between the signals and variations in experimental
conditions. Determine if future experiments can be performed in a way that reduces
the presence of these signals. Additionally, take a closer look at conditions for which
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either the interaction profiles or the experimental conditions that generated them arouse
suspicion in your experimentalist colleague.
15. Once you have identified all of the mutants and conditions to be re-
moved from the dataset, proceed to modify the gene barcode table
(<dir>/barcodes/barcodes.txt) and the sample information table (<di
r>/sample_table/sample_table.txt) such that the entries in the ‘in-
clude?’ column are changed to “False” for the mutants and conditions
to be removed, respectively. For this protocol, the modified gene bar-
code and sample information tables are given as supplementary data 4
and 5, respectively. They can also be downloaded to the appropriate
locations using the following commands:
$ wget http://csbio.cs.umn.edu/BEAN-counter/example_dataset/ba
rcodes/barcodes_filtered.txt -P barcodes
$ wget http://csbio.cs.umn.edu/BEAN-counter/example_dataset/sa
mple_table/sample_table_filtered.txt -P sample_table
Be sure to modify <dir>/config_files/config_file.yaml so that it references
the filtered gene barcode and sample information tables.
16. After removing the flagged mutants and conditions, re-run the proce
ss_screen.py command using the --start 5 flag and the modified
config_file.yaml (see step 6). Proceed from step 8 of this procedure
(visualizing the dataset) and identify any further mutants or conditions
that should be removed from the dataset. For the example dataset, no
further iterations are needed.
$ process_screen.py --start 5 config_files/config_file.yaml
17. Re-run process_screen.py using the --start 2 flag to generate a fi-
nal dataset guaranteed to have been processed with exactly the same
parameters through all substeps (figure 2.7c).
$ process_screen.py --start 2 config_files/config_file.yaml
PAUSEPOINT
For a small-scale screen (tens of compounds), the analysis is likely complete at this
stage. The dataset is not large enough to check for batch effects and other systematic
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variation. One possible exception is the very next step, which checks profile correlations
among replicate conditions.
18. Check the correlations of replicate conditions (figure 2.8a). Here, the “-
incl not_pos_neg_control” argument tells the script to include only
treatment conditions (via the ‘not_pos_neg_control’ column in the
sample information table, which is “True” if the condition is not a posi-
tive or negative control), the “name” argument indicates that each batch
is defined by the ‘name’ column in the sample information table, and
“none” indicates the absence of any potential confounding batches.
$ check_batch_effects.py -incl not_pos_neg_control output/i
nteractions/all_lanes_filtered/all_lanes_filtered_scaled_de
v.dump.gz sample_table/sample_table_filtered.txt name none
The output of the script is written to the directory: <dir>/output/int
eractions/all_lanes_filtered/all_lanes_filtered_scaled_dev/name_eff
ect_eval.
19. Check for index tag-related batch effects (figure 2.8b). Only positive
control conditions are excluded from the analysis (“-incl not_pos_control”),
as this allows us to assess if negative control conditions tagged with the
same index tag are correlated with each other and contributing to the
overall batch effect. Also, “name” is specified as a potentially con-
founding batch, which ensures that no index tag is mapped to multiple
replicates of the same condition.
$ check_batch_effects.py -incl not_pos_control output/inter
actions/all_lanes_filtered/all_lanes_filtered_scaled_dev.du
mp.gz sample_table/sample_table_filtered.txt index_tag name
The output is written to: output/interactions/all_lanes_filtered/all_l
anes_filtered_scaled_dev/index_tag_effect_eval/.
20. Check for lane-related batch effects (figure 2.8c). As with the index tag
effect correction, negative control conditions are included in the analysis
but positive control conditions are not. Also, only one instance of each
condition name replicate is retained for each lane.
$ check_batch_effects.py -incl not_pos_control output/inter
actions/all_lanes_filtered/all_lanes_filtered_scaled_dev.du
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(a) compound replicates
(b) index tag sequence
(c) sequencing lane
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Figure 2.8: Analysis of same-compound, same-index tag, and same-lane correlations
to detect the presence of batch effects and uninformative signal. (a) (i) Histogram
showing the mean profile correlation (Pearson’s correlation coefficient) within each group
(“same compound,” mean = 0.75) or between groups (“different compound,” mean
= 0.13) of compound replicates. (ii) Precision-recall analysis of compound replicate
correlations. (iii) Receiver-operator characteristic of compound replicate correlations.
(b) (i) Histogram showing the mean profile correlation within each group (“same index
tag,” mean = 0.11) or between groups (“different index tag,” mean = 0.06) of conditions
amplified with the same indexed primer. (ii) Precision-recall analysis of conditions
amplified with the same indexed primer. (iii) Receiver-operator characteristic analysis of
conditions amplified with the same indexed primer. (c) (i) Histogram showing the mean
profile correlation within each group (“same lane,” mean = 0.11) or between groups
(“different lane,” mean = 0.05) of conditions sequenced in the same HiSeq lane. (ii)
Precision-recall analysis of conditions sequenced in the same HiSeq lane. (iii) Receiver-
operator characteristic analysis of conditions sequenced in the same HiSeq lane. The
format of the plots was modified slightly from the default BEAN-counter output.
mp.gz sample_table/sample_table_filtered.txt lane name
The output is written to: output/interactions/all_lanes_filtered/all_l
anes_filtered_scaled_dev/lane_effect_eval/.
21. Next, check the average correlation between non-replicate conditions
(figure 2.8a). For the example dataset, this correlation is 0.13, but it
should theoretically be close to zero unless, for example, the data are
from a library of functionally similar compounds. These correlations
are explained by the signature that is present in 25% of mutants and
~20% of conditions and can be attenuated by removing the first SVD
component. For general dataset processing, you will have to decide if
this signature should be removed before or after any observed batch
effects. Here, no batch effects are observed, so we proceed with SVD
component removal. The following command creates a new “stacked
matrix” dataset that contains 5 matrices, each possessing a version of
the dataset with 0 to 4 SVD components removed:
$ svd_correction.py -incl not_pos_control output/interactio
ns/all_lanes_filtered/all_lanes_filtered_scaled_dev.dump.gz
sample_table/sample_table_filtered.txt 4 output/svd_correct
ion
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22. Generate clustered heat maps of each of the 0 to 4 SVD component-
removed datasets (figures 2.9a and 2.9b).
$ visualize_stacked_zscore_matrices.py output/svd_correctio
n/svd_corrected_datasets.dump.gz svd_correctionbarcodes/ba
rcodes_filtered.txt sample_table/sample_table_filtered.txt
Gene_name,Strain_ID screen_name,expt_id,name,lane,index_tag
_plate,index_tag_well,index_tag
The resulting clustered heat maps are in this directory: output/svd_co
rrection/CDTs. Browse them to become familiar with the outcome of
SVD component removal.
23. Now, re-examine the replicate condition correlations on the data from
which 0 to 4 SVD components have been removed (figures 2.9c and 2.9d).
$ check_batch_effects.py -incl not_pos_neg_control output/s
vd_correction/svd_corrected_datasets.dump.gz sample_table/s
ample_table_filtered.txt name none
The output is written to: output/svd_correction/name_effect_eval/.
Notice that the largest increase in separation of the same-name and
different-name condition correlations comes from removing the first SVD
component and that the distribution of non-replicate correlations is now
centered very close to zero (mean = 0.02).
24. Extract the dataset with 1 SVD component removed, generate a clus-
tered heat map, and export it to text for further analyses outside the
scope of this protocol.
$ extract_dataset.py output/svd_correction/svd_corrected_da
tasets.dump.gz 1
$ visualize_dataset.py output/svd_correction/svd_corrected_
datasets/1_components_removed.dump.gz final_dataset barcode
s/barcodes_filtered.txt sample_table/sample_table_filtered.
txt Gene_name,Strain_ID screen_name,expt_id,name,lane,index
_tag_plate,index_tag_well,index_tag
$ dataset_to_text.py output/svd_correction/svd_corrected_da
tasets/1_components_removed.dump.gz
The final clustered heat map is located here: output/svd_correction/svd
_corrected_datasets/1_components_removed/final_dataset.cdt. The
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(a) (b)
(c)
(d)
Figure 2.9: Removal of large, uninformative signature via singular value decomposition
(SVD). (a) Chemical-genetic interaction profiles after the first SVD component was
removed from the data. (b) Chemical-genetic interaction profiles after the first two
SVD components were removed from the data. (c) (i) Histogram showing the mean
profile correlation within each group (mean = 0.71) or between groups (mean = 0.02) of
compound replicates after removal of one SVD component. (ii) Same as (i), but for two
SVD components removed (within-group mean = 0.74, between-group mean = 0.01).
(d) (i) Precision-recall analysis of compound replicate correlations after removing 0 to 4
SVD components. (ii) ROC analysis of compound replicate correlations after removing
0 to 4 SVD components.
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final, text-formatted dataset is exported in the directory output/svd_co
rrection/svd_corrected_datasets/1_components_removed/ and is for-
matted as a matrix (matrix.txt) of interaction scores, a file (strains.txt)
of row identifiers (‘Strain_ID’) matching the rows of the matrix, and a
file (conditions.txt) of column identifiers (‘screen_name’ and ‘expt_id’)
matching the columns of the matrix. Alternatively, you can use the
--table flag for dataset_to_text.py to export the data to a single file in
table format, with the option of using the --value_name flag to specify
the name of the column that contains the interaction scores.
2.4 Timing
• Steps 1–4, setting up the working directory: < 5 min
• Step 5, transferring the raw sequencing data: variable, allow 1-2 h
• Step 6, initial round of interaction scoring: ~4 h (mostly parsing the fastq files,
~20 min per lane)
• Step 7, reviewing fastq parsing reports: <10 min
• Step 8, generating clustered heat maps: <5 min
• Steps 9–14, visualizing the data and flagging mutants/conditions for removal:
variable
• Step 15, modifying the gene barcode and sample information tables: <5 min
• Steps 16–17, reprocessing the dataset after removing mutants/conditions: <20
min
• Steps 18–20, checking replicate correlations and batch effects: <1 min computa-
tional time for each step, variable time for browsing output
• Steps 21–22, generating and visualizing SVD-corrected matrices: <5 min
• Step 23, checking replicate correlations on SVD-corrected output: <2 min com-
putational time, variable time for browsing output
• Step 24, generating final clustered heat map and text-formatted output: <1 min
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All timings were generated using an Intel Xeon E5-1620 CPU at 3.6 GHz, using 4
of 8 cores. The test dataset consists of 2592 conditions from 9 sequencing lanes (288
conditions per lane) subsampled from the full dataset of 38,400 conditions from 50 HiSeq
sequencing lanes (768 conditions per lane), screened against a pool of 310 mutants [34].
Datasets with more conditions, more mutants in the pool, and/or higher sequencing
depth will require more time to process. Processing time for the interaction scoring
component (substeps 2 and 6 of process_screen.py) does decrease with an increasing
number of cores, although the speedup is not linear.
2.5 Troubleshooting
If BEAN-counter encounters an error, it will most often print out an informative message
that will point you to the offending input. However, knowledge of the Python language,
and the numpy and pandas libraries in particular, will be useful in situations where
this is not the case. All scripts also accept verbosity arguments (either through the
main configuration file for process_screen.py or as a command line flag for the other
post-processing scripts) that specify the level of detail printed to the terminal while
the code is executing. You are welcome to post questions, errors, and bug reports to
the BEAN-counter Google Group (http://groups.google.com/d/forum/BEAN-counter)
as well as post issues and/or submit pull requests to the repository at https://github.c
om/csbio/BEAN-counter. Troubleshooting advice for individual steps can be found in
Table 1.
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Step Problem Possible reason Solution
7 Distributions of reads mapped to each
index tag or barcode deviate substan-
tially from those in figure 2.6. Alter-
natively, among the reads that match
the common primer sequence, less
than 50% map to index tags and ge-
netic barcodes.
Assuming the index tags and barcodes
are correct, issues may have occurred
with preparation of the sequencing li-
brary, particularly during the isolation
of genomic DNA or the PCR reaction.
First, ensure the index tag and bar-
code sequences are correct. Re-check
individual PCR reactions via a DNA
gel and re-prepare the sequencing li-
brary if necessary.
10 In the clustered heat map, all of the
positive control conditions from one
plate are absent from their respective
clusters and replaced by non-positive-
control conditions.
The plate was physically rotated
180Âř at some point during the ex-
periment or sequencing library prepa-
ration.
Change the condition names and
the ‘control?’ status in the sam-
ple information table to reflect the
flipped orientation of the plate in
question and reprocess the data
(process_screen.py --start 2).
10 In the clustered heat map, all of the
positive control conditions from one
plate exhibit weak interaction profiles
compared to the other plates
There may have been an issue during
the genomic DNA extraction, PCR
amplification, or agarose gel purifi-
cation for the samples in that plate.
Also, the stock solutions for the pos-
itive control compounds may need to
be remade.
Check the remaining conditions in the
plate to see if their profiles can be
trusted. If not, remove the entire plate
from the dataset. Re-do the experi-
ments or sequencing library prepara-
tion if desired.
55
Step Problem Possible reason Solution
11 When trying to view only the control
conditions using the “Summary
Popup” feature, Java TreeView
instead displays a clustered heat map
containing all conditions.
This is a bug in Java TreeView. It is
reproducible on a per-heat map basis
but not predictable.
Run the following commands to
generate a clustered heat map
containing only the control
conditions:
$ reduce_dataset.py --column
’control?’ output/interactions
/all_lanes_filtered/all_lanes_f
iltered_scaled_dev.dump.gz
sample_table/sample_table.txt o
utput/interactions/all_lanes_fi
ltered/all_lanes_filtered_scale
d_dev_DMSO.dump.gz
$ visualize_dataset.py output/i
nteractions/all_lanes_filtered/
all_lanes_filtered_scaled_dev_D
MSO.dump.gz DMSO_controls
barcodes/barcodes.txt
sample_table/sample_table.txt
Gene_name,Strain_ID screen_name
,expt_id,name,lane,index_tag_pl
ate,index_tag_well,index_tag
The desired heat map is here: <dir>
/output/interactions/all_lanes_filter
ed/all_lanes_filtered_scaled_dev_D
MSO/
12 Negative control conditions possess
strong interaction signal.
Conditions are mislabeled, issues
occurred during sequencing library
preparation, or control conditions
were contaminated with treatment
conditions.
Check to see if the plate is flipped (see
step 10 troubleshooting) and confirm
condition labeling. If this does not fix
the issue, remove the offending con-
ditions or mutants from the dataset.
If these conditions are part of a larger
group (such as a screening plate), con-
sider removing that entire group of
conditions from the dataset. If neces-
sary, re-prepare sequencing library or
perform experiment again.
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Step Problem Possible reason Solution
12 Negative control conditions cluster
into distinct groups that are associ-
ated with sample batches.
This is a batch effect. Score the interactions separately for
each batch. First, specify the
sample batch column of the sam-
ple information table as the value
for the sub_screen_column param-
eter in config_file.yaml. Then,
run process_screen.py with the
--start 2 flag.
Table 2.1: Troubleshooting table.
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2.6 Anticipated results
BEAN-counter computes interaction z-scores that represent the difference between mu-
tants’ observed and expected abundances in units of standard deviations. For analysis
of individual interactions (e.g. to identify mutants that confer resistance to a drug), we
recommend a strict cutoff of ± 5 to focus on the mutants that have clearly deviated
from their expected fitness values. We have found that negative interactions contain
the vast majority of the functional information from these interaction screens.
Importantly, the entire set of interactions for a perturbation across all mutants com-
prises an interaction profile, which is a high-dimensional, quantitative representation
of gene (or chemical) function. Similarity between two interaction profiles implies that
similar functions have been perturbed in the cell, a property you can use to identify, for
example, novel compounds that have similar modes of action to previously-characterized
compounds. To gain further insights into the cellular processes affected by your pertur-
bation(s), you can perform a Gene Ontology enrichment analysis on the set of interact-
ing mutants or use a tool such as CG-TARGET [74] to predict the perturbed cellular
bioprocesses using genetic interaction profiles as a functional reference (if the genetic
interaction profiles are available for your species of interest) [74]. Using CG-TARGET,
we identified over 1500 chemical compounds with high-confidence mode-of-action pre-
dictions from our large-scale screen of nearly 14,000 compounds, validated subsets of
these predictions in orthogonal assays, and used these predictions to make broader infer-
ences about the cellular bioprocesses that are more or less easily perturbed by chemical
compounds [34, 74].
2.7 Competing financial interests
A license is required to use the BEAN-counter software (http://z.umn.edu/beanctr). It
is free for academic use and must be purchased on a per-project basis for commercial
use.
2.8 Data availability
All data needed to process the example dataset into chemical-genetic interaction scores
are available at http://csbio.cs.umn.edu/BEAN-counter/example_dataset/. These data
are a subset of the complete large-scale chemical-genetic interaction dataset, which is
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available from http://mosaic.cs.umn.edu, the supplementary material of the associated
article [34], or the corresponding author upon reasonable request.
2.9 Code availability
The source code for BEAN-counter is available from https://github.com/csbio/BEAN-
counter.
2.10 Supplementary material
2.10.1 Supplementary data
Supplementary data 2.1. Gene barcode table that maps the genetic barcodes observed
in the sequencing data to their respective 310 mutant strains screened in the example
dataset.
Supplementary data 2.2. Amplicon structure file that defines how to parse sequencing
reads from experiments that used forward PCR primers with 10bp index sequences to
amplify the up-barcodes from the S. cerevisiae deletion collection. This file is speci-
fied within the configuration file and its structure is explained in both chapter A and
figure 2.3.
Supplementary data 2.3. Sample information table that maps the forward PCR primer
indexing sequences (“index tags”) to the different conditions they were used to tag in
the example dataset.
Supplementary data 2.4. Same as the gene barcode table from Supplementary data 2.1,
but with 16 mutant strains flagged for removal from the dataset during substep 5 of
process_screen.py.
Supplementary data 2.5. Same as the sample information table from Supplementary
data 2.3, but with 36 conditions flagged for removal from the dataset during substep 5
of process_screen.py.
2.10.2 Supplementary manuals
Supplementary manual 2.1. Shell script containing all commands invoked in the proce-
dure for processing the example dataset.
Chapter 3
Predicting bioprocess targets of
chemical compounds through
integration of chemical-genetic
and genetic interaction networks
3.1 Introduction
The ability to discover chemical compounds with desirable and interesting biological
activity is essential for understanding how compounds and biological systems interact.
Chemical-genetic interaction screening provides a means to characterize the biological
activity of compounds in an unbiased manner by measuring the response of defined gene
mutants to these molecules [24–27, 31–33, 43]. A chemical-genetic interaction profile
refers to the set of gene mutations that confer sensitivity (a negative chemical-genetic
interaction) or resistance (a positive interaction) to a compound and provides functional
insights into the compound’s mode(s) of action.
Similar to chemical-genetic interactions, genetic interactions identify pairs of gene
mutations whose combined effects are more or less severe than expected given the phe-
notypes of the individual mutants. In S. cerevisiae, the vast majority of all possible
gene double-mutant pairs have been constructed and scored for fitness-based genetic
interactions, yielding a global compendium of genome-wide genetic interaction profiles
that quantitatively describe each gene’s function. Similarity between two genes’ genetic
interaction profiles implies that these genes perform similar cellular functions, enabling
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the functional annotation of previously unannotated genes and the construction of a
global hierarchy of cellular function [27, 28].
Chemical-genetic and genetic interaction profiles derived from fitness measurements
contain analogous functional information on the cellular effects of chemicals and gene
mutations, respectively. Similarity between these two types of profiles therefore implies
that the respective chemical(s) and gene mutation(s) perturb similar functions in the
cell, which means that a compound’s chemical-genetic interaction profile should resemble
the genetic interaction profile(s) of its cellular target or target processes (figure 3.1) [27,
31]. The global genetic interaction network in S. cerevisiae therefore provides a resource
for interpreting chemical-genetic interaction profiles across a broad range of cellular
function. Importantly, this approach to interpretation does not depend on reference
chemical-genetic interaction profiles and thus enables the discovery of compounds with
novel modes of action.
Recent advances in DNA sequencing technology have paved the way for high-throughput
chemical-genetic interaction screening via multiplexed analysis of pooled, genetically-
barcoded mutant libraries grown in the presence of compound [26, 29, 33]. This would
enable, for example, functional profiling of compounds earlier in the drug discovery pro-
cess, with insights from these screens providing a means to prioritize compounds before
investing resources into their development as drugs. Despite the recent generation of
thousands of chemical-genetic interaction profiles across multiple studies [26, 33] and
the profound opportunities for genetic interaction-powered functional characterization of
thousands of novel compounds, the integration of chemical-genetic and genetic interac-
tion profiles has only been performed in the context of relatively small studies [27, 31].
A systematic investigation using a large-scale chemical-genetic interaction dataset is
therefore necessary to assess the compatibility between chemical-genetic and genetic in-
teraction profiles, with an emphasis on the ability of a genetic interaction-based method
to control the false discovery rate (of critical importance in high-throughput chemical
screening) and thereby prioritize compounds with the highest-confidence predictions.
Here, we present the use of genetic interaction profiles to systematically interpret
chemical-genetic interaction profiles on a large scale. Specifically, we developed a com-
putational method, called CG-TARGET (Chemical Genetic Translation via A Reference
Genetic nETwork), that integrates chemical-genetic and genetic interaction profiles to
predict the biological processes perturbed by compounds. We applied this method to a
high-throughput chemical-genetic interaction screen of nearly 14,000 compounds in S.
cerevisiae [34], using profiles from the global yeast genetic interaction network [27, 28] to
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interpret the chemical-genetic interaction profiles. CG-TARGET recapitulated known
information for well-characterized compounds and showed a marked improvement in the
ability to control the false discovery rate for novel compound mode-of-action discovery
compared to a baseline approach. Additionally, we experimentally validated two differ-
ent mode-of-action predictions, one in an in vitro system using mammalian proteins,
confirming both the accuracy of the predictions for novel compounds and the poten-
tial to translate these predictions across species. CG-TARGET is available, free for
academic use, at https://github.com/csbio/CG-TARGET.
3.2 Results
3.2.1 Overview of datasets used in this study
We obtained chemical-genetic interaction profiles from a recent large-scale chemical-
genetic interaction screen in S. cerevisiae [34]. This screen consisted of two batches,
the first of which containing 9850 compounds from the RIKEN Natural Product De-
pository [75] (the “RIKEN” screen) and the second containing 4116 compounds from
the NCI Open Chemical Repository’s compound libraries, the NIH Clinical Collection,
and GlaxoSmithKline’s Published Kinase Inhibitor Set (the “NCI/NIH/GSK” screen)
[76]. The compounds in the RIKEN screen consisted primarily of natural products and
natural product derivatives – most of which were previously uncharacterized – and ~200
approved drugs and chemical probes, a subset of which we used to assess the perfor-
mance of CG-TARGET as their modes of action in yeast are well-characterized. The
compounds in the NCI/NIH/GSK screen were more studied – having been tested against
the NCI-60 cancer cell line panel (the NCI collections), tested in clinical trials (the NIH
Clinical Collection) or designed and characterized as inhibitors against human kinases
(GSK) – but many of these compounds’ specific modes of action remain uncharacter-
ized. The final datasets consisted of 8418 chemical-genetic interaction profiles from the
RIKEN screen and 3565 from the NCI/NIH/GSK screen, which were obtained using a
diagnostic set of approximately 300 haploid gene deletion mutants that were optimally
selected to capture most of the information in the complete S. cerevisiae non-essential
deletion collection [34, 44]. Both datasets also contained a large set of experimental
control profiles (5724 and 2128 for the RIKEN and NCI/NIH/GSK screens, respec-
tively), in which the yeast were only treated with the solvent control (DMSO). Each
profile contains z-scores that reflect the deviation of each strain’s observed fitness from
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expected fitness in the presence of a compound.
Genetic interaction profiles were obtained from a recently assembled, genome-wide
compendium of genetic interaction profiles in S. cerevisiae [27]. These profiles were
generated by systematically constructing and analyzing the fitness of haploid double
mutant strains and consist of epsilon scores that reflect the deviation of each double
mutant’s observed fitness from that expected given the single mutant fitness values,
assuming a multiplicative null model [73]. The construction of each profile involved
crossing the mutant for the “query” gene into a genome-wide array of mutants, and we
mapped the query genes to Gene Ontology biological process terms [77, 78] to define the
bioprocess targets of compounds. Profiles were filtered to the ~35% with the highest
signal (see Materials and Methods).
3.2.2 Predicting perturbed bioprocesses from chemical-genetic inter-
action profiles
We developed CG-TARGET (Chemical Genetic Translation via A Reference Genetic
nETwork) to predict the biological processes perturbed by compounds in our recently-
generated dataset of ~12,000 chemical-genetic interaction profiles (figure 3.1). CG-
TARGET requires three input datasets: 1) chemical-genetic interaction profiles; 2)
genetic interaction profiles; and 3) a mapping from the query genes in the genetic inter-
action profiles to gene sets representing coherent bioprocesses. Predicting the biopro-
cesses perturbed by a particular compound involves four distinct steps. First, a control
set of resampled chemical-genetic interaction profiles is generated, each of which con-
sists of one randomly-sampled interaction score per gene mutant across all compound
treatment profiles in the chemical-genetic interaction dataset; these profiles thus provide
a means to account for variance in each mutant strain observed upon treatment with
bioactive compound but not upon treatment with experimental controls (DMSO with
no active compound). Second, scores reflecting both the strength of each compound’s
chemical-genetic interaction profile and its similarity to the profile of each gene mutant
are obtained by computing an inner product between all chemical-genetic interaction
profiles (comprising compound treatment, experimental control, and random profiles)
and all L2-normalized query genetic interaction profiles. Third, these “gene-level” pre-
diction scores are aggregated into bioprocess predictions; a z-score and empirical p-value
for each compound-bioprocess prediction are obtained by mapping the gene-level pre-
diction scores to the genes in the bioprocess of interest and comparing these scores to
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Figure 3.1: Overview of the integration of chemical-genetic and genetic interaction net-
works for bioprocess target prediction using CG-TARGET. Chemical-genetic interaction
profiles, obtained by measuring the sensitivity or resistance of a library of gene mutants
to a chemical compound, are compared against genetic interaction profiles consisting
of double mutant interaction scores. The resulting similarities are aggregated at the
level of biological processes to predict the bioprocess(es) perturbed by the compound.
Better agreement between chemical-genetic and genetic interaction profiles leads to
stronger bioprocess predictions. Each blue box represents a negative chemical-genetic
(i.e. sensitivity) or genetic interaction, while each black box represents the absence of
an interaction. Stronger bioprocess predictions are depicted with a darker red.
those from shuﬄed gene-level prediction scores and to distributions of the scores derived
from experimental control and resampled profiles. Finally, the false discovery rates for
these predictions are estimated by comparing, across a range of significance thresholds,
the frequency at which experimental control and randomly resampled profiles predict
bioprocesses versus that of compound treatment profiles (see Materials and Methods).
3.2.3 Application to and evaluation on large-scale chemical-genetic
interaction data
To provide a baseline method for benchmarking the performance of CG-TARGET on
these large screens, we implemented a simple, enrichment-based approach for predict-
ing bioprocess-level targets. The enrichment-based approach was designed to predict
bioprocess-level targets by testing for the enrichment of GO biological processes among
the top-n gene-level prediction scores for each compound. For the following compar-
isons, CG-TARGET was compared to top-20 enrichment, which showed the best overall
performance across a range of values of n (figure C.1).
We applied CG-TARGET to the RIKEN and NCI/NIH/GSK chemical-genetic in-
teraction screens, identifying 848 out of 8418 compounds (10%) from the RIKEN screen
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and 705 of 3565 compounds (20%) from the NCI/NIH/GSK screen with at least one
prediction that achieved false discovery rates of 25 and 27%, respectively (referred to
as “high-confidence” compounds and predictions) (table 3.1, figure 3.2). In all cases,
the false discovery rates derived from resampled profiles were more conservative than
those derived from experimental controls, suggesting that some sources of variance in
each gene mutant’s interaction scores arose only upon treatment with compound and
therefore could not be corrected using only solvent controls. Focusing on the results
from the RIKEN screen, CG-TARGET substantially outperformed the baseline method
with regard to the number of compounds that possessed at least one high-confidence
bioprocess prediction (FDR ≤ 25%). Compared to the 848 high-confidence compounds
identified by CG-TARGET, top-20 enrichment only identified seven compounds that
met this confidence threshold, and zero with a false discovery rate less than 21% (fig-
ure 3.3a).
Dataset RIKEN NCI/NIH/GSK
FDR cutoff p-value number of compounds p-value number of compounds
0.00 < 2 × 10-5 434 < 2 × 10-5 352
0.05 2 × 10-5 505 4 × 10-5 405
0.10 8 × 10-5 598 1.6 × 10-4 494
*0.25 2.8 × 10-4 848 4.7 × 10-4 705
*This cutoff is 0.27 for the NCI/NIH/GSK dataset
Table 3.1: The number of compounds discovered at selected false discovery rates upon
application of CG-TARGET to data from two large-scale chemical-genetic interaction
screens. The “RIKEN” screen consisted of 8418 total compounds from the RIKEN
Natural Product Depository, and the “NCI/NIH/GSK” consisted of 3565 compounds
across 6 chemical compound collections from the National Cancer Institute, National
Institutes of Health, and GlaxoSmithKline.
CG-TARGET was also benchmarked against the baseline method using two different
measures of prediction accuracy. The first accuracy-based evaluation was performed on
genetic interaction profiles with added noise, which provided a means to both simulate
chemical-genetic interaction profiles and annotate them with gold-standard GO biolog-
ical process annotations for evaluation. For the second accuracy-based evaluation, we
curated a set of gold-standard compound-bioprocess annotations from the literature for
35 compounds from the RIKEN screen and evaluated the ranks of the gold-standard
65
(a) (b)
(c) (d)
Figure 3.2: Rate of compound discovery and control of the false discovery rate for
the prediction of bioprocesses from chemical-genetic interaction profiles. Perturbed
bioprocesses were predicted using CG-TARGET for compounds, negative controls
(DMSO), and resampled chemical-genetic interaction profiles from the RIKEN and
NCI/NIH/GSK datasets. (a) The number of compounds, experimental controls, and
randomly resampled chemical-genetic interaction profiles discovered with at least one
bioprocess prediction passing the given significance thresholds, for the RIKEN dataset.
(b) DMSO and resampled profile-derived estimates of the false discovery rate of bi-
ological process predictions, for the RIKEN dataset, given the number of discovered
compounds. Values were calculated from (a). (c–d) Same as (a–b), respectively, but for
the NCI/NIH/GSK dataset.
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(a) (b) (c)
Figure 3.3: Performance comparison of CG-TARGET versus a baseline enrichment ap-
proach. Perturbed bioprocesses were predicted using both CG-TARGET and a method
that calculated enrichment on the set of each compound’s 20 most similar genetic in-
teraction profiles (“top 20”). (a) Bioprocess prediction false discovery rate estimates
derived from resampled chemical-genetic interaction profiles, performed on compounds
from the RIKEN dataset. (b) Precision-recall analysis of the ability to recapitulate
gold-standard annotations within the set of top bioprocess predictions for ~4500 simu-
lated compounds. Each simulated compound was designed to target one query gene in
the genetic interaction network and thus inherited gold-standard biological process an-
notations from its target gene. (c) For each of 35 well-characterized compounds in the
RIKEN dataset with literature-derived, gold-standard biological process annotations,
we determined the rank of its gold-standard bioprocess within its list of predictions.
The number of compounds for which a given rank (or better) was achieved is plotted.
The grey ribbons represent the median, interquartile range (25th to 75th percentiles),
and 95% confidence interval of 10,000 rank permutations.
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bioprocesses within each compound’s list of bioprocess predictions.
CG-TARGET performed comparably to the best-performing enrichment-based meth-
ods using our measures of accuracy. This is first shown in the evaluation of these
methods’ respective abilities to predict a gold-standard annotated bioprocess as the
top prediction for each simulated chemical-genetic interaction profile. Specifically, CG-
TARGET performed nearly as well as the top-20 enrichment-based method across both
low and high recall values (figure 3.3b). Both methods captured a gold-standard annota-
tion as the top predicted bioprocess for approximately 34% of the simulated compounds
(33.4% and 35.6% for CG-TARGET and top-20 enrichment, respectively), which rep-
resented more than a 22-fold enrichment over the background expectation of 1.5% (the
average number of gold-standard bioprocess annotations per simulated compound di-
vided by the number of bioprocesses).
Secondly, for the 35 gold-standard compounds with known target bioprocesses,
we observed that both methods captured the gold-standard bioprocess for 6 and 21
(out of 35) compounds above ranks of 2 and 40 (out of 1329), respectively, with
slightly decreased performance for CG-TARGET between these rank thresholds (fig-
ure 3.3c,table 3.2). The significance of these rank values was evaluated by randomizing
the order of each compound’s bioprocess predictions 10,000 times and recalculating the
ranks. Both methods achieved similar results in this respect, with CG-TARGET and
the top-20 enrichment method respectively identifying 22 and 21 gold-standard com-
pounds with significantly better ranks than the random expectation. CG-TARGET
and top-20 enrichment also performed similarly when comparing the “effective rank”
of each compound’s gold-standard bioprocess, with CG-TARGET and top-20 enrich-
ment respectively identifying 20 and 22 compounds for which the gold-standard or a
closely-related bioprocess achieved a rank of 5 or better.
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CG-TARGET top-20 enrichment
Compound GO ID GO term Target pro-
cess rank
Rank signifi-
cance
Effective
rank
Target pro-
cess rank
Rank signifi-
cance
Effective
rank
5-Fluorocytosine GO:0032774 RNA biosynthetic process 27 0.0208 2 3 0.0027 1
Aclacinomycin A GO:0071103 DNA conformation change 1 *0.0009 1 86 0.0643 2
Acriflavine GO:0006259 DNA metabolic process 30 *0.0238 1 5 0.0042 1
Benomyl GO:0007017 microtubule-based process 2 *0.0015 2 8 0.0056 2
Blasticidin S GO:0006412 translation 772 0.5842 57 1311 0.9883 247
Bortezomib GO:0030163 protein catabolic process 3 0.0026 1 8 0.0084 1
Brefeldin A GO:0006888 ER to Golgi vesicle-mediated
transport
565 0.4207 32 1172 0.8818 169
Caffeine GO:0031929 TOR signaling cascade 1 *0.0007 1 1 0.0007 1
Calcofluor White GO:0071554 cell wall organization or biogene-
sis
624 0.4675 90 1127 0.8526 176
Camptothecin GO:0071103 DNA conformation change 16 *0.0114 4 6 0.0040 1
Cisplatin GO:0006260 DNA replication 134 0.1018 23 10 0.0071 1
Daunorubicin GO:0006260 DNA replication 70 0.0530 21 1210 0.9092 178
FK228 GO:0006325 chromatin organization 23 *0.0169 2 17 0.0131 2
Fluconazole GO:0008202 steroid metabolic process 114 0.0870 12 708 0.5333 187
Furazolidone GO:0006260 DNA replication 20 *0.0148 4 5 0.0034 1
Gramicidin S GO:0071554 cell wall organization or biogene-
sis
286 0.2186 39 1151 0.8705 173
Griseofulvin GO:0007017 microtubule-based process 1291 0.9718 227 750 0.5673 216
Haloperidol GO:0008202 steroid metabolic process 5 *0.0035 2 37 0.0279 6
Hedamycin GO:0006281 DNA repair 4 *0.0029 1 3 0.0022 1
Hydroxyurea GO:0006260 DNA replication 29 0.0239 6 1236 0.9269 1
Itraconazole GO:0008202 steroid metabolic process 234 0.1786 29 696 0.5239 193
Latrunculin B GO:0007010 cytoskeleton organization 11 *0.0083 1 8 0.0068 2
Micafungin GO:0071554 cell wall organization or biogene-
sis
495 0.3718 47 1134 0.8577 150
Mitomycin GO:0006260 DNA replication 15 0.0104 4 2 0.0014 1
MMS GO:0006281 DNA repair 3 *0.0022 1 3 0.0022 1
Mycophenolic acid GO:0006259 DNA metabolic process 1 *0.0006 1 3 0.0025 1
Nigericin GO:0048193 Golgi vesicle transport 157 0.1158 13 1 0.0007 1
Nocodazole GO:0007017 microtubule-based process 2 *0.0015 2 14 0.0100 3
Oligomycin A GO:0009268 response to pH 9 0.0075 2 2 0.0012 1
Podophyllotoxin GO:0007017 microtubule-based process 53 0.0411 6 800 0.6038 157
Polyoxin D GO:0071554 cell wall organization or biogene-
sis
1302 0.9788 225 1168 0.8828 173
Rapamycin GO:0031929 TOR signaling cascade 156 0.1140 8 422 0.3117 9
Trichostatin A GO:0006325 chromatin organization 23 *0.0169 3 24 0.0173 1
Tunicamycin GO:0070085 glycosylation 1 *0.0005 1 1 0.0005 1
Tyrocidine B GO:0071554 cell wall organization or biogene-
sis
5 *0.0040 1 2 0.0019 1
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CG-TARGET top-20 enrichment
Compound GO ID GO term Target pro-
cess rank
Rank signifi-
cance
Effective
rank
Target pro-
cess rank
Rank signifi-
cance
Effective
rank
Num with significant rank 22 21
Num with significant rank and
FDR < 25%
16 0
Table 3.2: Evaluation of predictions made by CG-TARGET, and comparison to a baseline enrichment approach, for literature-
derived, gold-standard compound-process annotations. The target bioprocess rank was determined by its position in the list of all
bioprocess predictions for each gold-standard compound, with the significance computed empirically by shuﬄing the bioprocesses
and re-computing the rank (bold p-values indicate significance, p < 0.05). Asterisks indicate cases in which the false discovery
rate of the gold-standard compound-process prediction was less than 25%. The “top-20 enrichment” approach was selected as a
baseline for comparison. The “effective rank” of a compound-bioprocess prediction represents the top rank within the compound’s
list of predictions among bioprocesses that are similar to the original bioprocess.
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Given that the main performance advantage of CG-TARGET occurred in the con-
text of controlling the false discovery rate, we conclude that the issues with simple
enrichment-based approaches primarily emerge not when predicting the most likely
perturbed bioprocess for any single compound but when comparing the strength and
significance of bioprocess predictions across compounds to prioritize compounds from
a large-scale chemical-genetic interaction screen. The aforementioned rank-based anal-
ysis of 35 gold-standard compound-bioprocess annotations supports this assertion, as
none of the 21 significantly-ranked annotations predicted by top-20 enrichment passed
the high-confidence threshold (FDR ≤ 25%), while 16 of the 22 significantly-ranked
annotations predicted by CG-TARGET did so (table 3.2). This difference between
CG-TARGET and enrichment-based methods likely emerges from the ability of weak
chemical-genetic interaction profiles to generate strong, statistically significant predic-
tions in the absence of methods (such as CG-TARGET) that account for general signals
that arise upon treatment with bioactive compound – especially if these signals are
amplified through their similarity to a large cluster of profiles in the genetic interac-
tion network. Thus, the substantially superior ability of CG-TARGET to control the
false discovery rate relative to the enrichment-based approach is a critical quality in the
context of large-scale, systematic compound screens.
3.2.4 Characterizing performance with respect to individual biopro-
cess terms
In addition to benchmarking CG-TARGET’s ability to prioritize gold-standard anno-
tated bioprocesses for specific compounds, we also benchmarked its ability to prioritize
compounds that perturb specific bioprocesses. Specifically, each GO term was evalu-
ated based on the ranks of the predictions for the simulated chemical-genetic interaction
profiles derived from genes annotated to that GO term. The 100 best-performing terms
represented a diversity of bioprocesses related to the proteasome, glycolipid metabolism,
DNA replication and repair, replication and division checkpoints, RNA splicing, micro-
tubules, Golgi and vesicle transport, and chromatin state (figure C.2). In contrast,
the 100 worst-performing terms were bioprocesses primarily related to carbohydrate,
nucleotide, and coenzyme/cofactor metabolism, as well as the mitochondria, trans-
membrane transport, and protein synthesis and localization (figure C.3). The best-
performing terms were also significantly smaller than the worst-performing ones (8 and
35 genes on average, respectively; rank-sum p-value < 2.2 × 10-16), which, given the fact
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that we would expect the power to increase with gene set size assuming the correspond-
ing set was still functionally coherent, suggests that our method identifies functionally
specific signal. Interestingly, the relatively poor performance of many metabolism-
related bioprocess terms may result from the fact that the chemical-genetic and genetic
interaction screens were both performed in relatively rich medium, precluding analysis
of condition-specific phenotypes for genes only required for growth in minimal medium.
While the set of best-performing terms did include a diverse range of bioprocesses, the
possibility of “blind spots” should always be considered when interpreting the predic-
tions made by CG-TARGET, as they may lead to false negative results that either
exclude interesting compounds (e.g. those whose primary modes of action affect carbo-
hydrate metabolism) or mask potential side effects of compounds whose primary modes
of action are more easily observed by this method.
3.2.5 Application of CG-TARGET to protein complexes refines func-
tional specificity of mode-of-action predictions
The prediction of perturbed protein complexes offers the opportunity to enhance the
specificity of GO biological process predictions (especially for overly-general bioprocess
terms) and investigate functional space not accessible by bioprocess annotations. As
such, we investigated the potential to expand the use of CG-TARGET to the prediction
of perturbed protein complexes. When CG-TARGET was applied to predict protein
complex targets for the RIKEN screen data, 714 compounds were identified with at
least one high-confidence (FDR ≤ 25%) complex prediction, 604 of which also occurred
in our original set of RIKEN compounds with high-confidence bioprocess predictions.
Similar, but not completely overlapping, sets of genes (Jaccard index > 0.2) contributed
to the top 5 of both bioprocess and protein complex predictions for more than one
third of these compounds (219; 36%); this suggested that the two standards possessed
both shared and complementary functional information that could be used to improve
predictions.
We observed that protein complex predictions narrowed down less-specific biopro-
cess terms and enabled predictions in places where bioprocess annotations were sparser.
To assess the ability to refine bioprocess prediction specificity, we mapped each pro-
tein complex to the childless bioprocess terms that completely encompassed them and
looked for substantial improvements in prediction strength from the bioprocess to its
protein complex “child.” We observed several instances in which bioprocess predictions
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with FDR > 25% (not high confidence) could be converted to high-confidence predic-
tions by refining the bioprocess term to a constituent protein complex. For example,
we saw substantial gains for the following bioprocess-to-complex combinations (sizes
in parentheses): “mRNA polyadenylation” (bioprocess, not high confidence; size 8) to
“mRNA cleavage factor matrix” (complex, high confidence; size 4); “cytoplasmic trans-
lation” (51) to “cytoplasmic ribosomal large subunit” (24); “vacuolar acidification” (14)
to “H+-transporting ATPase, Golgi/vacuolar” (5); and “regulation of fungal-type cell
wall organization” (8) to PKC pathway” (4) (supplementary table 3.1). Importantly, 27
of the 110 compounds with high-confidence protein complex but not bioprocess predic-
tions achieved their high-confidence status purely based on protein complex predictions
that enhanced the specificity of a non-high-confidence, overlapping bioprocess predic-
tion. Additionally, a separate set of 22 out of 110 compounds achieved high-confidence
status based solely on predictions to protein complexes that did not strongly overlap
with any bioprocesses (Jaccard < 0.2), demonstrating that the current set of protein
complex annotations enabled predictions in functional space that was not well captured
by a GO biological process term.
3.2.6 Assessing the compatibility of chemical-genetic and genetic in-
teraction profiles
Our evaluations of CG-TARGET support the premise of the method that genetic inter-
action profiles can be used as a tool to interpret chemical-genetic interaction profiles.
However, we sought to better understand the extent to which these two types of profiles
actually agree with one another, and if their systematic differences could shed light
on the limits of the core assumption behind our method (i.e. that chemicals mimic
the interaction profiles of their genetic targets). To investigate the compatibility of
chemical-genetic and genetic interaction profiles, we quantified the contribution of in-
dividual gene mutants in the chemical-genetic interaction profiles to the prediction of
individual bioprocesses. For a single compound and predicted bioprocess, these “impor-
tance scores” were obtained by 1) computing a mean genetic interaction profile across
all L2-normalized query genetic interaction profiles that possessed an inner product of
2 or higher with the chemical-genetic interaction profile and mapped to the predicted
bioprocess, and 2) computing the Hadamard product (elementwise multiplication) be-
tween this mean genetic interaction profile and the compound’s chemical-genetic inter-
action profile. Each score could have been positive, indicating agreement in the sign of
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chemical-genetic and genetic interactions for a gene mutant, or negative, indicating that
the interactions did not agree for that gene mutant. As such, the importance scores
summarized the concordance between chemical-genetic and genetic interaction profiles,
conditioned on an individual compound and a perturbed bioprocess of interest.
We use the prediction of NPD4142, a compound from the RIKEN Natural Prod-
uct Depository, to the “mRNA transport” bioprocess to illustrate how the overlap
between chemical-genetic and genetic interactions led to bioprocess predictions (fig-
ure 3.4a). A qualitative examination revealed that, indeed, NPD4142 possessed a pat-
tern of chemical-genetic interactions similar to the genetic interactions for the query
genes annotated to mRNA transport. More quantitatively and as expected, we ob-
served that the contribution of each gene mutant to a bioprocess prediction depended
on the strength of its chemical-genetic interaction with NPD4142 and the number and
intensity of its genetic interactions with the mRNA transport query genes. Chemical-
genetic interactions with mutants of POM152, NUP133, and NUP188, which encode
components of the nuclear pore that facilitate import and export of molecules such as
mRNA, were the most important, followed by interactions with mutants in the Lsm1-
7-Pat1 complex, which is involved in the degradation of cytoplasmic mRNA.
Using this approach to assess the importance of individual mutants in the chemical-
genetic profile, we globally analyzed the contribution of chemical-genetic interactions
to each compound’s top bioprocess prediction (figure 3.5). We performed this analysis
twice: first, on all HCS compounds, and second, on a diverse subset of 130 compounds
to correct for potential functional biases in the full set [34]. We present here the results
from the 130-compound subset, although the results for the full set were qualitatively
similar. For each compound, an average of 42% of its chemical-genetic interactions
contributed to its top bioprocess prediction (chemical-genetic interaction cutoff ±2.5,
importance score cutoff +0.1) – a fraction that increased substantially (to 78%) when
limiting the analysis to each compound’s strong interactions that contributed strongly
(chemical-genetic interaction cutoff ±5, importance score cutoff +0.5).
Overall, we observed that more than one-third of chemical-genetic interactions (1112
/ 3129) contributed to a top bioprocess prediction (chemical-genetic interaction cutoff
±2.5; importance score cutoff +0.1). Strikingly, negative chemical-genetic interactions
much more frequently contributed to a bioprocess prediction: approximately one-half
(1071 / 2112) of negative chemical-genetic interactions contributed as compared to only
~4% (41 / 1017) of positive chemical-genetic interactions at the same cutoff. Further-
more, we observed differences in how the signs within chemical-genetic and mean genetic
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(a) NPD4142
(b) CVT Pathway (GO:0332258)
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(c) tubulin complex assembly (GO:0007021)
Figure 3.4: Detailed analysis of the contribution of individual gene mutants to biological
process predictions. Each panel shows, for a bioprocess and either a compound (a)
or a set of compounds (b–c) predicted to perturb that bioprocess, the subset of the
respective chemical-genetic and L2-normalized genetic interaction profiles with signal.
The importance profiles are the row-wise mean of the Hadamard product (elementwise
multiplication) of each chemical-genetic interaction profile and the genetic interaction
profiles for query genes with which it possessed an inner product of 2 or higher that
are annotated to the GO term; they reflect the strength of each strain’s contribution
to the bioprocess prediction. For all panels, a query gene from the genetic interaction
network was selected if it contributed to the importance score calculation for any selected
compound; query genes were ordered from left to right in ascending order of their
inner products (or their average, for (b–c) with the selected chemical-genetic interaction
profile(s). Each strain (row) was included if it passed at least one of three criteria: 1)
the magnitude of its mean genetic interaction score across the selected query genes
exceeded 0.04; 2) the magnitude of its chemical-genetic interaction score (for b–c, the
mean of such scores) exceeded 2.5; or 3) its importance score exceeded 0.1 (for b–c, the
mean of such scores). (a) Schematic showing the prediction of the “mRNA transport”
bioprocess (GO:0051028) for chemical compound NPD4142. (b) Schematic showing the
prediction of “CVT pathway” (FDR < 1%) for compounds whose top prediction was to
that term. (c) Schematic showing the prediction of “tubulin complex assembly” (FDR
<1%).
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Figure 3.5: Global visualization of the contribution of chemical-genetic interactions to
CG-TARGET bioprocess predictions. Chemical-genetic interaction profiles and their
corresponding importance score profiles (figure 3.4 legend) were gathered for each of
130 diverse compounds from the high confidence set (FDR ≤ 25%) and their associated
top bioprocess predictions. Importance is plotted as a function of chemical-genetic
interaction score. One thousand points from the regions of lowest density (white) are
plotted, with only density plotted in the remaining higher-density regions. Density
increases in order of white, yellow, green, and violet. The shaded region highlights
strains with strong negative (≤ −5) chemical-genetic interactions and no contribution
(±0.1) to a compound’s top bioprocess prediction.
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interaction profiles could disagree with each other despite the global profile similarity
that led to bioprocess prediction, with positive chemical-genetic interactions contribut-
ing negatively to bioprocess predictions (importance score cutoff < –0.1) over 10 times
more frequently than negative interactions (1.9% vs. 0.14%). This trend of negative
chemical-genetic interactions supporting strong bioprocess predictions was even more
pronounced when restricting this analysis to strong interactions (chemical-genetic inter-
action cutoff ±5; importance score cutoff +0.5), where negative interactions comprised
essentially the entire set of contributing chemical-genetic interactions (219 / 220, 99.5%).
These observations were also supported by analyses in which we predicted perturbed
bioprocesses using only negative or positive chemical-genetic interactions, finding that
negative chemical-genetic interactions were the primary drivers of bioprocess predic-
tions and overwhelmingly responsible for their accuracy [34]. We conclude that neg-
ative interactions in chemical-genetic interaction profiles contain the large majority of
the functional information necessary to predict modes of action.
Negative chemical-genetic interactions also contained information specific to chemi-
cal perturbations. Specifically, we identified nine mutant strains that exhibited strong
negative chemical genetic interactions (z-score < –5) yet were enriched for a lack of
contribution (importance score < 0.1) to bioprocess predictions (hypergeometric test,
Benjamini-Hochberg FDR ≤ 0.05; shaded region of figure 3.5). Manual inspection of
these mutants revealed connections to the high osmolarity glycol (HOG) pathway, cell
polarity (cytoskeletal actin polarization, kinetochore and chromosome segregation), and
other stress response mechanisms (supplementary table 3.2). As the HOG pathway is
important for the cellular response to high osmolarity and other stresses [79–81], and
repolarization of the cytoskeleton is required for cells to adapt and continue dividing
after stress [82, 83], we hypothesize that many of these overrepresented mutants inter-
act negatively with compounds due to an impaired ability to respond to external stress.
This chemical perturbation-specific information may complement or even completely
obscure the chemical-genetic signature of a compound’s primary mode of action, po-
tentially complicating the interpretation of chemical-genetic interaction profiles using a
genetic interaction network.
We compared the concordance of chemical-genetic and genetic interaction profiles
across multiple compounds predicted to the same bioprocess, revealing that some biopro-
cesses were predicted by homogenous sets of chemical-genetic interaction profiles while
others were much more heterogeneous despite their predicted targeting of the same
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bioprocess. For example, predictions made to the “CVT pathway” (FDR < 1%) de-
pended almost entirely on a suite of strong negative chemical-genetic interactions with
ARL1, ARL3, and ERV13, with contributions from IRS4 and COG8 (figure 3.4b).
This uniformity in the prediction of a bioprocess is contrasted by the diversity of pro-
files captured within “tubulin complex assembly” predictions (fig:cg:4c). Compounds
with top predictions to this term could potentially be partitioned into three classes,
divided according to strong contributions from: 1) CIN1/TUB3, PAN3/CIN4, and the
SWR1 complex (known tubulin polymerization inhibitors Benomyl and Nocodazole);
2) CIN1/TUB3 and DSE2 (NPD4098 and NPD2784); or 3) only CIN1/TUB3 (all re-
maining compounds except NPD4619). Interestingly, the structures of the compounds
in each of the former two groups are distinct from those in the other groups, suggesting
that the observed diversity in these compounds’ functional profiles is mechanistically
derived from their structures.
3.2.7 Experimental validation of compound-bioprocess predictions
Phenotypic analysis of cell cycle progression.
The genes and pathways that govern the cell cycle are highly conserved throughout eu-
karyotes, enabling researchers to infer from yeast how cells in higher organisms integrate
internal and external signals to decide when to divide [84]. As such, compounds that
inhibit the progression of the cell cycle in yeast may enable a better understanding of the
eukaryotic cell cycle or even form the basis for new therapeutic approaches for cancer,
in which the cell division cycle is dysregulated [85, 86]. We observed that compounds
from the RIKEN Natural Product Depository were enriched for predictions to cell cycle-
related bioprocesses [34], especially to the “mitotic spindle assembly checkpoint” that
occurs at the beginning of M phase. After manual inspection of these compounds’
chemical-genetic interaction profiles, we selected 17 to test if our predictions validated
experimentally. Specifically, we looked for increases in the percentage of cells in the G2
phase of the cell cycle (via fluorescence-activated cell sorting) and two budding pheno-
types (bud size and % cells with large buds) for yeast treated with compound, together
indicative of arrest at the G2/M checkpoint of the cell cycle (figures 3.6a to 3.6c). In-
deed, 6 of the 17 selected compounds induced increases in all phenotypes, while zero out
of 10 bioactive control compounds (with high-confidence predictions to bioprocesses not
related to cell cycle signaling and progression) induced increases in any of these pheno-
types (p < 0.05, one-sided Fisher exact test). As compounds can activate the G2/M
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checkpoint in multiple ways (e.g. induction of DNA damage, inhibition of chromosome
segregation), the set of compounds with spindle assembly checkpoint predictions can
serve as a resource for studying the diversity of mechanisms by which cell cycle progres-
sion is arrested at this checkpoint and which of these may have therapeutic potential.
In addition to our study of G2/M checkpoint-activating compounds, we also selected
two compounds with high-confidence predictions to the term “cell-cycle phase” (mutu-
ally exclusive with mitotic spindle assembly checkpoint), one of which (NPD7834) was
observed to arrest cells in G1 phase (figures 3.6a to 3.6c).
Inhibition of tubulin polymerization.
Compounds that disrupt microtubules are useful for studying cell organization and
division and remain promising candidates as antitumor agents [87–89]. As such, we
focused on all compounds with the strongest predictions to “tubulin complex assem-
bly” (FDR < 1%) and tested them for activity in an in vitro, mammalian (porcine)
tubulin polymerization assay (fig:cg:6d). Like the previous validation experiment, a
negative control set of compounds was selected at random to contain high-confidence
compounds (bioprocess predictions with FDR ≤ 25%) whose predictions were not re-
lated to microtubule assembly or related bioprocesses. We observed that the novel
compound NPD2784 strongly inhibited tubulin polymerization, nearly as well as the
drug nocodazole and more strongly than the microtubule probe benomyl. In addition,
the entire set of compounds predicted to perturb tubulin complex assembly showed sig-
nificantly increased inhibition of tubulin polymerization when compared to the negative
control compounds (p < 0.006, Wilcoxon rank-sum test). Strikingly, all previously-
uncharacterized members of this set would not have been discovered using a structure
similarity-based approach, as the highest structural similarity between any NPD com-
pound and six compounds representative of major classes of microtubule-perturbing
agents did not exceed 0.25 (fig:cg:6e) [90]. However, we did observe that structural
similarity was predictive of the top 20% of chemical-genetic profile similarities among
the compounds selected for validation (AUPR = 0.43 vs. 0.2 for a random classifier),
suggesting that their slight differences in function inside the cell are influenced by their
structures and that further exploration of compounds with similar structures may yield
even more tubulin polymerization inhibitors. With this experimental validation, we
have demonstrated the ability of CG-TARGET, and a genetic interaction network in
general, to capture a shared mode of action across diverse compounds that can be
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Figure 3.6: In vivo and in vitro experimental validations of biological process predic-
tions. (a–c) Phenotypic validation of cell cycle-related predictions, performed on drug-
hypersensitive yeast treated with solvent control (DMSO) or compounds predicted to
perturb the cell cycle. (a) Differential interference contrast microscopy (DIC) and flu-
orescence upon DAPI staining showing bud size and DNA localization, respectively,
after compound treatment. The scale bar represents a distance of 5 Îĳm. (b) FACS
analysis of cell populations in different cell cycle phases at 0, 2, and 4 hours after com-
pound treatment. The green curve overlay represents the estimated cell population in
G1, S and G2/M phases. (c) Budding index percentages induced by treatment with
compound or solvent control. (d) In vitro inhibition of tubulin polymerization by com-
pounds predicted to perturb “tubulin complex assembly” (FDR < 1%; red) compared
to randomly-selected negative control compounds with high-confidence predictions to
bioprocesses not related to chromosome segregation, kinetochore, spindle assembly, and
microtubules (blue). Vmax values reflecting the maximum rate of tubulin polymerization
for each compound from independent replicate experiments are plotted. Assay positive
and negative control compounds are colored grey. (e) Structural similarity-based hier-
archical clustering of compounds tested in (d). Single linkage was used in combination
with (1 – structural similarity) as the distance metric; as such, the structural similarity
of the two most similar compounds at each junction can be inferred directly from the
dendrogram. Compounds predicted to perturb “tubulin complex assembly” (FDR <
1%) are in bold, and known microtubule-perturbing agents are marked with an aster-
isk. Structural similarity was calculated as the Braun-Blanquet similarity coefficient on
all-shortest-path chemical fingerprints of length 8 (see section 3.4).
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biochemically-validated. Furthermore, we note that this validation was achieved with a
mammalian tubulin assay, demonstrating the power of yeast chemical genomics coupled
with CG-TARGET to predict modes of action that translate broadly to other species,
including mammalian systems.
3.3 Discussion
The scaling of chemical-genetic interaction screens from tens or hundreds of compounds
to tens of thousands of compounds has provided the opportunity, and the necessity, to
develop better methods for interpreting the interaction profiles and prioritizing high-
confidence compounds. We developed a method, CG-TARGET, to address this need
and used it to predict perturbed biological processes for the nearly 14,000 compounds
interrogated in our recent high-throughput chemical-genetic interaction screen [34]. CG-
TARGET demonstrated the ability to recapitulate known compound function while
controlling the false discovery rate, enabling high-confidence mode-of-action predic-
tion for 1522 largely uncharacterized compounds [34], which we prioritized for further
study. Further investigation of the profiles from these high-confidence compounds re-
vealed broad compatibility between chemical-genetic and genetic interaction profiles,
the overwhelming basis of which was contributed by negative chemical-genetic interac-
tions. Some interesting exceptions to this compatibility were observed for genes that
may reduce the ability of compounds to deal with external stress. We experimentally
confirmed the accuracy of our predictions for two different classes of previously un-
characterized compounds – tubulin polymerization inhibitors and mitotic checkpoint
inhibitors – and demonstrated the ability of CG-TARGET to predict activity against a
conserved mammalian target. In addition to these findings, the predictions made using
CG-TARGET were experimentally validated on a large scale for 67 compounds in an
orthogonal cell cycle assay and revealed insights into the distribution of functions per-
turbed by compounds in large compound libraries, which is described in the companion
paper [34].
In high-throughput chemical screens, it is important to prioritize the compounds
most likely to demonstrate desired biological activity in further studies. While CG-
TARGET and a baseline, enrichment-based approach achieved similar performance in
ranking gold-standard bioprocess annotations for simulated chemical-genetic interac-
tion profiles and compounds with known modes of action, CG-TARGET outperformed
the baseline approach with regard to controlling the false discovery rate, discovering
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two orders of magnitude more compounds at a false discovery rate of 25%. As a re-
sult, CG-TARGET was substantially better than the baseline approach at accurately
annotating, with high confidence, compounds with known modes of action. The fact
that our genetic interaction-based predictions were both accurate and achieved appro-
priate control of the false discovery rate is important, as the global genetic interaction
network provides a much more comprehensive and unbiased resource than the limited
set of gold standard compounds for predicting bioprocesses perturbed by compounds.
In addition, predicting compound function at the bioprocess level allowed functional
characterization of compounds whose effects in cells did not occur via direct action on
protein targets (e.g. damaging DNA or disrupting cell membranes,), which would have
been impossible with a method based purely on comparing chemical-genetic and genetic
interaction profiles.
While we demonstrated the ability to predict perturbed bioprocesses for compounds
and prioritize the highest-confidence predictions, many further steps are required to
identify lead compounds and ultimately develop molecular probes or pharmaceutical
agents. Perturbing a biological process does not necessarily require perturbing a spe-
cific protein target, and as such, further refinements to our methods are needed to
identify specific molecular targets (i.e. proteins) and prioritize the compounds most
likely to perturb a small number of defined targets in the cell. We envision the use
of multiple functional standards with CG-TARGET, such as biological processes and
protein complexes as demonstrated here, to improve our ability to predict compound
mode of action at different levels of resolution and predict the compounds that exert
specific versus general effects in the cell. Different modes of chemical-genetic interac-
tion screening can provide support in this endeavor, as heterozygous diploid mutant
strains, gene overexpression strains, and/or spontaneous compound-resistant mutants
can provide evidence for the direct, essential cellular target(s) of a compound [24, 26].
Regardless of the limitations in predicting precise molecular targets, information about
the bioprocesses perturbed by an entire library would be useful in selecting the com-
pounds most amenable to activity optimization and off-target effect minimization in the
development of a pharmaceutical agent or molecular probe.
The approach described here can be translated to work in other species for which
obtaining functional information on compounds would be useful. For example, genome-
wide deletion collections have been developed for Escherichia coli [91] and Schizosac-
charomyces pombe [92] and used to perform chemical-genetic interaction screens [93, 94]
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as well as genetic interaction mapping [52–54, 56]. Such efforts are even underway in hu-
man cell lines, enabled by genome-wide CRISPR screens [51, 57, 95, 96]. Furthermore,
future efforts to interpret chemical-genetic interaction profiles in a new species need
not wait for the completion of a comprehensive, all-by-all genetic interaction network
as exists in S. cerevisiae, as our work highlights the ability of a diagnostic set of gene
mutants to capture functional information and predict perturbed biological processes.
From the discovery of urgently-needed antibacterial or antifungal agents, to the treat-
ment of orphan diseases or a better understanding of drug and chemical toxicity, the
combination of chemical-genetic and genetic interactions in a high-throughput format,
with appropriate analysis tools, offers a means to achieve these goals via the discovery
of new compounds with previously uncharacterized modes of action.
3.4 Materials and Methods
3.4.1 Datasets
Chemical-genetic interaction data.
Chemical-genetic interaction profiles were obtained from a recent study [34], in which
nearly 14,000 compounds were screened for chemical-genetic interactions across ~300
haploid yeast gene deletion strains. The chemical-genetic interaction profiles consisted of
two sub-datasets: 1) the “RIKEN” dataset, containing chemical-genetic interaction pro-
files spanning 289 deletion strains for 8418 compounds from the RIKEN Natural Product
Depository [75] and 5724 negative experimental controls (solvent control, DMSO); and
2) the “NCI/NIH/GSK” dataset, containing chemical-genetic interactions spanning 282
deletion strains for 3565 compounds from the NCI Open Chemical Repository, the NIH
Clinical Collection, and the GSK kinase inhibitor collection [76], as well as 2128 neg-
ative experimental control profiles. The solvent control profiles consisted of biological
and technical replicate profiles.
Genetic interaction data.
The genetic interaction dataset was obtained from a recently assembled S. cerevisiae ge-
netic interaction map [27, 28]; it was filtered to contain quantitative fitness observations
for double mutants obtained upon crossing 1505 high-signal query gene mutants into
an array of 3827 array gene mutants. The procedure for selecting the 1505 high-signal
query genes out of the larger pool of 4382 is described in [34]. Briefly, each query profile
85
was required to possess at least 40 significant genetic interactions, a sum of cosine sim-
ilarity scores with all other query profiles greater than 2, and a sum of inner products
with all other query profiles greater than 2. The final genetic interaction dataset used
in this study was filtered to contain only array strains present in the chemical-genetic
interaction datasets.
GO Biological Processes and protein complexes.
A subset of terms from the “biological process” ontology within the Gene Ontology
annotations [78] were used as the bioprocesses. Query genes from the S. cerevisiae
genetic interaction dataset were mapped to biological process terms using annotations
from the Saccharomyces cerevisiae Genome Database [77]. Both gene ontology and S.
cerevisiae annotations were downloaded on September 12, 2013 from their respective
databases via Bioconductor in R [97]. Terms were propagated using “is_a” relationships,
such that each gene was also annotated to all parents of its direct biological process
annotations. The final set of bioprocesses consisted of the terms with 4 – 200 gene
annotations from the set of 1505 high-signal query genes in the genetic interaction
dataset.
Protein complex annotations were obtained from [28]. Complexes with 3 or more
genes annotated to them were used as the input biological processes for CG-TARGET-
based protein complex predictions.
Gold-standard compound-process annotations.
Biological processes were assigned to 35 primarily antifungal compounds with chemical-
genetic interaction profiles in the RIKEN dataset, based on known information about
their modes of action. Bioprocess terms were selected to be specific to the compounds’
modes of action where applicable.
3.4.2 Predicting perturbed bioprocesses from chemical-genetic inter-
action profiles
Our method to predict biological processes perturbed by compounds is briefly sum-
marized in the recent study from which the chemical-genetic interaction profiles were
obtained [34], and is more formally described here. Figure C.3 provides a schematic
representation of the method.
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Notation.
We first clarify here a few uses of mathematical notation that simplify the explanation
of the methods. First, the ith row and column vectors of a matrix A are denoted as Ai,*
and A*,i, respectively. Second, the Iverson bracket is used to convert logical propositions
into values of 1 or 0, depending on if the logical proposition is true or false, respectively.
This is used to simplify expressions for counting the number of elements in a vector that
meet given criteria. Specifically, for a logical proposition L, the definition of the Iverson
bracket is:
[L] =
10 if L is trueif L is false
(Eqn. 1).
Data representation and overview of procedure.
CG-TARGET requires chemical-genetic interaction profiles, genetic interaction profiles,
and a mapping from genes to biological processes, all of which will be represented as
matrices here (illustrated in figure C.3, along with example matrix dimensions and a
graphical description of the bioprocess prediction procedure). For chemical-genetic in-
teraction matrices, let us consider an nm x nα matrix of compound treatment profiles
Cα, an nm x nβ matrix of negative experimental control profiles Cβ, and an nm x nγ
matrix of resampled profiles Cγ , where nm is the number of mutant strains in each
chemical-genetic interaction profile, nα is the number of profiles derived from treatment
with compound, nβ is the number of profiles derived from negative experimental con-
trols, and nγ is the number of chemical-genetic interaction profiles resampled from Cα.
The matrix G of genetic interaction profiles is nm x nq and the binary matrix B of gene
to bioprocess mappings is nq x np, where nm is the number of mutant strains in the
chemical-genetic interaction and genetic interaction profiles, nq is the number of genetic
interaction profiles, and np is the number of bioprocesses in B annotated from the nq
genetic interaction profiles in G.
To predict perturbed biological processes, chemical-genetic interaction matrices for
each profile type a ∈ {α, β, γ} are first converted to matrices of compound-gene similar-
ity scores and then to matrices containing the sums of these compound-gene similarity
scores for each compound-process pair. Three different z-score/p-value matrix pairs
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are then computed for each profile type a, two of which are derived from the con-
trol chemical-genetic interaction profile types b ∈ {β, γ} (“control-derived” z-scores/p-
values) and one of which is derived by randomizing the scores within each compound’s
vector of compound-gene similarity scores (“within-compound” z-scores/p-values, de-
noted as δ). The z-score and p-value matrices across all scoring approaches c ∈ {β, γ,
δ} are then combined into a final z-score/p-value matrix pair for each profile type a.
The false discovery rate is estimated by comparing the rate of prediction for the treat-
ment profiles α against that of the control profiles b ∈ {β, γ} across a range of p-value
thresholds. For the comparison of CG-TARGET to an enrichment-based approach, one
enrichment factor/p-value matrix pair replaces the final z-score/p-value matrix pair for
each profile type a, with the same false discovery rate calculations occurring afterward.
Resampled chemical-genetic interaction profiles.
An nm x nγ matrix of resampled chemical-genetic interaction profiles Cγ is constructed
such that interaction scores for each gene are sampled randomly with replacement across
the chemical-genetic interaction profiles. Assuming that rand(x) is a function to ran-
domly sample one value from the set of integers x in a uniformly random fashion, and
{1..nα} is the set of integers between and including 1 and nα, the interaction score for
the ith mutant in the jth resampled profile is denoted by:
(Cγ)i,j = (Cα)i, rand({1..nα})
(Eqn. 2).
Mapping the similarity between chemical-genetic and genetic interaction
profiles onto biological processes.
Scores reflecting the concordance between chemical-genetic and genetic interaction pro-
files were derived by taking the inner product between each chemical-genetic interaction
profile and each L2-normalized genetic interaction profile. As such, a column-normalized
genetic interaction matrix G ′ is constructed from the genetic interaction matrix G by:
G′i,j =
Gi,j
‖G∗,j‖2
(Eqn. 3).
88
Matrices Sα (nα x nq), Sβ (nβ x nq), and SR (nγ x nq), containing the similarity
scores between the genetic interaction profiles and the profiles from each compound-
treated, negative experimental control, and resampled condition, respectively, are then
generated as denoted by (where the superscript T indicates the matrix transpose):
Sα = (Cα)T G′; Sβ = (Cβ)T G′; Sγ = (Cγ)T G′
(Eqn. 4).
To map these similarity scores onto biological processes, the inner product is taken
between each row vector of compound-gene similarity scores (from Sα, Sβ, and Sγ) and
the column vector of binary gene annotations from each bioprocess in matrix B. This
generates matrices Xα (nα x np), Xβ (nβ x np), and Xγ (nγ x np) that contain the sum
of gene similarity scores within each biological process for each compound treatment,
negative experimental control, and resampled condition, respectively. These matrices
are denoted by:
Xα = SαB; Xβ = SβB;Xγ = SγB
(Eqn. 5).
Computing biological process predictions with CG-TARGET.
Once the compound-gene similarity scores are mapped onto biological processes and
summed into compound-process scores, we compute z-score matrices Z*(a,b) and empir-
ical p-value matrices PZ*(a, b), where a denotes the type of profile we are predicting bio-
processes for and b denotes the type of control distribution used to compute the z-scores
and p-values. For two of the values of b (α and β), these scores are “control-derived,”
as we compare each compound-process score (Xa)i,j to the distribution of control profile
compound-process scores (Xb)*,j within the respective jth bioprocess. For the remaining
value of b (δ), we refer to these scores as “within-compound,” as we compare the ith
compound’s average compound-gene similarity score within genes annotated to the jth
bioprocess (Xa)i,j/dj (where dj is the size of the jth bioprocess) to the distribution of
compound-gene similarity scores (Sa)i,* for the ith compound.
The computation of each control-derived z-score requires an estimate of the mean
and standard deviation of the compound-process scores within each bioprocess for both
the negative experimental control and resampled profiles. The length np mean vector
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ub and standard deviation vector vb for each control profile type b ∈ {β, γ} are thus
defined as:
(ub)j =
1
nb
nb∑
i=1
(Xb)i,j
(vb)j =
√√√√ 1
nb − 1
nb∑
i=1
(
(Xb)i,j − (ub)j
)2
(Eqn. 6).
Z-score matrices derived using both types of control profile are computed for all
compound treatment, negative experimental control, and resampled profile conditions,
yielding six z-score matrices. These matrices, one for each combination of profile type
a ∈ {α, β, γ} and control profile type b ∈ {β, γ}, are defined as:
(
Z∗(a,b)
)
i,j
=
(Xa)i,j − (ub)j
(vb)j
(Eqn. 7).
The control-derived p-values are computed by counting the number of times that
a compound-process score (Xa)i,j for the ith compound and jth bioprocess is less than
the corresponding control-derived compound-process scores (Xb)*,j. Again, this yields
six p-value matrices, one for each combination of profile type a ∈ {α, β, γ} and control
profile type b ∈ {β, γ}, which are given by:
(
PZ∗(a,b)
)
i,j
= 1
nb
nb∑
k=1
[
(Xa)i,j ≤ (Xb)k,j
]
(Eqn. 8).
The within-compound z-score is computed for each pair of ith compound and jth
bioprocess by comparing the mean of the ith compound’s similarity scores with genes
in the bioprocess to the mean and standard deviation of the ith compound’s similarity
scores across all genes. To perform this calculation, length na mean and standard
deviation vectors wa and ya, respectively, are generated, as well as a length np vector
d that contains the number of genes annotated to each bioprocess in B. Z*(a,δ) refers
to the matrix of z-scores for each profile of type a ∈ {α, β, γ} computed using the
within-compound z-score approach (represented by δ) and given by:
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(wa)i =
1
nq
nq∑
j=1
(Sa)i,j
(ya)i =
√√√√ 1
nq − 1
nq∑
j=1
(
(Sa)i,j − (wa)i
)2
dj =
nq∑
i=1
Bi,j
(Eqn. 9).
For each compound-process pair, the within-compound empirical p-value is com-
puted for each profile type a ∈ {α, β, γ} by randomly permuting the compound’s
compound-gene similarity scores, re-computing within-compound z-scores, and count-
ing the number of times that the z-scores derived from randomly-permuted compound-
gene similarity scores are greater than the observed compound-process z-score. This
calculation conveniently reduces to a comparison of the sum of observed vs. permuted
compound-gene similarity scores for genes in the respective bioprocess, as the number
of genes that map to the bioprocess (dj) and the mean ((wa)i) and standard devia-
tion ((ya)i) of compound-gene similarity scores do not change upon permutation of the
compound-gene similarity scores. Permuted matrices of compound-gene similarity scores
are denoted by kSa, which represents, for profile type a, the kth row-wise permutation
of the compound-gene similarity score matrix. Each resulting matrix that contains the
sums of compound-gene similarity scores for all compound-process pairs with respect to
random permutation k is denoted by kXa. Across nl permutations, the within-compound
empirical p-value for each profile type a ∈ {α, β, γ} (within-compound p-value signified
by subscript δ) is denoted by:
kXa = kSaB
(
PZ∗(a,δ)
)
i,j
= 1
nl
nl∑
k=1
[
(Xa)i,j ≤
(
kXa
)
i,j
]
(Eqn. 10).
Ultimately, the different p-values and z-scores for each compound-process pair are
combined into one p-value and z-score for that pair. These scores are combined such
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that the largest (least significant) p-value is chosen along with its associated z-score.
If multiple p-values tie for the largest value, then the one with the smallest associated
z-score is chosen. As such, the resulting combination of p-value and z-score represents
the most conservative estimate of the strength and significance of the prediction from
compound to perturbed biological process.
To combine the p-values and z-scores, a matrix Psourcea for each profile type a ∈ {α,
β, γ} is first created to determine, for each compound-process pair, which p-value and
z-score matrices will contribute the final p-value and z-score. For each z-score/p-value
scoring approach c ∈{β, γ, δ}, each entry of this matrix is denoted by:
fP () =
(
PZ∗(a,)
)
i,j
fZ () =
(
Z∗(a,)
)
i,j
(Psourcea)i,j = fZ
(
b
′)where b′ ∈ fP (b)
(Eqn. 11).
The resulting final p-value and z-score matrices for each profile type a ∈ (α, β, γ)
are then:
(
Z(a)
)
i,j
=
(
Z∗(a,(Psourcea)i,j)
)
i,j
(
PZ(a)
)
i,j
=
(
PZ∗(a,(Psourcea)i,j)
)
i,j
(Eqn. 12).
Computing biological process enrichments.
An enrichment-based method for predicting biological processes perturbed by com-
pounds was also implemented to provide an appropriate baseline for assessing the per-
formance of CG-TARGET. This enrichment-based method computes biological process
enrichment within the genes that contribute the top n out of nq compound-gene similar-
ity scores for each compound (from each compound-gene similarity score matrix Xa for
profile types a ∈{α, β, γ}). Ultimately, two sets of matrices are computed, E (a,n) and
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PE(a,n), which respectively contain the enrichment factor and hypergeometric p-value
for each compound and biological process pair. Enrichments were computed for n ∈{10,
20, 50, 100, 200, 300, 400, 600, 800}.
First, a binary matrix X is derived from the matrix of compound-gene similarity
scores Xa, such that in each row, the positions corresponding to the top n scores are set
to 1 and the remaining positions are set to 0. This is denoted as:
(
Xtop(a,n)
)
i,j
=
[
(Xa)i,j ≥
(
sortDesc((Xa)i,∗)
)
n
]
(Eqn. 13)
where (Xa)i,* is the ith row vector of matrix Xa and sortDesc(x) is a function that
returns the values in a vector x sorted in descending order. The final enrichment factor
and p-value matrices are then computed as:
(
E(a,n)
)
i,j
=
((
Xtop(a,n)
)
i,∗B∗,j
)
nq
(∑B∗,j)n
(
PE(a,n)
)
i,j
= 1− hygeCDF(nq,
∑
B∗,j , n,
((
Xtop(a,n)
)
i,∗B∗,j
)
− 1)
(Eqn. 14)
where B*,j is the column vector of the binary bioprocess matrix B containing gene
annotations for the jth bioprocess, Σ B*,j is the number of genes annotated to the
jth bioprocess, and hygeCDF(N, K, n, k) is the cumulative hypergeometric distribution
given a population size of N withK success states and n draws with k observed successes.
Estimating the false discovery rate.
The false discovery rates of the compound-process predictions are estimated by compar-
ing, using the entire range of observed p-values as thresholds, the number of compounds
with at least one bioprocess prediction against the number of experimental controls and
resampled profiles with at least one bioprocess prediction. We compute a false discovery
rate matrix FDRb for the treatment profiles α against each control profile type b ∈ {β,
γ}. This FDRb matrix is individually computed for the CG-TARGET-based compound-
process predictions as well as for each version of the enrichment-based compound-process
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predictions (using the p-value matrices PZ(a) and PE(a,n)); for simplicity, we do not
change the notation of FDRb to reflect if the false discovery rate values were computed
on the output from CG-TARGET or our baseline enrichment-based approach.
The first step in computing the false discovery rate is obtaining length na vectors
ptopa that contain the smallest p-value within each profile’s bioprocess predictions,
for each profile type a ∈ {α, β, γ}. Additionally, the union of all observed p-values
pall defines the universe of p-values for which corresponding false discovery rates will
be computed. Given p-value matrices Pa (PZ(a) or PE(a,n) for one value of n) and a
function sortAsc() that returns the input values sorted in ascending order, the vectors
ptopa and pall are given by:
(ptopa)i =
(
(Pa)i,∗
)
pall = sortAsc
 ⋃
i,j,a∈{α, β,γ}
(Pa)i,j

(Eqn. 15).
We then compute a mapping from each observed p-value to its corresponding false
discovery rate, with mappings generated with respect to each control profile type b ∈ {β,
γ}. First, a vector of false discovery rates r*b is computed, each value corresponding to a
p-value threshold in pall, by dividing the fraction of treatment profiles with one or more
bioprocess predictions that pass the threshold by the fraction of control profiles that
also pass the threshold. As the p-values in the vector pall are monotonically increasing,
it is desirable for the false discovery rate to increase monotonically with the p-value.
However, it is possible for the false discovery rate to decrease as p-value increases (if
the fraction of treatment profiles passing the threshold increases faster than the fraction
of control profiles passing the threshold), and thus we adjust each false discovery rate
value in the vector r*b to be the minimum of its current value or any value at a larger
index to generate a new vector rb (similar to the Benjamini-Hochberg procedure [98]).
The final p-value to false discovery rate mappings can be written as a function of the
p-value p, with the procedure to generate these mappings given by:
(r∗b )i =
1
nb
∑nb
j=1
[
(ptopb)j ≤ (pall)i
]
1
nα
∑nα
j=1
[
(ptopα)j ≤ (pall)i
]
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rb = rev (cumMin (rev (r∗b )))
fFDR(b) (p) = (rb){i : (rb)i = p}
(Eqn. 16).
Given this mapping of p-value to false discovery rate, the resulting matrices of false
discovery rates with respect to control profile types b ∈ {β, γ} are given by:
(FDRb)i,j = fFDR(b)
(
(Pa)i,j
)
(Eqn. 17).
3.4.3 Computational evaluation of bioprocess predictions
Performance on simulated chemical-genetic interaction profiles.
We generated a set of simulated chemical-genetic interaction profiles derived from ge-
netic interaction profiles [34]. Each simulated chemical-genetic interaction profile was
a query genetic interaction profile augmented with noise sampled from a Gaussian dis-
tribution with a mean of 0 and a variance for each array gene twice that of the same
array gene in the genetic interaction dataset. Three simulated profiles were generated
based on each query gene, resulting in 4515 total profiles. Because each simulated
chemical-genetic interaction profile was derived from a query genetic interaction profile,
it inherited the gold-standard bioprocess annotations from its parent genetic interaction
profile in subsequent benchmarking efforts.
We then used CG-TARGET and each top-n enrichment method to predict perturbed
bioprocesses for this set of 4515 simulated chemicals x 289 deletion mutants. For each
simulated chemical, its top bioprocess prediction was compared to the set of inherited
gold-standard bioprocess annotations, counting as a true positive if the top prediction
matched an existing annotation and a false positive if it did not. Precision-recall curves
were then generated by sorting the list of each simulated chemical’s top bioprocess pre-
dictions (p-value ascending, z-score or enrichment factor descending) and computing the
precision (true positives / (true positives + false positives)) and recall (true positives)
at each point in this list.
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Performance on gold-standard compound-bioprocess annotations.
The predicted perturbed bioprocesses for each of the gold-standard compounds were
sorted, first in ascending order by their p-value and then descending order by their
z-score (for CG-TARGET) or enrichment factor (top-n enrichment), and the rank of
each compound’s gold-standard bioprocess annotation was recorded. To assess the sig-
nificance of each rank, each pair of p-value and z-score was randomly assigned to a
new bioprocess (without replacement), the lists re-ordered, and the ranks of each com-
pound’s target bioprocess re-computed. The empirical p-value for each gold-standard
compound-process pair was computed as the number of times the rank from the shuﬄed
bioprocesses achieved the same or better rank as the observed rank, divided by the num-
ber of randomizations. These randomizations were also used as a baseline against which
to compare the number of compounds (out of 35) that achieved a given rank, as seen in
figures C.1 and 3.3; the displayed ribbons were generated by calculating, for each rank,
the relevant percentiles on the distribution of compounds with randomized predictions
that achieved that rank. The “effective rank” of a compound’s gold-standard bioprocess
annotation was determined as the minimum rank of any bioprocess term with which it
possessed sufficient gene annotation similarity (overlap index ≥ 0.4, where the overlap
index of two sets is defined as the size of the intersection divided by the size of the
smaller set).
Characterizing performance with respect to individual bioprocess terms.
For each propagated GO biological process term used for bioprocess prediction, we gath-
ered all predictions to that term across the 4515 simulated chemical-genetic interaction
profiles and sorted the predictions in ascending order by p-value and then in descend-
ing order by z-score. The area under the precision-recall curve (AUPR) was calculated
across this sorted list of simulated compounds, with a true positive defined as the occur-
rence of a simulated compound that was annotated to the bioprocess (via the simulated
compound’s parent gene). To obtain the final evaluation statistic for each GO term, this
AUPR was divided by the AUPR of a random classifier, which is equal to the number
of true positives divided by the total number of simulated compounds.
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3.4.4 Assessing the compatibility of chemical-genetic and genetic in-
teraction profiles
Analysis of bioprocess prediction drivers in chemical-genetic interaction data.
Given a compound and a predicted bioprocess, a profile of “importance scores” de-
scribes the contribution of each gene mutant to that compound’s bioprocess prediction.
To obtain this score, a mean genetic interaction profile was first computed across all
L2-normalized genetic interaction profiles annotated to the biological process for which
the inner product with the compound’s chemical-genetic interaction profile was 2 or
greater. The importance score profile was then obtained by taking the Hadamard prod-
uct (elementwise multiplication) between this mean genetic interaction profile and the
compound’s chemical-genetic interaction profile.
Overrepresentation analyses of gene mutants with strong chemical-genetic
and/or genetic interactions.
After restricting the data to the top biological process prediction for each compound,
gene mutants that possessed strong, negative chemical-genetic interaction scores (z-
score < –5) were assessed for overrepresentation with respect to the number of times
they did not contribute (importance score within ±0.1) to a compound’s top bioprocess
prediction. Specifically, the number of times each strain occurred inside and outside the
region described above (grey box in figure 3.5) was compared to the number of times
all strains occurred inside and outside the region using a hypergeometric test, using
all strains with interaction z-scores < –5 as the background set. Details on the genes
overrepresented in this region are given in supplementary table 3.2.
3.4.5 Experimental validation of compound-bioprocess predictions
Phenotypic analysis of cell cycle progression.
To examine the effect of compounds on arresting cells in G2/M phase, we looked for
differences in budding index and cell DNA content between compounds predicted to
perturb the cell cycle versus negative control compounds. Seventeen compounds with
high-confidence predictions to the bioprocess term “mitotic spindle assembly check-
point” and strong negative chemical-genetic interactions with PAT1 and LSM6 (a
common signature for compounds with this bioprocess prediction) were selected for
validation. Additionally, ten bioactive (growth inhibition 50–80% compared to DMSO
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control) compounds with high confidence predictions (false discovery rate ≤ 25%) to
bioprocess terms not related to cell cycle signaling and progression were selected as neg-
ative controls. Two compounds predicted to perturb “cell cycle phase” were also tested
in these experiments. All compounds were tested at a concentration of 10 µg/mL, which
was also the concentration used for chemical genomic screening [34].
To quantify budding index, logarithmically-growing pdr1∆pdr3∆snq2∆ cells were
transferred to fresh galactose-containing medium (YPGal) containing compounds and
incubated at 25 ÂřC for 4 hours. The budding status of at least 200 cells was visually
determined under the microscope. The percentage of the budded cells in no compound
or compound-treated samples was counted.
For flow cytometry analysis, log phase pdr1∆pdr3∆snq2∆ cells were grown in YP-
Gal media in the presence or absence of a compound for 4 hours; they were then fixed
in 70% ethanol for 1 hour at 25 ◦C. Cells were collected by centrifugation, washed,
and resuspended in buffer containing RNase A (0.25 mg/mL in 50 mm Tris, pH 7.5) for
1.5 hours. Cells were further incubated in 20 µL of 20 mg/mL proteinase K at 50 ◦C
for 1 hour. Samples were then stained with propidium iodide, briefly sonicated, and
measured using FACSCalibur ver 2.0 (Becton Dickinson, CA, USA).
The proportions of predicted active compounds and negative controls with positive
phenotypic results were compared using the prop.test function in R to assess significance.
Inhibition of tubulin polymerization.
In vitro tubulin polymerization assays using a fluorescent-based porcine tubulin poly-
merization assay (Cytoskeleton, BK011P) were performed following manufacturer spec-
ifications. Compounds were tested at a concentration of 10 µg/mL (with the exception
of assay controls), which was identical to the concentration used for chemical genomic
screening. All ten compounds predicted to perturb “tubulin complex assembly” with
the minimum estimated false discovery rate (FDR < 1%) were selected for testing.
Twelve compounds with predictions of false discovery rate ≤ 25% to any bioprocess
except those related to chromosome segregation, kinetochore, spindle assembly, and
microtubules were randomly selected as negative controls.
The degree of tubulin polymerization inhibition was summarized in a single Vmax
statistic for each compound treatment replicate. The Vmax for each compound’s flu-
orescence time-course was calculated as the maximum change in fluorescence between
consecutive time points, which were measured at 1-minute intervals. Three batches of
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experiments were performed in total (resulting in N ≥ 2 for each compound), and we
normalized the Vmax values in each batch by subtracting the difference between that
batch’s mean DMSO (solvent control) Vmax and the overall mean DMSO Vmax. To de-
termine if the tubulin-predicted compounds inhibited polymerization to a significantly
greater degree than the controls, we calculated the mean of the normalized Vmax values
for each compound and performed a one-sided Wilcoxon rank-sum to test for a difference
in the ranks of these values between the two classes of compounds.
Chemical structure similarities between each pair of compounds selected for tubulin
polymerization validation were obtained by first computing an all-shortest-paths finger-
print with path length 8 for each compound [99]. Similarities were computed on the
fingerprints using the Braun-Blanquet similarity coefficient, which is defined as the size
of the intersection divided by the size of the larger set. In a recent study, this combi-
nation of structure descriptor and similarity coefficient performed well when evaluated
globally on our entire chemical-genetic interaction dataset [100].
3.5 Supplementary tables
Supplementary table 3.1. Using protein complexes to refine CG-TARGET GO bio-
logical process mode-of-action predictions. Compounds, GO biological processes, and
protein complexes are shown if the mode-of-action prediction to the protein complex
was stronger than that to the associated GO biological process (comparison first based
on p-value, then on z-score in the case of a tie). Protein complexes were limited to those
of size 4 or greater whose gene annotations were a subset of those for the corresponding
GO biological process term. The final column indicates compounds that did not achieve
a false discovery rate of 25% or less for any GO biological process mode-of-action pre-
dictions but did for at least one protein complex prediction (with “HCS” denoting “high
confidence set”).
Supplementary table 3.2. Overrepresentation analysis of mutant strains with strong
negative chemical-genetic interactions and no contribution to top bioprocess predic-
tions. Overrepresentation within the shaded region of figure 3.5 was evaluated using
a hypergeometric test to compare the occurrence of one strain versus all strains inside
and outside of the region, with the background containing only strains that possessed
strong (z-score < –5) negative chemical-genetic interactions. The compounds and top
bioprocess predictions associated with each strain’s occurrences in the region are given,
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as well as the appropriate background list of strains and information on the gene deleted
in each strain.
Chapter 4
Comparing different modes of
chemical-genetic interaction
screening
4.1 Introduction
All of the work discussed in this document so far deals with the diagnostic set of
nonessential yeast deletion mutants. By leveraging a reference set of genetic interaction
profiles to select an informative subset of deletion mutants for correlation-based mode-
of-action prediction, we predicted mode-of-action based on chemical-genetic interaction
profiles for an unprecedented number of compounds in one experiment. This diagnostic
mutant collection has thus proven itself an integral component of our efforts to perform
chemical-genetic interaction screens of the same magnitude as other high-throughput
chemical screening campaigns.
However, the diagnostic mutant set may not contain all of the functional informa-
tion that can be extracted from fitness-based profiling of genetic mutants. For example,
the functional redundancy in genetic interaction space that enabled the compression
of ~5000 to 310 mutants may not be recapitulated in chemical-genetic interaction ex-
periments. If some mutants exhibit interactions in the presence of compounds but not
in standard genetic interaction conditions, this would cause the compression algorithm
that generated the diagnostic set to exclude these mutants that are uninformative in
genetic interaction space. Additionally, a subset of mutants may lose some ability to
differentiate two compounds with generally similar chemical-genetic interaction profiles.
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Finally, the diagnostic mutants do not represent essential genes, mutants of which were
used in the first barcode sequencing experiments [24] and are known from genetic inter-
action experiments to be a rich source of functional information that is complementary
to that obtained from nonessential genes [28]. In the screens discussed in this chapter,
we expand our screens both into the complete nonessential gene space and into essential
gene space, obtaining profiles that collectively span the entire yeast genome.
4.1.1 Functional profiling of essential genes
A few different techniques enable the generation of functional profiles across essential
gene mutants despite the challenges associated with fitness-based profiling of genes
that are essential for growth. These techniques are designed to perturb a gene the
minimum amount needed to generate a functionally informative phenotype, balancing
the need to reduce the relative functional gene dose against the lethal consequences of
completely ablating its function. Three techniques stand out in particular, each utilizing
perturbations that exert their primary effects at different levels of the central dogma.
At the genetic level, heterozygous diploid mutants are constructed such that only
one copy of the gene of interest is present within an otherwise diploid wild type ge-
nomic background. These have been useful for directly identifying protein targets of
compounds, as the reduction in gene dose should sensitize that protein’s genetic mutant
to the presence of that compound compared to the mutants for non-targets [24, 39, 40].
This hypothesis also suggests that heterozygous diploid chemical-genetic interaction
profiles should be sparse, with strain sensitivity only manifesting when a compound
targets the product of an essential gene mutant in the collection. However, it is possible
that other essential genes could act as either negative or positive modifiers of a chemical
perturbation when their dose is reduced to half of wild type.
Interference with transcriptional machinery for a specific gene can also reduce its
dose in the cell, and this is the basis of DAmP (Decreased Abundance by mRNA Per-
turbation) mutants. Specifically, the insertion of an antibiotic resistance marker in a
gene’s 3′ UTR destabilizes the corresponding transcript, as this disruption essentially
tags it for degradation by the cell’s mRNA surveillance machinery [101, 102]. The
first systematic collections of DAmP mutants were constructed in yeast to investigate
pathways of interest using genetic interaction screens (for example, the early secretory
pathway and genes controlling chromatin organization) [101, 103]. These collections
were subsequently adapted to chemical-genetic interaction screens, with the resulting
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studies showing that, similar to heterozygous diploid mutants, DAmP mutants for the
targets of compounds also exhibit sensitivity compared to mutants of non-target genes
[104, 105].
Finally, protein-level perturbations of essential genes can be achieved through the
introduction of point mutations. In traditional genetic analyses of essential genes, mu-
tations are generally sought that impact the viability of the cell at a high, “restrictive”
temperature but not at a low, “permissive” temperature. These mutants are usually
considered to act by changing the stability of the protein’s secondary or tertiary struc-
ture, with higher temperatures aggravating the destabilizing effect of the mutation by
encouraging protein disorder and unfolding. As functional profiling experiments require
viable cells, these temperature-sensitive, hypomorphic alleles are usually screened at a
permissive temperature of 26 or 30 ◦C. Temperature-sensitive mutants were recently
used to complete the global genetic interaction network between all pairs of genes in
S. cerevisiae by allowing the interrogation of essential gene space [28, 106–108]. In-
terestingly, the genetic interaction network between essential genes exhibited a higher
interaction density than that between nonessential genes. Even though the strains car-
rying these hypomorphic alleles are functionally perturbed, this flavor of perturbation’s
relationship to gene dose is not as clear. As such, their chemical-genetic interaction
scores do not directly link compounds to targets as heterozygous diploid and DAmP
mutants have been shown to do. Instead, these profiles should be interpreted using
reference genetic interaction profiles obtained against the same collection, using a tool
such as CG-TARGET (see chapter 3).
4.1.2 Expanding chemical-genetic interaction space for high-confidence
compounds
As part of our international chemical genomics collaboration, we sought to narrow the
bioprocess-level predictions from our large-scale screen against the diagnostic mutant
collection down to predictions against individual protein targets, with the eventual goal
of validating these predictions using multiple lines of evidence. This focusing of our
predictions requires additional and complementary information, and for compounds with
essential gene targets it is imperative to screen against a collection with the potential
to directly implicate individual proteins as compound targets. Using the CG-TARGET
pipeline described in chapter 3, 848 compounds were selected for further study based on
high statistical confidence in their predicted perturbations of biological processes (false
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discovery rate ≤ 25%). Another 167 compounds were selected for screening at reduced
concentrations because they were too growth-inhibitory in the initial screen to generate
profiles that passed quality control. These compounds were also potentially interesting
because higher levels of growth inhibition were associated with a higher rate of high
confidence bioprocess predictions [34].
In total, we screened our set of ~1000 high-confidence compounds against 3 addi-
tional mutant collections: the full nonessential deletion collection (~5000 strains—a su-
perset of the diagnostic set), hypomorphic mutants of essential genes (1181 temperature-
sensitive strains), and heterozygous diploid mutants of essential genes (964 strains). All
of these mutant collections were constructed using the same pdr1∆pdr3∆snq2∆ drug-
hypersensitive background that was used for the diagnostic collection, and thus the
information obtained across these collections for one compound at a defined concentra-
tion should be a functional reflection of the same underlying compound-induced cellular
state. In the remainder of this chapter, I will refer to the four mutant collections with
the following nomenclature: nonessential (NE), diagnostic (diag.); nonessential, full;
essential (E), hypomorphic (hypo.); essential, heterozygous (het.).
As described in chapter 2, the processing of large-scale chemical-genetic interaction
datasets using BEAN-counter involves more than just a “push-button” generation of
chemical-genetic interaction scores. Systematic biases are more easily observed when the
dataset was generated from multiple smaller experiments, and certain uninformative or
uninteresting signals can account for much of the variation in the data. The framework
provided by BEAN-counter allows the user to determine which of these effects 1) exist,
2) can be removed, and 3) should be removed first. It is intentionally flexible because
the datasets I have processed, even using the same mutant collection, do not always
show the same patterns in the same order of intensity. With the introduction of three
new data types, this flexibility was key in letting the data inform the decisions I made
during processing.
As our goal is to refine our previous bioprocess-level predictions by integrating them
with predictions from our more recently acquired datasets, it is important to character-
ize global properties of the individual datasets and assess where they may share or offer
complementary information. Sufficient sharing of information is required to boost de-
sired signals when combining data, while complementary information allows for making
predictions even when one dataset is blind to certain functional effects of compounds.
In this chapter, I describe the work I have performed not only to process these datasets
but also to characterize them in terms of network properties, functional information
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content, and interesting global relationships. These characterizations were enabled by
a careful compound matching procedure across the datasets, mitigating the effects of
an experimental design that did not focus on obtaining profiles for all compounds at
the exact same concentrations. I also characterize the data at different stages during
processing, as I believe it a valuable exercise to quantify using orthogonal measures the
effects of the processing schemes I used.
4.2 Results
4.2.1 Data processing
In processing the aforementioned four types of datasets, my goal was to define common
stages that would allow comparisons across the data types during the different stages
of processing. I settled on three data processing stages: raw, clean, and post-processed.
The “raw” data were the immediate output of chemical-genetic interaction scoring,
with the only manually removed mutants and conditions being those that behaved in-
appropriately in negative control conditions (signals that should not be trusted at all).
“Clean” data underwent another stage of manual review, removing strains and condi-
tions with strong signals that may have confounded the post-processing steps (which
attempt to detect signals that explain the largest amount of variance in the dataset).
“Post-processed” data were subjected to a user-defined combination of supervised and
unsupervised effect removal and represent a thoroughly examined and finalized version
of the data. The techniques used in post-processing are described in chapter 2 and are
discussed more in detail below. Most of the data processing discussion centers on the
post-processing procedures, as they exert the most impact on the final structure of the
data.
Post-processing involves the supervised and unsupervised removal of signals deemed
to be nonspecific or related more strongly to technical attributes of the experiments
than to the underlying biology. However, it would be foolish to assume that we know
exactly what a dataset that directly reflects the underlying biology would look like.
Thus, the goal of these post-processing procedures was to reveal the maximal amount
of biologically-relevant information in the data while minimizing the amount of ma-
nipulation that was performed to reveal that information. As described in chapter 2,
supervised removal of batch-related effects was performed using a multiclass version of
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linear discriminant analysis (LDA), and unsupervised removal of dominant yet uninfor-
mative signals was performed using singular value decomposition (SVD). These analyses
decompose the data matrix into orthogonal (unrelated) signals, called components, look-
ing first for the signals that explain the most variance. The primary difference between
SVD and LDA is that SVD learns these signals directly from the data without any ex-
ternal information, while LDA, as a supervised technique, learns signals that separate
predefined groups of samples (the “batches”). Thus, the variance explained by SVD
components is the variance across all of the samples, while the variance explained by
LDA components is that which differentiates known sample groups. One can then re-
move these components in order of most to least variance explained, thereby removing
unwanted signals from the data.
The post-processing procedure requires a user to make number of judgment calls,
some of which – speaking from experience – can be very challenging. It is therefore
extremely important to have access to reliable, quantitative tools for evaluating the
changes these procedures introduced to the data. Even with such tools, the results
they generate do not always suggest the same course of action. This is where the
analyst must make tough judgment calls, as evidenced in the remainder of section 4.2.1.
These tools come in the form of histograms, precision-recall (PR) analysis, and receiver-
operator characteristic (ROC) analysis, and we use them to analyze changes in the
relationship between pairwise condition correlations and known condition labels such
as compound names or batch membership. As the simplest of these tools, histograms
show the distributions of same-batch and different-batch condition correlations, allowing
the analyst to visually assess the separation of these distributions and determine if
the between-batch correlations are centered on zero (the expected outcome, with some
exceptions). ROC and PR analyses frame the evaluation as a prediction problem in
which all pairwise condition correlations above a threshold are predicted to indicate
same-batch membership of those pairs, with the remaining correlations predicting pairs
with different-batch membership. The resulting ROC curves provide an evaluation of the
separation of same-batch and different-batch correlation distributions, while PR curves
more stringently evaluate the ability of the strongest N correlations to recapitulate
same-batch relationships. PR curves can be plotted with recall represented on the x
axis as either the number of same-batch pairs or as the ratio of true positives at the
given threshold to the total number of true positives (recall in the traditional sense).
The former allows for more interpretation and scrutiny of the PR curves, while the
latter enables comparisons across datasets with different numbers of true positive pairs.
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Nonessential deletion collection, diagnostic mutants
Our original set of large-scale chemical-genetic interaction profiles was obtained across
a diagnostic subset of 310 nonessential deletion mutants [34]. Thinking of the selection
problem in terms of a genetic interaction matrix, where row and column labels indicate
single mutants and the matrix entries represent interaction scores for the corresponding
double mutants, we selected a subset of rows that retained the ability to cluster the
columns similarly to all rows [44]. A chemical-genetic interaction profile is then a
column vector across the same subset of mutants, with its mode-of-action predictions
deriving from the ability of the mutant subset to capture functional similarities between
the chemical-genetic and genetic interaction profiles. This original screen consisted of
9850 chemical compounds from the RIKEN Natural Product Depository – each with
triplicate technical replicates at the PCR stage, and some with biological replicates
– along with 5724 DMSO control conditions, for a total of 38,400 potential profiles.
After the original round of processing and bioprocess-level target prediction using CG-
TARGET (see chapter 3), we identified 848 compounds with high-confidence (FDR ≤
25,%) predictions that warranted further study. These compounds, in addition to a small
set of compounds that did not yield profiles due to their extreme growth inhibition, were
screened not only against different mutant collections but also against the diagnostic set,
with the purpose of adding more biological replicate profiles for our high-confidence set
of compounds. In all, the dataset discussed here contained an additional 2788 conditions
for a total of 41188 potential profiles. After initial interaction scoring and collapsing
of the technical replicates into mean profiles, the dataset consisted of interaction scores
between 283 mutants and 9827 conditions (figure 4.1a). Further manual removal of
mutants and conditions reduced the number of mutants to 281 (figure 4.1b–c).
The data processing procedures described here represent a reanalysis of the original
data in our recently published screen, with additional biological replicates added for
high-confidence compounds. In contrast to the original post-processing procedure, which
involved the removal of the 5 most-prominent index tag-related batch effects and one
SVD component, this round of processing saw no supervised removal of batch effects and
instead the removal of 2 SVD components. The absence of detectable index tag batch
effects was likely due to increased stringency of index tag quality control defaults during
the interaction scoring component of the pipeline. The removal of 2 SVD components
was a bit surprising, as datasets generated using the diagnostic set usually benefit
the most, according to our metrics, from the removal of 1 component. However, as
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(a) Raw (283 mutants × 9827 conditions) (b) Clean (281 mutants × 9827 conditions)
(c) Post-processed (281 mutants × 9827 condi-
tions)
Figure 4.1: Processing stages of the diagnostic nonessential mutant dataset, visualized
using hierarchically clustered heat maps. Mutants are on the rows and conditions on
the columns.
just described, the dataset in its current form contains two separate screens, which
were performed more than a year apart. Thus, it is not unreasonable to conclude
that the removal of uninformative, dominant signals masking more useful underlying
information would require the removal of more than one SVD component to account
for differences between the separate datasets. As shown in figure 4.2, both the PR and
ROC-based evaluations of biological replicate correlations supported the removal of 2
SVD components.
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(a) (b)
Figure 4.2: Evaluation of replicate correlations in the diagnostic nonessential mutant
dataset upon successive removal of SVD components. The PR (a) and ROC (b) curve
analyses assess the ability of pairwise profile correlations to predict if two profiles were
generated using the same compound.
Nonessential deletion collection, all mutants
We screened a total of 961 compounds against the entire pooled, nonessential deletion
collection, resulting in 1161 chemical-genetic interaction profiles across 3285 mutants.
Further manual inspection of the dataset resulted in the removal of 70 conditions, for
a total of 1091. Like the aforementioned dataset obtained against the diagnostic subset
of these mutants, as well as many others I have processed, this dataset shows a domi-
nant signature across a large percentage of mutants and conditions. No batch-related
effects were detected, and thus I pursued the removal of the dominant signal via SVD
correction.
However, the lack of biological replicates in the design of this experiment presented
a challenge in the evaluation of SVD component removal. Precision-recall analysis is
sensitive to class-imbalance issues in binary classification problems, meaning that, for
example, increases in the ratio of negative class to positive class members will gen-
erally decrease precision measurements. In a dataset containing very few replicates,
the members of the negative class (different-compound correlations) vastly outnumber
those in the positive class, and thus precision-recall analysis is not useful for evaluating
SVD correction on this dataset figure 4.4a. In contrast, ROC analysis is not sensi-
tive to the class-imbalance issue, as it captures the separation between the same- and
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(a) Raw (3285 mutants × 1161 conditions) (b) Clean (3285 mutants × 1091 conditions)
(c) Post-processed (3285 mutants × 1091 condi-
tions)
Figure 4.3: Processing stages of the full nonessential mutant dataset, visualized using
hierarchically clustered heat maps. Mutants are on the rows and conditions on the
columns.
different-compound correlation distributions, regardless of their sizes. Using the his-
tograms and ROC curves, I could judge that removing 1 SVD component dramatically
improved this separation, with no benefits associated with further component removal
figure 4.4b. It is interesting to note that my initial efforts to process this dataset oc-
curred while the post-processing procedures in BEAN-counter were still under heavy
development—this dataset may have been the impetus for introducing ROC curve anal-
ysis as a post-processing evaluation tool to complement my qualitative analyses of the
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correlation distributions.
(a) (b)
Figure 4.4: Evaluation of replicate correlations in the full nonessential mutant dataset
upon successive removal of SVD components. The PR (a) and ROC (b) curve analyses
assess the ability of pairwise profile correlations to predict if two profiles were generated
using the same compound.
Essential hypomorphic mutants
Entering essential gene space, we screened 952 compounds against our collection of drug-
sensitive, hypomorphic mutants of essential genes. Most compounds were screened with
one biological replicate each at 2, 10, and 50µg/mL, with some compounds screened at
lower concentrations. The resulting dataset required a rather extensive set of cleaning
and post-processing procedures and provides lessons on the effects of dose selection.
After initial interaction scoring, the dataset consisted of interaction scores between
3255 conditions and 866 mutants (figure 4.5).
Manual inspection did not reveal any strains that required removal from the dataset
but did reveal a few hundred conditions that satisfied removal criteria. Most of these
conditions were from the cluster exhibiting the very dominant signature present in the
data and were most likely to be drawn from the set of compounds screened at 50µg/mL.
The largest set of conditions I removed possessed profiles whose scores were essentially
split into two classes: mutants with scores near zero and those with very positive scores.
In these profiles, growth was inhibited so much that the null hypothesis for abundance
across the strains became zero, with positive interactions that resulted from nonzero
abundances being the only observable deviations. This signature contrasts with the
remainder of the dominant signature in the dataset, which was less extreme and still
111
(a) Raw (866 mutants × 3255 conditions) (b) Clean (866 mutants × 2881 conditions)
(c) Post-processed (866 mutants × 2881 condi-
tions)
Figure 4.5: Processing stages of the hypomorphic essential mutant dataset, visualized
using hierarchically clustered heat maps. Mutants are on the rows and conditions on
the columns.
showed both positive and negative interactions. From previous experience processing
these data, I knew that the subset of profiles induced by the most extreme levels of
growth inhibition – due to their prevalence, strength of signal, and fundamentally dif-
ferent score distribution – would likely confound the post-processing procedures. In
addition, these profiles appear to have lost all of their functional information in lieu
of this one bifurcated signature, most likely rendering them useless for the purposes of
predicting compound function. I manually removed 381 conditions, leaving a total of
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2881 conditions.
Extensive post-processing efforts continued in the form of SVD correction and batch
effect removal. The dominant signature, due to its higher intensity than in any of the
other datasets discussed in this chapter, was the obvious candidate for correction prior
to supervised batch effect removal. While the precision-recall curves showed continuous
improvement across the removal of 1–4 components, the ROC curve showed no extra
benefit after the removal of two components figure 4.6. It was thus challenging to make
the decision to stop at removing two SVD components.
(a) (b)
Figure 4.6: Evaluation of replicate correlations in the hypomorphic essential mutant
dataset upon successive removal of SVD components. The PR (a) and ROC (b) curve
analyses assess the ability of pairwise profile correlations to predict if two profiles were
generated using the same compound.
However, the decision on SVD correction was also made in the context of a lane-
related batch effect that manifested itself upon SVD component removal figure 4.7.
Further SVD component removal did not alleviate this effect, so I subjected the SVD-
corrected dataset to lane effect removal. In contrast to the effects of SVD correction
on the observed lane effect, supervised lane effect removal showed continuous reduc-
tions in this signal when removing 1–4 LDA components figure 4.8. Interestingly, lane
effect correction showed increased performance in predicting compound replicate sta-
tus according to precision-recall metrics but decreased performance according to ROC
curves figure 4.9. This suggests that removing the lane-related batch effect affected
the correlation structure of the dataset such that the highest profile correlations gained
predictive power while the intermediate correlations lost power. I thus removed 4 LDA
components to correct for the observed lane effect and finalize the dataset.
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(a) (b)
Figure 4.7: Evaluation of lane correlations in the hypomorphic essential mutant dataset
upon successive removal of SVD components. The PR (a) and ROC (b) curve analyses
assess the ability of pairwise profiles correlations to predict if two profiles were in the
same lane for Illumina sequencing.
(a) (b)
Figure 4.8: Evaluation of lane correlations in the hypomorphic essential mutant dataset
upon successive removal of lane-related LDA components. The PR (a) and ROC (b)
curve analyses assess the ability of pairwise profiles correlations to predict if two profiles
were in the same lane for Illumina sequencing.
Essential heterozygous diploid mutants
Finally, we screened the same set of ~950 compounds against our collection of drug-
sensitive, heterozygous diploid mutants. The dosing scheme used for the hypomorphic
essential mutant screen was also used in generating this dataset. In contrast to the
hypomorphic essential mutant screen, this dataset required much less cleaning and
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(a) (b)
Figure 4.9: Evaluation of replicate correlations in the hypomorphic essential mutant
dataset upon successive removal of lane-related LDA components. The PR (a) and
ROC (b) curve analyses assess the ability of pairwise profiles correlations to predict if
two profiles were generated using the same compound.
post-processing to yield a satisfactory final dataset. After initial interaction scoring,
the dataset consisted of interaction scores between 3495 conditions and 918 mutants
(figure 4.10a). No mutants met my criteria for exclusion, but I did remove 79 condi-
tions (for a total of 3416) that mostly exhibited seemingly random patterns of zero and
positive interaction scores (in contrast to the conditions removed from the hypomorphic
dataset, which shared a common pattern of zero and positive scores) (figure 4.10b).
Similar to the other datasets, this dataset possessed a common, albeit less intense,
signature that could not be attributed to any experimentally derived batches. In the
absence of any observable batch effects, I performed SVD correction to remove this
signature and improve the ability of profile correlations to predict compound replicate
status. Removing one SVD component resulted in the largest performance increase
according to precision-recall analysis and the best overall performance according to
ROC analyses figure 4.11.
4.2.2 Dataset alignment for comparative analyses
Calculating global properties on chemical-genetic interaction networks is subject to bi-
ases that can be partially but not completely controlled. In contrast to genetic interac-
tion networks, where the notion of an “all by all” or “complete” network is scientifically
valid and achievable with modern technology, a “complete” chemical-genetic interac-
tion network would require testing mutants for all genes against all known chemicals,
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(a) Raw (918 mutants × 3495 conditions) (b) Clean (918 mutants × 3416 conditions)
(c) Post-processed (918 mutants × 3416 condi-
tions)
Figure 4.10: Processing stages of the heterozygous essential mutant dataset, visualized
using hierarchically clustered heat maps. Mutants are on the rows and conditions on
the columns.
across a range of doses. As more than 166 billion molecules can be enumerated from
just 17 atoms of C, N, O, S, and halogens (F, Cl, Br, I), our efforts to character-
ize chemical-genetic interaction networks will always be subject to potential bias in
chemical space [109]. Additionally, while relative gene dose is well-defined for mutants
screened in genetic interaction experiments (e.g. 0 versus 1 copy for haploid deletion
mutants, 1 versus 2 copies for heterozygous diploid mutants), the emergence of a partic-
ular chemical-genetic interaction profile depends on the screening dose of the compound
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(a) (b)
Figure 4.11: Evaluation of replicate correlations in the heterozygous essential mutant
dataset upon successive removal of SVD components. The PR (a) and ROC (b) curve
analyses assess the ability of pairwise profile correlations to predict if two profiles were
generated using the same compound.
[94]. Thus, no compound possesses a single chemical-genetic interaction profile. Global
properties computed on chemical-genetic interaction networks should thus be consid-
ered approximations that may suffer from major biases depending on the chemicals and
doses sampled.
Because of these potential biases, a comparative analysis of global properties across
different types of chemical-genetic interaction screens should match the sampled chem-
ical space, even at the expense of compound and dose coverage. The compounds in the
high-confidence set were not screened using the same dose regime across the different
mutant collections, and thus the datasets must be aligned before performing these com-
parisons. Both nonessential deletion collections were primarily screened at 10µg/mL,
with lower screening concentrations used when 10µg/mL was too growth-inhibitory. In
contrast, the essential mutant collections were screened at multiple concentrations. The
default concentrations were 2, 10, and 50 µg/mL, and reduced concentration schemes
were usually, 2, 5, and 10 or 0.5, 1, and 2 µg/mL. As such, the most common concentra-
tion across the four datasets was 10 µg/mL, which allowed for the matching of 762 out
of the 843 common compounds across the datasets. Exact matching on other concen-
trations, however, was not successful, yet the profiles obtained at lower concentrations
are also valuable to retain in case the 10 µg/mL dose was too high. For the comparisons
in this section, I chose to aggregate each compound’s doses ≤ 10 µg/mL into a single
median profile, which allowed the matching of 49 more compounds (for a total of 811)
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across the datasets. Replicate screens at 10 µg/mL for each compound were also aggre-
gated, such that all four datasets possessed one chemical-genetic interaction profile for
each compound-dose combination.
Before performing network property comparisons, it is possible to use growth inhibi-
tion data that accompanies each screen as a way to orthogonally quantify the similarity
of each compound’s effects across the different mutant collections. These data repre-
sent the relative growth, compared to negative control conditions and measured using
absorbance, of the entire pool of mutants when treated with each compound. While
growth inhibition of the pool is not a readout of function, it does provide a baseline
expectation of functional overlap between the datasets based on the consistency of each
compound’s general effects in the different collections. Low concordance in this measure
could be a warning that for any particular compound, only some of the datasets possess
valid functional readouts. It could additionally reflect low technical consistency across
the experiments, which would also negatively impact the resulting profiles.
In our data, growth inhibition correlations across the datasets appear to be rea-
sonable (figure 4.12). It is difficult, if not impossible, to place a lower bound on the
expected cross-collection reproducibility of pool growth inhibition without an in-depth
investigation of the contributing factors. As our measurements of growth inhibition pri-
marily served the purpose of a quality-control check to determine when a compound’s
dose should be adjusted, we do not necessarily expect the correlation to be 1. Indeed,
all correlations are above 0.5 and appear to be driven by values across the range of
relative growths. As might be expected, correlations between datasets generated at
the same time (the essential mutant datasets) were much higher than those between
datasets obtained years apart from each other (all other comparisons). The difference
in growth rate distribution between the two nonessential mutant collections is striking
and may reflect a difference in the number of compound molecules each cell is exposed
to. As others have shown [94], the ratio between compound concentration and inocu-
lation cell density influences the resulting chemical-genetic interaction profiles. In this
case, the tenfold increase in the number of mutants for the full versus the diagnostic
collection could result in a tenfold dilution in the effect of compounds on each mutant
cell, dampening not only the growth inhibition of these compounds but probably also
the intensity of their chemical-genetic interaction profiles.
These aligned datasets are the input data for the comparative analyses in sec-
tions 4.2.3 and 4.2.4.
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Figure 4.12: Comparison of growth inhibition induced by each condition for each pair of
chemical-genetic interaction datasets. Values shown reflect growth of the mutant pool
relative to DMSO solvent control (1 = no inhibition, 0 = full inhibition). Conditions
were matched on compound name and concentration, with concentration divided into a
10 µg/mL bin and a ≤ 10 µg/mL bin. The median relative growth value from each bin
is shown here.
4.2.3 Functional information content
In section 4.2.1, I discussed heavily the post-processing procedures involved in generat-
ing chemical-genetic interaction datasets, and in particular the importance of biological
replicate profile correlations in determining the functional information content of signals
that have been slated for removal from a dataset. However, I find it advisable to look to
additional gold standards as validation that these post-processing steps – rather exten-
sive in some cases – are successful in their stated goal of revealing functional information
buried underneath batch-related effects and dominant yet uninformative signals. The
Chemical Entities of Biological Interest (ChEBI) ontology [110] or the Medical Sub-
ject Headings (MeSH) controlled vocabulary (https://www.nlm.nih.gov/mesh/) could
satisfy the role of a gold standard, as both map compounds to terms related to their bi-
ological function, medical uses, and other characteristics that could ultimately be used
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to assess the quality of pairwise condition correlations. However, only a small frac-
tion of the compounds we have screened overlap with these databases, as our goal was
to demonstrate the rapid annotation of novel, uncharacterized compounds. As such,
I do not expect these standards to be useful in assessing improvements in functional
information content during dataset post-processing.
In the absence of useful functional standards on the condition side of our chemical-
genetic interaction datasets, one can ask a slightly different question that leverages the
high quality of functional annotations on the mutant side. Specifically, one can ask how
well the mutants in the dataset cluster according to known biological function based
on the correlations of their interaction scores across the compounds. If the dominant
signal that I remove from nearly every dataset I process truly lacks functionally specific
signal, then the quality of the mutant clustering should improve upon removal of that
signal. Conversely, a decrease in the quality of mutant clustering upon removal of this
dominant signal would raise serious questions about the validity of this procedure.
The specific approach I take for evaluating the mutant clustering induced by each
dataset is called a coannotation analysis. In this analysis, we pose a similar prediction
problem to that of biological replicate evaluation. However, instead of using the con-
ditions’ pairwise profile correlations to predict if two conditions are replicates of each
other, we use the mutants’ pairwise profile correlations to predict if the two mutants’
respective genes are functionally related to each other. Just as the former analysis re-
quires knowledge of the compound names, the latter analysis requires a gold standard
that maps genes to functionally coherent gene sets. For the subsequent analyses, I used
Gene Ontology biological process terms with less than 50 annotations. The size restric-
tion is important in making sure the gold standard term annotations are reasonably
functionally specific compared to the set of all terms [111]. A list of protein complex
memberships is another useful gold standard for this type of analysis. The actual quan-
titative evaluation is performed using PR but not ROC analysis, as clustering typically
concerns itself with the strongest pairwise correlations and not the separation between
distributions of coannotated and non-coannotated correlation.
Indeed, I find that in all four datasets, removing the dominant signal improved
the ability of mutant similarities to predict biological process coannotation, just as it
improved the prediction of replicate status (figure 4.13). In addition to improved per-
formance at the beginning of the PR curves, the overall area under the curves (AUPRC)
increased consistently throughout the stages of processing (table 4.1). Improvements in
AUPRC ranged from 11% for the full nonessential deletion collection to 51% for the
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essential hypomorphic collection. The essential hypomorphs exhibited the most drastic
improvement, with post-processing revealing functional mutant-side information where
it appeared that none existed previously (figure 4.13c). This is particularly encour-
aging given the extent of the post-processing procedures I performed on this dataset.
For the full nonessential collection, both manual condition removal and post-processing
contributed to increasing, by a factor of ~4, the maximum recall at which a precision of
0.1 is achieved (figure 4.13b). Combined with the improvement in predicting replicate
status, this is the strongest collection of evidence so far showing that the dominant
signal in all of these datasets does not contain functionally specific signal.
(a) Nonessential, diagnostic (b) Nonessential, full
(c) Essential, hypomorphic (d) Essential, heterozygous
Figure 4.13: Assessing the mutant-side functional information content of each chemical-
genetic interaction dataset at each stage of processing through coannotation analysis.
Precision-recall analysis was performed to assess the ability of pairwise profile correla-
tions on the mutant side to predict if two genes were coannotated to a Gene Ontology
Biological Process term.
Evaluating mutant clustering allows enables testing of other hypotheses about the
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AUPRC (fold enrichment)
Raw Clean Post-processed
NE, diag. 0.054 (1.9) 0.054 (1.9) 0.074 (2.6)
NE, full 0.018 (1.1) 0.018 (1.1) 0.020 (1.1)
E, hypo. 0.035 (1.2) 0.037 (1.2) 0.053 (1.7)
E, het. 0.037 (1.3) 0.042 (1.5) 0.048 (1.7)
Table 4.1: Areas under the precision-recall curve assessing the ability of mutant-wise
chemical-genetic interaction profiles to predict coannotation to known biological pro-
cesses.
functional information content of the datasets. By matching the datasets to contain
the same compounds and concentrations, one can compare the quality of clustering
across the datasets and test specific hypotheses regarding which mutant collections
should show better or worse clustering. For example, one might hypothesize that the
quality of heterozygous diploid mutant clustering will be lower than that of the other
collections. This is based in the idea put forth by certain experts in the field that
heterozygous diploid profiles reflect specific compound-target interactions, which would
result in profiles that are too sparse to provide functionally-relevant correlations between
mutants. However, this is obviously not the case, as the heterozygous mutants show
similar performance to the hypomorphs based upon both upon visual inspection of
the PR curves (figure 4.14) and AUPRC enrichment over the background expectation
(table 4.1).
Overall, the full nonessential deletion collection showed the worst coannotation per-
formance, which is a striking contrast to the best-performer status of the diagnostic
nonessential collection. Given that the diagnostic collection is a subset of the full col-
lection, it is worth considering the factors that might account for this difference. These
mutants were selected from the “array” side of the genetic interaction network based
on their ability to recapitulate correlations between the “query” mutant profiles. As
such, one might not expect good clustering among the diagnostic mutants because the
selection procedure was essentially performed with the intent of eliminating functional
redundancy among the mutants. Conversely, a side effect of the selection procedure
would likely be an enrichment for mutants that show informative genetic interaction
profiles across a range of biological functions, which would likely increase the quality
of clustering. As noted in the comparative growth inhibition analysis (section 4.2.2), it
is possible that the effects of compounds were weaker against the full nonessential col-
lection, and this would likely result in sparser profiles with lower information content.
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Figure 4.14: Comparison of mutant-side coannotation performance across all final (post-
processed) chemical-genetic interaction datasets. Recall is presented in the traditional
sense as the fraction of positive examples recovered at a given threshold, which enables
comparisons across datasets of different numbers of mutants. The “Nonessential, full –
diagnostic subset” (orange) line was generated by performing coannotation PR analysis
on the full nonessential dataset (blue) after limiting its mutants to only those in the
diagnostic nonessential dataset.
Screens with 4000 mutants may also exhibit dampened interaction signals compared
to those with 300 mutants due to the reduced capacity for growth of each individual
mutant. Interestingly, the set of diagnostic mutants within the full nonessential collec-
tion showed similar coannotation performance to the diagnostic mutant-only dataset,
revealing that, in this case, the pool context had little effect on these strains’ ability
to capture functional information (figure 4.14, “Nonessential, full – diagnostic subset”).
Therefore, it seems that the selection of mutants with good genetic interaction profiles
in addition to residual functional redundancy drove the high comparative coannotation
performance of the diagnostic mutant collection. Additionally, technical considerations
such as the number of compound molecules per cell, growth inhibition differences, and
the potential dampening effect of a larger pool appear not to have influenced the func-
tional information content captured by these mutants.
In chapter 3, I discussed the finding that negative chemical-genetic interactions con-
tained most of the information that enabled target prediction through integration with
genetic interaction profiles. To further investigate potential asymmetry in the functional
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information content of chemical-genetic interaction profiles, I performed the same coan-
notation analysis after restricting the sign of the interactions. As was discovered during
target prediction for the diagnostic nonessential mutant profiles, the functional informa-
tion content of both nonessential mutant datasets came almost exclusively from nega-
tive interactions (figure 4.15). In contrast, both collections of essential mutants showed
an increase in information contributed by positive chemical-genetic interactions. The
heterozygous mutants were the most extreme in this regard, with the vast majority
of functional information that contributed to mutant clustering deriving from positive
interactions. This reversal in asymmetry for heterozygous diploid profiles could sug-
gest that negative chemical-genetic interactions, as previously thought, reflect specific
compound-target interactions, but that much denser functional information emerges on
the positive side and enables clustering of the mutants according to their biological
function.
Figure 4.15: Comparison of mutant-side coannotation performance across all final (post-
processed) chemical-genetic interaction datasets after limiting to only positive or neg-
ative interaction scores. Recall is presented in the traditional sense as the fraction
of positive examples recovered at a given threshold, which enables comparisons across
datasets of different numbers of mutants.
4.2.4 Interaction density and degree
Screening four different mutant collections against an overlapping set of compounds
also enabled the investigation of general trends regarding the frequency of interactions.
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Specifically, I investigated the interaction density – the number of observed interactions
divided by the total number of possible interactions – and mutant interaction degree –
reported as the number of observed interactions divided by total possible interactions
for each individual mutant. When the sampling space is defined, such as interactions
across a genome, degree is often reported as an integer value. However, in the case of
counting each mutant’s interactions across a tiny fraction of possible chemical space, it
is more reasonable to report degree as a fraction. These fractions should not be thought
of as absolute, definitive density and degree values but rather approximations that
are useful for comparison purposes. I performed both within-dataset comparisons to
characterize differences in the frequency of positive and negative interactions and cross-
dataset comparisons to characterize differences in interaction frequency for different
sets of mutants. The analyses below can be considered quantitative companions to the
clustered heat maps shown previously in this chapter.
Interaction density varied across mutant set and decreased with further processing
stages (figure 4.16). All chemical-genetic interaction datasets possessed interaction den-
sities between 0.03 and 0.052 after post-processing, which induced a range of density
reductions across the datasets (~2-fold for nonessential mutant collections, 1.3-fold for
the essential heterozygous diploid mutants, and 5-fold for the essential hypomorphic
mutants). The most dramatic reduction in interactions occurred with the essential hy-
pomorphic mutant dataset and resulted in this dataset transitioning from the status of
most- to least-dense and also changing its ratio of negative to positive interactions to
1.35, near the median of this value across the other datasets. With the exception of the
essential heterozygous diploid mutants, which had a nearly equal ratio of negative to
positive interactions, the remaining datasets possessed between 1.35 and 1.84 negative
interactions per positive interaction. Interestingly, the diagnostic subset of nonessen-
tial mutants possessed both a higher frequency of interactions (0.052 vs. 0.041) and a
higher ratio of negative to positive interactions (1.84 vs. 1.48). When comparing to
these mutants’ interaction densities in genetic interaction experiments [28], some of the
observed trends were retained, such as a higher density for the diagnostic nonessential
vs. all nonessential mutants, and the generally higher density of negative vs. positive
interactions. Strikingly, the essential hypomorphic mutants did not retain the overall
density trend, with the highest interaction density in genetic interaction datasets but
the lowest in our chemical-genetic analyses. Some or all of this difference may be due
to the drastic reduction in density induced by post-processing procedures, and further
experiments would help to clarify if these mutants do perform differently under chemical
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Figure 4.16: Comparison of chemical-genetic interaction density for the datasets in
this chapter across different stages of dataset processing (interaction cutoff: z-score
±2.5). Blue and yellow bars indicate density of negative and positive interactions,
respectively, and the number in each yellow bar represents the total interaction density.
The additional “GI network” panel provides a comparison to the genetic interaction
densities of the relevant subsets of strains screened for genetic interactions (interaction
cutoff: epsilon score ±0.08, p-value < 0.05) [28].
or further genetic perturbations.
Analyzing interaction degree for individual mutants provides more detailed insights
into chemical-genetic interactions beyond bulk interaction density analysis. figure 4.17.
Specifically, I compared each mutant’s chemical-genetic interaction degree from the
chemical-genetic interaction datasets in this chapter to the same mutant’s genetic in-
teraction degree [28]. Previous investigations have shown correlation between chemical-
genetic and genetic interaction degree [25, 27], and I wanted to characterize the robust-
ness of this trend across a different set of chemical compounds and different mutant
collections. Indeed, this trend occurs in our datasets across mutant collections and
regardless of interaction sign, with the highest correlations observed for subset of the
diagnostic nonessential mutants. Previous work had not investigated the robustness
of this trend for hypomorphic (temperature-sensitive) essential mutants. Despite the
differences in overall interaction density between the chemical-genetic and genetic inter-
action datasets, these mutants also reproduced this trend, providing further evidence
that the same genes generally buffer cells against both genetic and environmental insults.
126
Figure 4.17: Comparison of total, negative, and positive chemical-genetic and genetic
interaction degree for the sets of strains analyzed in this chapter that were also screened
for genome-wide genetic interactions (nonessential mutants – both diagnostic and full
sets – and hypomorphic essential mutants) [28]. Degrees are represented after log10-
transformation, and Pearson correlation coefficients calculated on the log10-transformed
values are shown as well. The cutoff for chemical-genetic interactions was a z-score ±2.5,
and that for genetic interactions was an epsilon score ±0.08 and p-value < 0.05.
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4.2.5 Growth inhibition effects
Across all datasets referenced in this document (in chapter 2 and section 4.2.1) and
almost all other datasets I have processed using BEAN-counter, the common post-
processing step has been the unsupervised removal of the largest source of variance
in the data by removing the first one or two SVD components (supervised removal
of batch effects with LDA is much less common and consistent). In sections 4.2.1
and 4.2.3, I demonstrated that removing this large source of variance improves clustering
of both the conditions and the mutants, as evaluated using condition replicate and
coannotation status, respectively. Because of the seeming lack of functional information
in this signature, its cause and meaning have remained elusive. This section discusses
my efforts to characterize the primary source of variance in each of the previously
introduced datasets.
The first step in characterizing the patterns that comprised the primary sources of
variance in each of these datasets was to determine if they shared a biological origin.
This was important to determine if this type of pattern is a universal property of our
chemical-genetic interaction experiments or if it somehow arises independently within
the different mutant collections. One of the ways to determine this would be to ask
if the same compounds screened at the same concentration caused the same degree of
effect in each of the datasets. Because the datasets were matched on compound and
concentration, I could directly ask this question of the data. Indeed, by projecting the
chemical-genetic interaction profiles onto the first SVD component of their respective
datasets, I observed that compounds strongly associated with the dominant signature in
one dataset were also strongly associated with the dominant signature in another dataset
figure 4.18. While the strongest correlations were observed for the two nonessential and
the two essential mutant-based datasets, all pairs of datasets showed nonzero correla-
tions for this association. With the exception of the two nonessential mutant-based
datasets, one of which contains mutants that are a subset of the other, all dataset pairs
compared here were derived from completely different mutant collections based on dif-
ferent perturbation technologies, and their cross-dataset concordance in terms of the
dominant signature strongly suggests that this signature is a universal property of our
chemical-genetic interaction screens.
Now with strong evidence that the dominant signal in each dataset reflected a com-
mon property in all of the datasets, I next investigated if this signal could actually be
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Figure 4.18: Comparison of the degree to which the same compounds were associ-
ated with the dominant signature in each dataset. For each pairwise combination of
datasets, each point represents one compound screened at one concentration (present
in both datasets), and its x and y coordinates reflect the projection of that condition’s
chemical-genetic interaction profile onto the first SVD component of the column- and
row-annotated datasets, respectively. The correlation values reported are Pearson cor-
relation coefficients on the scatterplots reflected across the diagonal.
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represented more appropriately by a trajectory that progresses from low to high inten-
sity. As hierarchical clustering-based visualizations greedily assemble the profiles into
groups instead of organizing them linearly, the clustered heat maps we use for visualiza-
tion may have obscured directional relationships between certain signals and properties
of the conditions. Embedding the chemical-genetic profiles in each dataset into a one-
dimensional space revealed that, indeed, the profiles can be sorted from low to high
intensity in terms of their dominant signature in a completely unsupervised manner
figure 4.19. This confirms both the dominance and directionality of this signature.
To construct a trajectory for each dataset, I used a dimensionality reduction tech-
nique called t-stochastic neighbor embedding (t-SNE), a recently popularized technique
in biological data analysis that has seen extensive use in the rapidly growing field of
single cell analysis [112–114]. In contrast to principal component analysis (PCA) and
SVD, which provide dimensionality reduction by computing eigenvectors and associated
eigenvalues that point in the primary directions of variance in the data, t-SNE reduces
the dimensionality of the data by probabilistically embedding the data points in a lower
dimensional space in a way that minimizes the distance between points that are close to-
gether in the higher dimensional space. One key difference between these two techniques
is that dimensionality reduction via PCA or SVD, for the purposes of data visualiza-
tion, typically involves retaining only the first two or three components, while t-SNE
theoretically uses all of the available information to determine a data point’s location
in the resulting lower-dimensional embedding. In this way, t-SNE not only potentially
captures more information, it also captures nonlinear relationships such as those that
may be present in a trajectory derived from cells grown in competition with each other.
One potential disadvantage of t-SNE is that it recapitulates local distances at the ex-
pense of medium- to long-range distances between points, so any effort to recapitulate
a trajectory must involve fine sampling along the dimension of the trajectory.
The directionality of the common dominant signal in our chemical-genetic inter-
action datasets suggests a relationship with a continuous variable associated with the
conditions. One such variable that has aroused suspicion within our collaboration is the
level of growth inhibition induced by a compound. For each chemical-genetic interac-
tion screen, the growth of the pool is compared to the average growth of pools grown
under the negative control condition (usually the solvent control, DMSO), yielding a
relative growth value. Plotting each condition’s relative growth versus its coordinate
in a one-dimensional t-SNE embedding revealed that the unsupervised sorting of pro-
files recapitulates a directional relationship between the dominant signature and relative
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(a) Nonessential, diagnostic (b) Nonessential, full
(c) Essential, hypomorphic (d) Essential, heterozygous diploid
Figure 4.19: Ordering of chemical-genetic interaction profiles by their coordinates in a
one-dimensional space generated using t-stochastic neighbor embedding (t-SNE).
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Figure 4.20: Inferring relative growth of the yeast pool from chemical-genetic interac-
tion profiles. For each dataset, profiles were ordered in an unsupervised manner by
embedding them into a one-dimensional space using t-SNE. Growth of the yeast pool
that generated each profile (represented by one dot) is plotted as the y-coordinate.
growth (figure 4.20). This directly implicates the suppression of growth as the source
of the dominant signal in each of these datasets and in the remainder of our datasets as
well.
4.3 Discussion
Nearly every chemical-genetic interaction dataset generated within our collaboration
has exhibited systematic effects or other unwanted variation that merits removal. The
BEAN-counter pipeline described in chapter 2 provides a standardized approach to re-
moving this variation, and here I demonstrated its ability to process four different modes
of chemical-genetic screen in S. cerevisiae. These screens were performed against both
nonessential and essential mutant collections, with the nonessential collections repre-
sented by the diagnostic and full sets of deletion mutants and the essential collections
represented by heterozygous diploid and hypomorphic mutant collections. Importantly,
all screens shared a common set of of ~1000 compounds, enabling cross-dataset analyses
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that would otherwise be influenced by biases in screened chemical space.
Individual processing of the datasets required different degrees of effect removal to re-
veal functional information as measured by pairwise condition correlations. I performed
the most drastic corrections on the hypomorphic essential mutant dataset, removing
2 SVD components and 4 lane-related LDA components. PR and ROC curves calcu-
lated based on the ability of pairwise condition correlations to recapitulate replicate
status primarily guided these decisions, which were otherwise restricted to the removal
of one or two SVD components. In the case where replicated conditions comprised a
tiny fraction of the dataset, the immunity of ROC analysis to class imbalance ensured
a reasonable evaluation of my effect correction efforts. However, chemical-genetic inter-
action datasets – and any dataset in general, for that matter – should contain biological
replicate conditions to provide basic quality control.
A careful process to align the datasets based on compound dose and concentra-
tion enabled additional, orthogonal characterizations of functional information content.
These evaluations quantified the ability of pairwise similarities of mutant-side profiles
across the conditions to recapitulate known co-annotation relationships between the mu-
tants. When applied to common post-processing stages across the datasets, the mutant-
side co-annotation analyses revealed that BEAN-counter’s post-processing procedures
revealed functional information among the mutants. Surprisingly, the hypomorphic
mutant dataset, which initially showed no mutant co-annotation enrichment over back-
ground and was subjected to a substantial degree of correction during post-processing,
showed the most drastic recovery in mutant-side functional information content upon
SVD and lane effect correction.
Further investigation into the source of mutant-side functional information revealed
that positive interactions actually contributed to the clustering of essential mutants (un-
like nonessential mutants) and, surprisingly, that positive interactions were the dom-
inant contributor of functional information in the heterozygous diploid dataset. The
presence of functional information on the positive side of these profiles conflicts with
the accepted wisdom that the primary signal comes from specific, negative interactions
that directly implicate proteins as compound target. Due to this conflict, the behaviour
of heterozygous diploid mutants should be further investigated to test the general valid-
ity of the field’s assumptions about their information content and utility. Perhaps the
information derived from positive interactions is useful for characterizing the functional
effects of compounds and even predicting their targets.
One of the most striking findings from this multi-dataset analysis was the fact that
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growth inhibition effects are the dominant source of variation in all of our chemical-
genetic interaction datasets. In fact, they were so dominant that an unsupervised,
one-dimensional projection of the conditions actually enabled the prediction of growth
inhibition measurements based on a condition’s coordinate in the projection. Our tra-
ditional data visualizations based on hierarchical clustering tended to destroy this rela-
tionship by ultimately forcing this continuous trajectory into groups with no incentive
to preserve the trajectory order. However, sorting the profiles by their coordinate in
this one-dimensional space and supplementing this visualization with the growth inhi-
bition measurements provides a clear visualization of this relationship in addition to the
prediction results.
The effects of growth inhibition ultimately violate the assumptions of the interac-
tion scoring model in BEAN-counter by inducing large shifts in the relative distribution
of mutant abundances (figure 4.21). Under a conservative interpretation, these shifts
render the control conditions inappropriate for scoring interactions from even relatively
mild growth-inhibitory conditions such as the 70 % relative growth advocated by some
in the field. The current approach of removing these effects post-hoc via SVD correction
has been successful, but known effects should ultimately be removed using more super-
vised techniques. An automated, supervised approach to detect and remove these effects
before or during interaction scoring would eliminate unnecessary judgment calls that
can lead to inconsistency in processing across datasets and prevent less computationally-
and statistically-inclined users from generating corrected profiles.
The development of a new interaction scoring model capable of accounting for broad
relative abundance shifts in pooled screens presents certain challenges but also a valuable
opportunity to improve the analysis of these screens. One open question is whether or
not the trajectory induced by increased growth inhibition resembles the reverse of the
temporal changes in pool composition (figure 4.21a). If so, this raises the possibility
of defining a reference trajectory based on a time course of negative control profiles.
Each treatment profile would be scored against the profile (or interpolated profile) that
minimized differences in the abundance distributions (figure 4.21d). The location of the
treatment profile along this trajectory would also serve as a growth inhibition prediction.
However, one reference trajectory might not be appropriate, as differences in abundance
distribution can arise from screening on different days, possibly from using different
aliquots of pool stock (figure B.1). Despite the challenges, the feasibility of such a
scoring model should be investigated given the potential implications for the burgeoning
field of pooled mutant screening in higher organisms.
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(a) (b)
(c) (d)
Figure 4.21: Possible origin of and analytical correction for growth inhibition effects
in chemical-genetic interaction datasets. (a) Hypothetical growth trajectories for a
pool of five mutants grown over 48 hours, and hypothetical abundance distributions
induced by non-growth-inhibitory compound A and growth-inhibitory compound B. (b)
Interaction scoring procedure for compound A, for which the control-derived abundance
distribution at 48 hours serves as an appropriate reference and reveals strong sensitivity
of the green-colored mutant. (c) Interaction scoring procedure for compound B using
the 48-hour control-derived abundance distribution as the reference. Assuming the
reproducible mutant abundance trajectory in (a), spurious interactions are introduced
because the degree of growth inhibition is not matched between the compound and
control treatments. (d) Interaction scoring procedure for compound B using the 16-
hour control-derived abundance distribution as the reference. In this model, matching
the growth-inhibited abundance distribution induced by the compound to an earlier
point in the trajectory substantially reduces spurious interactions and reveals a possible
sensitivity of the red-colored mutant to compound B.
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4.4 Materials and Methods
4.4.1 Chemical-genetic interaction dataset processing and visualiza-
tion
Chemical-genetic interaction datasets were processed using BEAN-counter version 2.6.0,
available at https://github.com/csbio/BEAN-counter/releases/tag/2.6.0. Details re-
garding the specific processing steps performed on each dataset are provided in sec-
tion 4.2. All clustered heat maps were generated using hierarchical agglomerative clus-
tering with 1− PCC as the distance metric (PCC = Pearson’s correlation coefficient)
and average linkage.
4.4.2 Precision-recall and receiver operating characteristic curves
Precision-recall (PR) and receiver operating characteristic (ROC) curves were generated
to assess the ability of condition-side or mutant-side pairwise PCC to predict a common
status on the conditions or mutants, respectively. Condition pairs with common sta-
tus were those derived from the same compound treatment (biological replicates), and
strain pairs with common status were those that shared annotations to at least one Gene
Ontology (GO) biological process term. For the Gene Ontology-based analysis, the on-
tology itself was downloaded on 09/02/2016 from http://www.geneontology.org and the
annotations from S. cerevisiae genes to GO terms were downloaded on 05/17/2017 from
https://www.yeastgenome.org. The GO terms were propagated using all relationship
types and were filtered to those with 50 or fewer annotations mapped from the entire
S.cerevisiae genome.
To construct the PR and ROC curves, the compound or mutant pairs were first
sorted in descending order based on their PCC. For each compound or mutant pair, a
confusion matrix (table 4.2) was then constructed to compare the predicted common
and non-common status pairs (those above and below the PCC threshold, respectively)
to the actual (“condition”, in table 4.2) common and non-common status pairs. Recall
(PR and AUC), also known as the true positive rate, was calculated as the ratio of
the number of true positives to condition positives (for PR curves, this can also be
represented as just the number of true positives). Precision (PR only) was calculated
as the ratio of true positives to predicted positives. False positive rate (AUC only) was
calculated as as the ratio of false positives to condition negatives.
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Predicted
Positive Negative
Condition Positive True Positive False Negative
Negative False Positive True Negative
Table 4.2: Confusion matrix for evaluating the performance of binary classifiers.
4.4.3 Interaction degree and density
Degree and density values were computed on chemical-genetic interaction data bina-
rized by applying a z-score threshold of ±2.5 and genetic interaction data binarized
by applying both an epsilon score threshold of ±0.08 and a significance threshold of
p < 0.05.
Genetic interaction data were obtained from the recently assembled global genetic
interaction network for S. cerevisiae [28].
4.4.4 Growth inhibition effects
The relative growth of the mutant pool for each chemical-genetic interaction screen was
determined by dividing the absorbance of the culture at 600 nm (OD600) by the mean
absorbance of the negative control cultures (treated with vehicle control, DMSO).
t-stochastic neighbor embedding analysis was used to assign the conditions from
each chemical-genetic interaction dataset to a coordinate in a one-dimensional space.
Specifically, I used the Barnes-Hut implementation in the Rtnse package for the R
statistical environment [112, 115, 116], with 40 set as the perplexity parameter and 500
as the maximum number of iterations (all remaining parameters set as defaults).
Chapter 5
Conclusion
5.1 Summary
The construction of genome-wide mutant collections has enabled high-throughput, high-
dimensional quantitative characterization of gene and chemical function, particularly via
genetic and chemical-genetic interaction experiments. As the throughput of these exper-
iments increases with improvements in sequencing technology and sample multiplexing,
appropriate tools must be developed that can handle the large volume of data produced.
In this dissertation, I have described multiple contributions I made during my PhD
work to advance the field of pooled interaction screening and chemical-genetic inter-
action screening in particular. These contributions centered on the analysis and in-
terpretation of high-throughput chemical-genetic interaction experiments and resulted
in the release of two open source software pipelines to the broader community. These
pipelines make our data analysis tools and knowledge available to researchers outside of
our broader collaboration to use within their own interaction screens, and they addition-
ally serve as benchmarks for measuring the improvement of future analytical techniques
in the field.
The first of these pipelines – BEAN-counter (Barcoded Experiment Analysis for
Next-generation sequencing) – possesses tools for converting the raw data into mutant
abundance counts, scoring interactions, and removing batch effects and other unwanted
signal from pooled interaction screening experiments. It was designed primarily to
process large-scale (thousands of compounds) chemical-genetic interaction screens, but
it is equally applicable to, and easier to use for, smaller-scale screens (tens of com-
pounds). Basic users who would like to process smaller-scale screens need only possess
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basic command line proficiency, as we have multiple biologist collaborators who have
processed data from their screens on their own. Advanced users who which process
larger-scale screens should also be familiar with concepts in analysis of high-throughput
biological data. BEAN-counter encapsulates the knowledge accumulated from and suc-
cessfully applied to high-throughput, pooled barcode sequencing experiments, and I
believe it will be useful to those in the community interested in generating their own
high-dimensional, quantitative characterizations of gene or chemical function in a high-
throughput manner. With a user base that spans academia and industry, BEAN-counter
has scored at least twenty million chemical-genetic interactions across many tens of
thousands of interaction profiles. The software is freely available for academic use at
https://github.com/csbio/BEAN-counter.
The second pipeline, called CG-TARGET (Chemical Genetic Translation via A Ref-
erence Genetic nETwork), integrates large-scale chemical-genetic interaction screening
data with a genetic interaction network to predict the biological processes perturbed
by compounds. The concept of using genetic perturbation-derived functional profiles to
elucidate compound mode of action is at least two decades old and was demonstrated
nearly fifteen years ago for the integration of chemical-genetic and genetic interaction
profiles. However, large-scale integrative analyses of genetic and chemical-genetic in-
teraction profiles have not been systematically evaluated. The CG-TARGET method
I developed compared favorably to a baseline enrichment approach across a variety of
benchmarks, achieving similar accuracy while substantially improving the ability to con-
trol the false discovery rate of biological process predictions. I applied CG-TARGET
to a recent screen of nearly 14,000 chemical compounds in Saccharomyces cerevisiae,
integrating this dataset with the global S. cerevisiae genetic interaction network to
prioritize over 1500 compounds with high-confidence biological process predictions for
further study. Upon investigation of the compatibility of chemical-genetic and genetic
interaction profiles, it was observed that one-third of observed chemical-genetic inter-
actions contributed to the highest-confidence biological process predictions and that
negative chemical-genetic interactions overwhelmingly formed the basis of these predic-
tions. This approach successfully demonstrated the use of genetic interaction networks
in the functional annotation of compounds to biological processes.
BEAN-counter was originally developed using data obtained from screens against
the diagnostic collection of 310 mutants. More recently, our broad collaboration focused
on a set of ~1000 compounds and expanded the interrogated gene space to as much of the
genome as possible. This effort resulted in a total of four datasets of chemical-genetic
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interaction profiles, obtained across nonessential and essential genes and generated us-
ing a common set of ~1000 compounds. Even as I standardized the procedures for
removing batch effects and uninformative signal from the data, I harbored questions
about possible effects of these procedures that I was not detecting. Especially as some
of these procedures caused drastic changes in the structure of the data, I was concerned
about the potential destruction of information at the expense of strengthening replicate
correlations.
I therefore used these new datasets to deeply characterize the effects of BEAN-
counter post-processing procedures on within- and cross-dataset functional information.
In the absence of a functional standard for assessing profile similarity (beyond replicate
correlations) that sufficiently overlapped the compounds in our study, I asked a slightly
different question of the data to assess the quality of mutant-side profile similarities.
Encouragingly, I found that the post-processing procedures I standardized for chemical-
genetic interaction data did, in fact, remove uninformative signal that obscured more
functionally-relevant relationships in the data. Especially of note was the recovery of
functional information from the screen against the hypomorphic essential gene mutants,
both because the post-processing procedures I employed on this dataset were substan-
tially more extensive than on the other dataset and the initial amount of functional
information appeared to be zero. As we might have hypothesized, the negative chemical-
genetic interactions drove almost all of the informative similarities between mutants in
the datasets generated against nonessential mutants. However, both collections of es-
sential mutants possessed positive interactions that were more functionally informative,
with these interactions dominating the information content of the heterozygous diploid
dataset. This property of the heterozygous mutants conflicts with general wisdom that
their profiles are informative only for identifying direct protein targets of compounds
and warrants further computational and experimental investigation.
One of the most striking discoveries from the analysis of cross-dataset correlations is
that growth inhibition contributed the largest source of variation in the data. This intu-
ition had been slowly gaining strength within our broader collaboration, but the trend
was not necessarily clear from our initial explorations of the data. Not until I analyzed
the most recent datasets, both independently and collectively, did this conclusion gain
multiple credible lines of evidence. It is very striking that profiles from diverse condi-
tions can be organized, in a completely unsupervised manner, into a one-dimensional
trajectory that correlates with growth inhibition. This finding has suggested follow-
up experiments to determine if the trajectory of growth inhibition reflects the natural
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population trajectory over time when grown in the absence of compound. If these two
trajectories align, then it not only supports our hypothesis but also suggests potential
strategies for correcting for these effects earlier during data processing. In general, a su-
pervised method for removing the dominant signature in the data would be preferable to
an unsupervised approach, which could accidentally remove other large sources of vari-
ation that are biologically relevant. The success of such an approach would depend on
the degree to which each mutant pool’s trajectory is reproducible across experiments.
Given the current and likely continued popularity of pooled screening approaches, it
would be prudent to investigate further the effects of general growth inhibition on mu-
tant pool composition to ensure that the resulting interaction scores are as accurate as
possible.
The growth inhibition signature is partially a result of our collaboration’s emphasis
on scaling chemical-genetic interactions up to throughput levels similar to drug screen-
ing campaigns. Compounds were first screened against the diagnostic set at one dose to
determine the presence of any interesting activity. Compounds were then screened at
lower doses if necessary, but generally only if they inhibited growth >80%. The essen-
tial mutant collections were treated with three doses of each compound (or sometimes
more), which provided some information along the dose axis but at the expense of same-
compound, same-concentration biological replicates. Usually at least one of the doses
in this scheme was too high, leading to a dominant growth inhibition signature and
ambiguity regarding the "correctness" of the profiles obtained at the remaining doses.
As shown in my analyses, the phenomenon of overdosing is common throughout all of
our datasets, and thus a new model that can adjust for these effects is attractive.
5.2 Future directions
I believe we have barely scratched the surface of what chemical-genetic interaction
screening can offer, in terms of both the experimental and analytical aspects of low-
and high-throughput experiments. At low-throughput, we can increase the complexity
of our experiments and associated models to more quantitatively describe the observed
interactions. We can also move into more complex model systems that would not be use-
ful for screening thousands of compounds but would provide more information regarding
chemical-genetic interactions relevant to a specific phenotype of interest. In general, but
especially at high throughput where the complexity of the experimental design is con-
strained, we can also increase the sophistication and efficiency of our computational
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methods for interpreting chemical-genetic interaction profiles. Currently, CG-TARGET
has high runtimes due to its heavy reliance on empirical statistics, and future efforts
should seek to retain its demonstrated benefits while increasing its efficiency. The pre-
dictions it makes at the level of processes (or other gene sets) can be difficult to interpret
in general, and the quality of these predictions depends on the scope and quality of gene
set annotations for the organism of interest. More sophisticated techniques might iden-
tify where it is appropriate to increase the specificity of predictions, or possibly remove
the reliance on gene sets altogether.
The idea of an interaction scoring model that accounts for growth inhibition effects
also raises the broader possibility of reevaluating interaction scoring models for pooled
screens in general. New models could be designed to extract more information from the
pool and would require simultaneous optimizations in experimental design. In contrast
to the model used by BEAN-counter, which calculates interaction z-scores that represent
the deviation of the observed abundance from a null expectation, it should be possible,
with careful design, to estimate more traditional interaction metrics such as the fitnesses
of the individual mutants, the relative growth of compound-treated wild-type cells, and
the interaction effect size and statistical significance for each compound-mutant pair.
Such metrics would provide more context describing how the interactions arise than
our current z-score, but the combined experimental design and analytical model would
have to overcome the difficulties in estimating fitnesses and deviations therefrom in
the context of a pooled competition. This would likely require, at a minimum, the
inclusion of controls within the interaction screens to help estimate the null expectation
of abundance (instead of relying solely on the distribution of mutant fitnesses) as well
as careful drug-induced and mutant fitness measurements outside of the interaction
screens.
No compound possesses a single chemical-genetic interaction profile, as its functional
effects in the cell depend on its concentration (or more specifically, the molecule-to-cell
ratio) [94]. The benefits of profiles obtained in a dose course remain an open question
in the field, and I would argue that we currently lack the analytical tools to fully answer
this question for pooled screens. Given what we now know about growth inhibition in
pooled screens, any attempt to extract quantitative information from a series of pro-
files obtained across a dose course would need to successfully differentiate between two
concentration-dependent effects: the emergence of real interactions and general growth
inhibition effects. Tracking interactions across dose presents inherent signal-to-noise is-
sues, in terms of both identifying the first emergence of an interaction and subsequently
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detecting interactions from a compound’s secondary effects when its primary effect is
strong. One could ideally differentiate between a multifunctional compound’s indepen-
dent effects by grouping the responsive mutants based on the concentration at which
an interaction is first observed or half of the total effect is observed (the “MIntC” and
“IntC50”, respectively). Both of these measures would depend on the ratio between
a mutant’s final effect size and the biological and technical noise as well as the dose
resolution, and this goal of differentiating independent effects may require integration
with external information such as genetic interaction profiles. In general, dose-response
experiments enable different representations of interaction profiles whose utility have
not been explored. Specifically, mutants’ interaction-effect-size versus dose curves could
be aggregated into MIntC, IntC50, or AUIntC (Area under the interaction curve)
profiles that summarize different aspects of the compound-dose relationship and enable
cross-compound comparisons based on traditional profile similarity measures.
The development of the CG-TARGET pipeline demonstrated the utility of integrat-
ing chemical-genetic and genetic interaction profiles on a large scale, and it has been ex-
tremely useful for interpreting the chemical-genetic interaction profiles generated within
our broader collaboration. It also demonstrated the importance of incorporating infor-
mation on the general effects of compound treatment in generating reasonable estimates
of the false discovery rate. However, its heavy reliance on empirical statistics substan-
tially increases its runtime, and the quality of these empirical measures depends on
the presence of a large diversity of profiles to resample. This has posed problems for
the interpretation of small-scale screens. I have implemented one solution that works
best for small screens performed against the diagnostic nonessential mutant collection
by leveraging the diversity of profiles from our screen of ~14,000 compounds. However,
for the remaining mutant collections, the only sets of reference profiles were obtained
against the high-confidence set of compounds. Comparisons against a null expecta-
tion derived from these compounds would likely lead to excessively conservative false
discovery estimates. Thus, it is worth investigating why exactly the incorporation of
resampled treatment profiles leads to improved control of the false discovery rate and
if this effect can be achieved in a manner that is more practically applied across small-
and large-scale screens. Perhaps the benefits of resampling would become less appar-
ent if general growth inhibition effects can be better controlled—this remains an open
question. Regardless of the correct answer, there is no shortage of data to support the
development of improved methods.
Another major class of improvements to genetic interaction-based target prediction
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would be those that leverage the hierarchical structure of either the gene set annotations
or the genetic interaction network itself [28]. Currently, CG-TARGET only handles
flattened gene sets and addresses the non-independence of tests against overlapping gene
sets through its empirical false discovery rate estimation procedure. It would be very
useful from an interpretation standpoint if the algorithm could further identify the most
appropriate term to report as the target out of a local hierarchy, for example by choosing
the most specific term that meets certain confidence criteria. These improvements,
however, cannot overcome issues with annotation quality, and we have encountered
multiple instances where a compound’s top predicted gene-level target lacks specific (or
any) annotations. In these cases, it would be useful to have access to less supervised
methods that report direct correlations with genetic interaction profiles and can also
report results at the most appropriate level of the genetic interaction profile hierarchy.
Such methods would need to carefully consider the redundancy inherent in genetic
interaction profiles to ensure that target predictions are not unnecessarily biased toward
large clusters of genes (they will always have higher statistical power). An approach in
this vein would be extremely useful if the redundancy issue can be addressed.
As the popularity of chemical-genetic interaction screening in higher organisms con-
tinues to increase, new opportunities and challenges arise. The mutant pools for higher
organism screens are much more complex, as they must cover much larger genomes and
are generated “on-demand” using viral vectors encoding complex (3-10 unique guide
RNAs or short hairpin RNAs per gene) sets of reagents. As a result, these screens
require orders of magnitude more cells to perform and much deeper sequencing for
analysis, precluding their use as high-throughput in terms of the number of chemicals
that can be screened. One important conclusion from our efforts to integrate chemical-
genetic and genetic interaction networks is that a diagnostic subset of mutants can be
used successfully in place of the entire set. With gRNA and shRNA libraries up to
50 times as complex as a pool of S. cerevisiae nonessential mutants, the possibility of
using a diagnostic mutant subset should be seriously considered if higher throughput is
a goal. The success of a compressed mutant pool, however, likely depends on a com-
panion set of genetic interaction profiles, which currently only exist on very small scale
in mammalian cells. However, alternative analytical approaches could be used to pri-
oritize profiles against a compressed pool with follow-up screens of the most interesting
compounds performed against the high-complexity pool.
Additionally, pooled screening in mammalian cells raises the question of appropriate
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phenotypes for detecting genetic interactions. For yeast and other single-cell organ-
isms, the phenotype of fitness reflects one of the organism’s evolutionary imperatives,
rendering it a functionally informative, though simple, phenotype. In higher organ-
isms, the analogous property is cellular proliferation rate, which is a tightly-controlled
process and only one of many cellular characteristics, even for cancer cells, that would
lead to the survival of a cell in its natural context or subjected to a perturbation in
vitro. Recent genetic interaction screening work in Drosophila emphasized the utility
of measuring phenotypes specific to the process of interest or measuring multidimen-
sional phenotypes [117]. In the latter case, multidimensional phenotypes derived from
image-based analysis of cellular features were shown to increase the space of detectable
genetic interactions and could even be used to infer the directionality of epistatic re-
lationships. Indeed, similar types of experiments to measure genetic interactions have
now been performed in mammalian cells using single-cell approaches and the transcrip-
tome as the multidimensional phenotype [118–120]. Additional methods to measure
non-proliferative phenotypes in pooled screening include those that link the gene or
pathway activity to an antibiotic resistance marker or a fluorescent protein (for cell
sorting), or in an impressive demonstration of creativity, magnetic separation of cells
that take up magnetically conjugated particles to identify genes required for phagocy-
tosis [121].
Genetic tools have a role to play in advancing efforts to discover new pharmaceu-
ticals, ensure chemical safety, and perturb cellular functions in a precise manner. The
power of these tools lies in their ability to reverse engineer biological systems and ex-
pose previously unseen genetic dependencies upon introduction of a perturbation of
interest. The experimental designs and associated analytical tools developed within our
broader collaboration and described in this document have enabled compound screening
on a scale approaching that of high-throughput campaigns in pharmaceutical discov-
ery but yielding genome-wide, functional information. While the molecular phenotypes
obtained through functional profiling may not be specific enough to determine if a
compound has a specific desirable or undesirable effect, they do quantitatively capture
compound function in a high-dimensional format that can be linked to phenotypes of
interest. In the quest to identify compounds that perturb functions across the genome,
compound-centric techniques such as chemical-genetic interaction profiling enable the
rapid, genome-wide identification of candidate compounds and targets without the need
for thousands of target-based assays. These techniques thus represent a valuable class
of tools for understanding the nature of interactions between chemical compounds and
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biological systems.
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Appendix A
BEAN-counter configuration
parameters
The table below contains the definitions of all parameters included in the configuration
file and the setup_screen.py setup script. All parameters in the configuration file can
be set using the setup script, and the setup script also includes extra parameters for
generating a template sample information table. The formats of files referenced through
configuration parameters are also described here.
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Parameter Default value Explanation
Files, folders and relevant specifications (for a visual depiction of the relationships between these files, see
figure 2.3
output_folder <dir>/output The directory to which processing output is written.
lane_location_file <dir>/config_files/la
ne_locations.txt
A two-column, tab-delimited text file that maps the
“lane” column in the sample_table_file to the folder
containing the raw sequencing data for that lane. Col-
umn headers must be “lane” and “location.”
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Parameter Default value Explanation
sample_table_file if setup_screen.py
constructs a
sample_table_file,
default location is: <d
ir>/sample_tables/sa
mple_table.txt
A tab-delimited text file that contains information
on each condition. The required columns are:
• “screen_name” (a unique name for your
screen; for later convenience, do not use
underscores)
• “expt_id” (a unique identifier for each
condition within the screen – we recommend
fixed-length numbers starting with “1” so that
the text file can be loaded into Excel without
number reformatting)
• “control?” (True/False; whether or not the
condition is a negative control)
• “include?” (True/False; whether or not the
condition should be included in the final
dataset, and if it is a negative control, if it
should contribute to the mean control profile
in any interaction scoring steps)
• “lane” (sequencing lane id that maps to raw
data location via the lane_location_file)
Additionally, if using the single-indexing scheme
described in this protocol (index tag and gene
barcode contained in a single amplicon that is read
by a single forward read on an Illumina sequencer),
one column is required that maps the observed index
tag sequence in the PCR amplicon to each condition.
The name of this column (we use “index_tag”) and
the coordinates of this sequence in the PCR
amplicon are specified in the amplicon_struct_file.
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Parameter Default value Explanation
gene_barcode_file (none) A tab-delimited text file that contains information
on each strain in the pool. A “Strain_ID” column
is required that provides a unique identifier for each
strain in the pool. For the single-indexing scheme
described in this protocol, one column is required that
maps the observed gene barcode sequence in the PCR
amplicon to each strain. The name of this column (we
use “Barcode”) and the coordinates of this sequence
in the PCR amplicon are specified in the amplicon
struct_file.
amplicon_struct_file (none) A YAML-formatted text file specifying the coordi-
nates of the common primer, index tag, and gene
barcode sequences in the PCR amplicons and how
these sequences map to their respective strains and
conditions through the gene_barcode_file and sam-
ple_table_file. The index_tag, common_primer,
and genetic_barcode parameters each specify a
“start” coordinate (where 0 represents the first base
pair in the amplicon), and the respective lengths of
each sequence in the PCR amplicon are inferred auto-
matically from the given index tag, common primer,
and gene barcode sequences (only the gene barcode
sequences can be of variable length).
Additional and advanced parameters
verbosity 1 The level of detail printed out to the console while
running BEAN-counter
sub_screen_column (none) A column within the sample_table_file that defines a
partitioning of the conditions, for separately scoring
interactions within each group of conditions. This
is useful to overcome batch-related effects in large-
scale screens, provided a sufficient number of negative
controls exists in each partition (tens or more).
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Parameter Default value Explanation
num_cores (none) The number of CPU cores to use during interaction
scoring steps. If blank, it defaults to 1/2 of the cores
on your machine. Values between 0 and 1 (exclusive)
specify a fraction of the available CPU cores (with
“all” specifying all available cores), and integer values
of 1 and above specify an exact number of CPU cores.
remove_barcode_specific_conditions
barcode_specific_template_correlation_cutoff
True
0.3
We have observed interaction profiles in which one
of the four possible first letters of the gene barcode
is necessary and sufficient to drive large, positive
interaction scores, while the remaining interaction
scores remain near zero (for example, only strains
with barcodes beginning with “C” possess
interactions, and these interactions are only strong
positives). This behavior is often consistent among
multiple conditions tagged with the same indexed
primer, but other conditions tagged with that same
primer are unaffected. Thus, we construct 4
“barcode_specific” template profiles and remove any
condition that resembles that profile with greater
than the given correlation.
remove_correlated_index_tags
index_tag_correlation_cutoff
True
0.4
If True, all conditions amplified with an indexed
primer will be removed if the negative controls
amplified using that primer show an average
correlation higher than the given threshold. These
effects typically can only be detected in larger-scale
screens, where the same indexed primer is used to
amplify multiple negative control conditions.
common_primer_tolerance 2 The number of substitution errors allowed in the com-
mon priming site.
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Parameter Default value Explanation
index_tag_tolerance 0 The number of substitution errors allowed in the in-
dex tag. Note that an indel in the index tag will cause
a shift in the remainder of the amplicon, rendering it
unmappable to the common primer sequence (unless
there is a compensating indel prior to the common
primer sequence). Can be specified as a fraction or
decimal to denote the number of errors allowed per
base.
barcode_tolerance 2 The number of substitution errors or indels allowed
in the gene barcode. Note that each indel currently
counts as two errors due to the current fastq pars-
ing scheme in BEAN-counter. Can be specified as a
fraction or decimal to denote the number of errors
allowed per base.
control_detection_limit 20 When computing the mean control profile from neg-
ative control conditions, each read count below this
threshold is labeled as “not detected” and does not
contribute.
sample_detection_limit 20 During normalization against the mean control pro-
file, any count below this value is set to this value.
strain_pass_read_count
strain_pass_fraction
20
0.25
For a strain to pass automatic filtering, the fraction
of conditions with read counts âĽě
strain_pass_read_count must be âĽě
strain_pass_fraction.
condition_pass_read_count
condition_pass_fraction
20
0.25
For a condition to pass automatic filtering, the
fraction of strains with read counts âĽě
condition_pass_read_count must be âĽě
condition_pass_fraction.
Parameters unique to setup_screen.py, for setting up directories and creating a template sam-
ple_table_file when setting up a new screen
clobber False When set to True, files created by setup_screen.py
will overwrite existing files. This is useful if a
mistake was made during the first attempt to use
setup_screen.py. It is False by default to prevent ac-
cidental overwrites.
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Parameter Default value Explanation
num_lanes (none) The number of sequencing lanes in the screen. This is
used to create the raw data directories (one per lane)
and inform the creation of a new sample table.
new_sample_table False Should a new blank sample table be generated?
screen_name (none) A unique name for your screen (for later convenience,
do not use underscores)
plate_size 96 Number of conditions that fit in an assay plate. This
informs the number of rows in the new sample table,
if created.
plates_per_lane (none) Number of plates from which the conditions can be
multiplexed in a single lane of sequencing. This in-
forms the number of rows in the new sample table, if
created.
extra_columns (none) Any extra column headers to include in the new sam-
ple table, if created.
Appendix B
Partitioning the data prior to
interaction scoring with
BEAN-counter
In certain cases, there exists a viable alternative to performing batch correction in post-
processing for correcting batch effects associated with large groups of conditions. Specifi-
cally, it involves specifying a column in the sample information table that partitions the
dataset into arbitrary “sub-screen” groups (sub_screen_column in config_file.yaml),
followed by scoring these groups separately for interactions and then recombining the
data. This results in z-scores that more accurately reflect the variation in mutant abun-
dances within each group’s respective negative control conditions.
We have found this special procedure useful in cases where samples can be parti-
tioned by obvious differences in experimental conditions (e.g. inoculation date, length
of incubation, number of PCR cycles, etc.) such that the negative control conditions
in each group are the only appropriate reference for the remaining conditions in that
group. Each group should possess at least 10, and ideally a full 96-well plate of, neg-
ative control conditions. One example is an optimization experiment in which mutant
pools are grown for different lengths of time or the PCR amplicons are generated using
different numbers of PCR cycles. While it is possible to process these partitions en-
tirely separately using different BEAN-counter runs (indeed, this is what we did before
implementing the partitioning procedure), we have found this procedure of specifying
“sub-screens” to be much more efficient and convenient.
Specifying sub-screens has also been useful when screens performed days or weeks
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apart show obvious differences between their negative control profiles that propagate
to all profiles within their respective groups. For example, the profiles from two ex-
periments performed multiple weeks apart by the same person and processed in the
same BEAN-counter run clustered almost entirely based on their inoculation date (fig-
ure B.1a). In contrast, defining sub-screens based on the inoculation date resulted in a
dataset in which clustering between conditions inoculated on different dates was much
more apparent (figure B.1a). A more quantitative evaluation based on precision-recall
and receiver-operator characteristic analyses also showed a clear change from near-
perfect associations between profile similarity and batch to near-background levels of
association (figure B.1a), demonstrating the utility of partitioning the data prior to
interaction scoring in this case.
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(a) (b)
(c)
Figure B.1: An inoculation date-related effect in one of our datasets. (a) Chemical-
genetic interaction profiles computed from data not partitioned into inoculation date-
based groups. (b) Chemical-genetic interaction profiles computed on data partitioned
into inoculation date-based groups. (c) (i) Precision-recall analysis evaluating the ability
of profile correlation to predict if two profiles were derived from inoculations performed
on the same date, for interaction profiles computed from non-partitioned (“combined”)
and inoculation date-partitioned (“per-date”) data. (ii) Receiver-operator characteristic
analysis of profile correlations from non-partitioned and inoculation date-partitioned
data.
Appendix C
Supplementary figures for
chapter 3
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(a) (b) (c)
Figure C.1: Performance comparison of CG-TARGET versus baseline enrichment ap-
proaches. Perturbed biological processes were predicted using both CG-TARGET and
methods that calculated enrichment on the set of each compound’s n most similar ge-
netic interaction profiles (“top n,” n ∈ {10, 20, 50, 100, 200, 300, 400, 600, 800}). (a) Bio-
logical process prediction false discovery rate estimates derived from resampled chemical-
genetic interaction profiles, performed on compounds from the RIKEN dataset. (b)
Precision-recall analysis of the ability to recapitulate gold-standard annotations within
the set of top bioprocess predictions for ~4500 simulated compounds. Each simulated
compound was designed to target one query gene in the genetic interaction network
and thus inherited gold-standard biological process annotations from its target gene.
(c) For each of 35 well-characterized compounds in the RIKEN dataset with literature-
derived, gold-standard biological process annotations, we determined the rank of its
gold-standard bioprocess within its list of predictions. The number of compounds for
which a given rank (or better) was achieved is plotted. The grey ribbons represent the
median, interquartile range (25th to 75th percentiles), and 95% confidence interval of
10,000 rank permutations.
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Figure C.2: Induced GO hierarchy of the 100 best-performing GO biological process
terms, evaluated using simulated chemical-genetic interaction profiles. Each term was
evaluated using precision-recall statistics (area under the precision-recall curve divided
by the area under a curve produced by a random classifier) to analyze its ability to
rank simulated chemical-genetic interaction profiles from which it was annotated as
a gold-standard bioprocess. Green nodes represent the 100 best-performing GO bio-
logical process terms, yellow nodes represent terms for which predictions were made
but did not rank among the top 100, and white nodes represent terms in the Biologi-
cal Process ontology that were not selected for bioprocess prediction. In the interactive
version, found at http://csbio.cs.umn.edu/CG-TARGET/manuscript/s2.html, hovering
the mouse over each node reveals its GO ID and name.
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Figure C.3: Induced GO hierarchy of the 100 worst-performing GO biological process
terms, evaluated using simulated chemical-genetic interaction profiles. This is the same
as figure C.2, but for the 100-worst performing GO biological process terms. The inter-
active version is found at http://csbio.cs.umn.edu/CG-TARGET/manuscript/s3.html.
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Figure C.3: Schematic representation of CG-TARGET bioprocess prediction procedure. Further details on the presented proce-
dures, including equations, are given in section 3.4.2.
